Construction and characterization of H5N1-recombinant fowlpox viruses co-expressing host cytokines by Abdul Razak, Mariatulqabtiah & Abdul Razak, Mariatulqabtiah
  
 
 
CONSTRUCTION AND CHARACTERIZATION OF  
H5N1-RECOMBINANT FOWLPOX VIRUSES  
CO-EXPRESSING HOST CYTOKINES 
 
 
 
 
 
 
 
 
 
 
MARIATULQABTIAH ABDUL RAZAK 
 
 
 
 
 
 
 
 
 
 
 
FACULTY OF MEDICINE 
IMPERIAL COLLEGE LONDON 
 
 
DOCTOR OF PHILOSOPHY 
2011 
 2 
DECLARATION 
I declare that the work described herein is my own except where all citations and 
contributions of others have been acknowledged. I declare that cDNA copies of H5, N1 
and NP genes of avian influenza (AI) from strain A/Chicken/Malaysia/5858/2004 used in 
this study has been cloned and sequenced by Nurul Hidayah Abdullah Zawawi from 
Universiti Putra Malaysia, and has been exploited by four individuals in their 
dissertations for examination in Universiti Putra Malaysia. 
I also declare that no part of this dissertation has been submitted for any other degree in 
the UK or overseas.  
 
 
 
________________________ 
MARIATULQABTIAH ABDUL RAZAK 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3 
ABSTRACT 
 
Possessing a large double stranded DNA genome up to 300 kb, fowlpox virus (FWPV) 
has been developed to express avian influenza virus (AIV) antigens since the late 1980s. 
A more advanced approach would be to coexpress host cytokines from such 
recombinants. This thesis describes the strategy to construct H5N1-recombinant FWPV 
(rFWPV) coexpressing chicken Interleukin 12 (IL-12) or Interleukin 15 (IL-15), and 
discusses the immunogenicity of the recombinants following inoculation into specific-
pathogen-free (SPF) chickens. 
 
Previously cloned and sequenced cDNAs encoding full-length H5 and N1 of influenza 
strain A/Chicken/Malaysia/5858/2004 genes were amplified by PCR and inserted into 
plasmid pEFL29, under the control of a copy of the vaccinia virus p7.5 early/late 
promoter. The expression cassettes were recombined into the genome of the FP9 strain of 
FWPV at the fpv002 locus. Recombinant viruses were produced by transfection of the 
plasmid into chicken embryo fibroblasts (CEFs) after infection with FP9, and isolated by 
six fold plaque purification on CEFs using X-Gal selection. Chicken IL-12 or IL-15 
genes, under control of a synthetic/hybrid poxvirus promoter, were inserted into a 
‘transient dominant selection’ recombination plasmid, pPC1.X. The cytokine expression 
cassettes were then recombined, at the fpPC1 (fpv030) locus, into rFWPV already 
carrying AIV genes. Following three rounds of passage in CEFs in the presence of 
mycophenolic acid (MPA), recombinant viruses carrying the gpt gene were isolated. 
These unstable recombinants were plaque-purified in the absence of MPA until they lost 
the gpt gene spontaneously, verified by their failure to replicate in the presence of MPA. 
Recombinant proteins were successfully detected using western blotting and indirect 
immunofluorescence assay (IFAT).  
 
Parental and rFWPV (10
5
 PFU) were inoculated subcutaneously into one-day-old SPF 
chickens. Sera from chickens immunized with rFWPV/H5 and rFWPV/H5/IL-15 
demonstrated viral neutralizing activities, based on the haemagglutation inhibition (HI) 
test, in which reached a peak at Week 3. A competitive enzyme-linked immunosorbent 
(ELISA) assay detected N1-specific antibodies induced by rFWPV/N1 and 
rFWPV/N1/IL-12 at Weeks 4 and 5. Non-specific cellular immune responses were 
assessed by flow cytometric analysis to enumerate CD4+ and CD8+ T-lymphocytes in 
peripheral blood. Results of Experiment 2 showed chickens vaccinated with rFWPV/H5, 
rFWPV/H5/IL-15, rFWPV/N1 and rFWPV/N1/IL-12 demonstrated a higher increase in 
CD8+ than CD4+ T cell population, relative to control and chickens vaccinated with 
parental FWPV. Weekly weighing showed that chickens vaccinated with rFWPV/H5/IL-
15 had the highest body weight compared to other groups, while the rFWPV/N1/IL-12 
group showed the significantly lowest body weight.  
 
In summary, this study showed diverse immunogenicity of H5N1-rFWPV coexpressing 
IL-12 or IL-15. It also demonstrated a weight sparing effect of co-expressing IL-15 in 
rFWPV vaccines. The results provide the basis for future homologous challenge studies, 
using live H5N1 virus to evaluate the protective efficacy of the rFWPV vaccines.  
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CHAPTER 1 
Introduction 
 
1.1 Influenza 
Influenza, which is caused by single-stranded, negative-sense RNA viruses of the family 
Orthomyxoviridae is an infectious disease of birds and mammals, including humans. 
Although the first relatively well-recorded influenza pandemic occurred in 1580, the most 
notorious was the 1918 influenza pandemic, which killed an estimated 40 million people 
worldwide, with approximately 675,000 in United States alone (Potter, 2001; 
Taubenberger, 2006).  
 
1.1.1 Influenza classification 
Influenza viruses exist in 3 major genotypes: A, B and C. Influenza B and C, which are 
predominantly human pathogens, have not caused pandemics. In contrast, influenza A 
(infecting humans, horses, swine, birds, whales, seals, cats, leopards, tigers, civets and 
dogs (Suarez and Schultz-Cherry, 2000a; van den Berg et al., 2008)) causes annual 
endemics, epidemics every few years and pandemics at irregular intervals of decades. 
Influenza A viruses are divided into subtypes based on antigenic differences between 
their surface glycoproteins, haemagglutinin (HA) and neuraminidase (NA), both of which 
are important determinants for neutralizing antibodies. To date, 16 HA subtypes and 9 
NA subtypes have been identified (Fouchier et al., 2005). All avian influenza viruses are 
of type A. Historically, all influenza A virus subtypes, except H13 (Webster et al., 1992), 
occur asymptomatically in wild birds of the Orders Anseriformes (ducks, geese, and 
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swans) and Charadriformes (i. e., gulls, terns, surfbirds, and sandpipers). Shedding of the 
virus in the faeces of these host species, particularly by wild waterfowl, contaminates the 
environment thus permitting consistent cycles of infection (reviewed by van den Berg et 
al., 2008). 
 
1.1.2  Molecular biology 
The influenza A virus genome consists of eight negative strand RNA segments, the 
complements of which encode eleven different proteins. The HA segment (number 4) 
encodes the full-length HA protein (HA0, in which giving two fragments, HA1 and HA2, 
upon cleavage by proteases at the polybasic region), membrane attachment/fusion 
glycoprotein, which is synthesized on membrane-bound ribosomes. The protein binds 
specifically to sialic acid receptors that are linked to galactose, generally by an α2,3-
linkage in avian and equine hosts, or α2,6-linkage in human host, thus allowing influenza 
virion to attach to the cell (Subbarao et al., 2000; Neumann et al., 2010). Upon successful 
attachment, the virion is endocytosed into the cell. Acidified-endosome activates the 
fusion domain of the HA protein hence releases the viral RNA into cytoplasm. NA, 
which is a surface glycoprotein and enzymatically active, promotes the penetration of 
avian influenza virus into target cells during the onset of infection, and the release of 
budded virus particles from the cell membrane by cleaving sialic acid residues from 
carbohydrate moieties on surfaces-bound receptors of infected cells, at the final stage of 
viral replication (Ohuchi et al., 2006). The neuraminidase activity also helps to prevent 
virus from self-aggregating or remaining to cell membranes (Li et al., 1993).   
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In any glycoprotein, the sugar moieties (glycans) linked to the polypeptide (by an 
enzymatic process termed glycosylation) play vital biological roles in the folding of the 
glycoproteins during biosynthesis and in stabilizing the protein conformation in the active 
form (Vliegenthart and Montreuil, 1995). Core glycosylation, which occurs in the lumen 
of the endoplasmic reticulum (ER), is essential to the creation of a functional HA protein 
(Roberts et al., 1993). Recent studies also implicate N-glycans flanking the receptor-
binding site of HA as potent regulators of influenza virus replication (Wagner et al., 
2000). Apart from the trimming and processing of HA glycans, other post translational 
modifications of HA, including its proteolytic cleavage into subunits, have also been 
studied extensively (Roberts et al., 1993).  
 
The M2 membrane protein acts as an ion channel, which is important for maintaining the 
internal pH of the virion, offering optimal conditions for uncoating of the virus after cell 
entry (Betakova, 2007). The surface proteins HA, NA and M2 are embedded in the viral 
envelope. The other proteins, PA, PB1, PB2 and NP, form ribonucleoprotein (vRNP) 
complexes responsible for transcription of the viral genome. The complexes are 
connected with the viral envelope by the matrix protein, M1, which is required to induce 
the nuclear export of vRNP (Bui et al., 2000; Suarez and Schultz-Cherry, 2000a). Studies 
of fifty five sequences of nine or more amino acids of the polymerases (PB2, PB1, and 
PA), NP, and M1 proteins of avian and human influenza A virus isolates, show that the 
proteins are at least 80% conserved, despite the evolutionary variability (Heiny et al., 
2007). PB1-F2 protein, derived from a second open reading frame (ORF) of PB1, can 
induce apoptosis by interacting with the inner mitochondrial membrane adenine 
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nucleotide translocator 3, ANT3, and the outer mitochondrial membrane voltage-
dependent anion channel 1, VDAC1 (Chen et al., 2001, Zamarin et al., 2005). It interacts 
directly with a viral polymerase PB1 protein, and localizes to both the cytoplasm and the 
nucleus of infected cells, suggesting a pivotal function in AIV replication (Mazur et al., 
2008) 
 
The NS segment encodes NS1 and NEP proteins, using different open reading frames, 
from the same RNA segment.  While NEP proteins mediate the nuclear export of vRNPs 
(Neumann et al., 2000; Suarez and Schultz-Cherry, 2000a), NS1 protein antagonises the 
host cell antiviral interferon (IFN) system in multiple ways. It also regulates temporal 
viral RNA (vRNA) synthesis (Falcon et al., 2004; Min et al., 2007), inhibits pre-mRNA 
splicing (Lu et al., 1994), suppresses RNA interference (Li et al., 2004) and activates 
phosphatidylinositol 3-kinase (PI3K) to mediate anti-apoptotic response (Hale et al., 
2006; Ehrhardt et al., 2007; Shin et al., 2007). 
 
1.2  Avian influenza virus 
1.2.1 Pathogenicity 
Avian influenza viruses infecting poultry can be further divided into two distinct groups 
(pathotypes) based on their ability to cause disease (pathogenicity). The endemic form, 
low pathogenicity avian influenza (LPAI), causes mild symptoms and low mortality 
rates; the highly pathogenic avian influenza (HPAI), defined as ‘fowl plague’ in 1878, 
was initially recognized in Italy as causing flock mortality as high as 100% in chickens 
(Capua and Alexander, 2004; Lupiani et al., 2009). Avian influenza virus (AIV) 
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pathogenicity level is indexed by measuring the intravenous virus pathogenicity index 
(IVPI). The IVPI is the mean score per bird per observation over a 10-day period after 
AIV infection. During this period, an index of 0.00 is denoted to living birds without any 
clinical sign, while an index of 3.00 is denoted if all birds died within 24 hours. 
 
HPAI viruses are only of H5 and H7 subtypes but not all viruses of these subtypes cause 
HPAI. The deduced amino acid sequence at the HPAI cleavage site of the precursor 
haemagglutinin (HA0) contains multiple basic amino acids, arginine (R) and lysine (K) 
(Wood et al., 1994). The cleavage site allows ubiquitous proteases (furin and PC6) 
present in many body tissues, which may be induced by a subtilisin endoprotease, to 
activate the haemagglutinin (Horimoto et al., 1994). This will enable virus replication 
throughout the host, causing lethal damage to vital organs and tissues. Proteolytic 
activation is therefore crucial for effective virus spread and for virus pathogenicity (Rott, 
1979; Rott, 1992; Stieneke-Grober et al., 1992). In cell culture, a polybasic motif of –
R/K-X-K/R-R (X represents a nonbasic residue) is sufficient for a complete 
haemagglutinin cleavage but, if a carbohydrate chain is nearby, a X-X-R-X-R/K-R motif 
is needed (Vey et al., 1992; Wood et al., 1993, Horimoto et al., 1994; Senne et al., 1996; 
Ito et al., 2001). Alterations to the consensus sequence may lead to loss of pathogenicity 
for chickens.  
 
In contrast, LPAI have a single arginine at the cleavage site which limits cleavage to that 
by host proteases such as trypsin and trypsin-like enzymes, restricting the replication of 
the virus to sites in the host where such enzymes are found, such as in the respiratory and 
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intestinal tracts (Capua and Alexander, 2004). Recent evidence (Li et al., 1990; Rohm et 
al., 1995; Banks et al., 2000) clearly supports the hypothesis that HPAI may arise 
unpredictably from LPAI, in poultry or in the wild birds in which LPAI are endemic, by 
mutation at the cleavage site, probably by polymerase slippage in H5, or in other 
subtypes by recombination with other viral or non-viral RNAs (Garcia et al., 1996; 
Perdue et al., 1998). 
 
1.2.2 Determinants of host range and pathogenicity 
Pathogenicity determinants are found in several proteins independently or in 
combination. In addition to the widely-accepted HA and NA proteins of AIV as 
important AIV pathogenic determinants (Section 1.1.2), PB2, NS1 and PB1-F2 proteins 
have been recently identified to possess similar character. 
 
1.2.2.1 PB2 
In 1993, Subbarao and colleagues recognized a single amino acid substitution at position 
627 of PB2 as a host range determinant, with lysine often found in mammalian isolates 
and glutamate being normal in avian isolates. Eight years later, Hatta et al. demonstrated 
the importance of the lysine at PB2-627 in the HPAI H5N1 strain A/Hong Kong/438/97, 
compared to the glutamate at the same position in the LPAI H5N1 strain A/Hong 
Kong/436/97, to virulence in a mouse model, indicating the first report on pathogenicity 
effect of polymerase gene PB2. During a H7N7 influenza virus outbreak in poultry in 
2003, PB2-627K was found in the virus isolated from a lethal case, that of a Dutch 
veterinarian who died with pneumonia, while PB2-627E was invariably found in non-
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fatal human cases (Fouchier et al., 2004). It was later established that a lysine to 
glutamate alteration at PB2-627 of influenza A H1N1/PR/8/34 has profound effects upon 
the surface electric charges of PB2 3/3 domain (amino acids 535-759) and lowers its 
RNA-binding ability (Kuzuhara et al., 2009). However, this mutation does not increase 
the virulence of H1N1 2009 pandemic viruses in a mouse model (Zhu et al., 2010). Apart 
from substitutions at position 627, substitution of aspartate to asparagine at position 701 
of the PB2 protein of H5N1 Hong Kong 1997 or Vietnam 2003-2008 human isolates was 
found to confer lethality in mammals (Hiromoto et al., 2000; Li et al., 2005; Le et al., 
2010). Salomon et al. (2006) also emphasize that the human H5N1 A/Vietnam/1203/04, 
containing a polybasic HA cleavage site, still requires adaptive changes in proteins of the 
polymerase complex to retain its lethal phenotype. 
 
1.2.2.2 NS1 
In 2006, Li et al. demonstrated that two goose-derived H5N1 virus isolates, which both 
possessed polybasic amino acids at their HA cleavage sites, have divergent pathogenicity 
profiles in chickens. They showed that an alanine to valine substitution at position 149 of 
the NS1 protein in A/goose/Guangdong/1/96 results in antagonism of type I IFN 
production, resulting in a high mortality rate, while the inverse substitution attenuates 
A/goose/Guangdong/2/96.  
 
In a mouse model, substitution of proline for serine at NS1-42 increased the virulence of 
H5N1 A/duck/Guangxi/12/03 (Jiao et al., 2008), and a serine to glycine substitution at 
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the same position of the RNA-binding-defective NS1 of A/WSN/33 increased its 
virulence (Donelan et al., 2003).  
 
Recently, the presence of a PDZ ligand domain (acronym combining the first letters of 
three proteins, post synaptic density protein (PSD95), Drosophila disc large tumor 
suppressor (DlgA), and zonula occludens-1 protein (zo-1)) at the C-terminal residues 
(ESEV-COOH) of the NS1 protein (Obenauer et al., 2006), has been demonstrated to 
have the ability to enhance virulence in mice (Jackson et al., 2008). In chickens, 15-
nucleotide deletions at position 263-277 (Long et al., 2008) and 612-626 (Zhu et al., 
2008) of the NS1 gene were also found to increase or attenuate the H5N1 virus 
pathogenicity, respectively.  
 
1.2.2.3 PB1-F2 
Marjuki et al. (2010) reported a three amino acid changes in PB1-F2 protein of the H5N1 
virus A/Vietnam/1203/2004 associates with lethality rate of mallard ducks. In a mouse 
model, a single amino acid substitution, PB1-F2 66 N-S, was discovered to affect the 
pathogenicity of H5N1 Hong Kong 1997 virus and resurrected H1N1 pandemic 1918 
virus (Conenello et al., 2007). This point mutation also delays induction of IFN-β, 
retinoic inducible gene-I, RIG-I, and several IFN-inducible genes (Conenello et al., 
2010). PB1-F2 66 N-S substitution from the H1N1 pandemic 2009 virus also enhances 
expression of the proinflammatory genes IFN-γ, IL-1β, monocyte chemotactic protein-1 
(MCP-1), macrophage inflammatory protein (MIP-1β) and chemokine (C-C motif) 
ligand-5 (CCL-5, also known as RANTES [Regulated upon Activation, Normal T-cell 
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Expressed, and Secreted]) of infected mice, and dysregulates peripheral leukocyte and 
neutrophil levels in ferrets. The mutation is not, however, detrimental to the survival of 
either host (Hai et al., 2010).  
 
1.2.3 Immune responses to avian influenza virus  
1.2.3.1 Innate immune responses 
IFNs are secreted from most cells of vertebrate organisms. In response to viral infection, 
the IFN system is the key mechanism to inducing an antiviral state, which involves 
signalling pathways to induce the expression of a large number (Sen, 2001) of genes, the 
so-called IFN-stimulated genes (ISGs). The absence of IFN has even been shown to 
increase lethality upon viral infection of mice (Bouloy et al., 2001; Ryman et al., 2000) 
and humans (Dupuis et al., 2003) with an otherwise intact adaptive immune system.  
 
The roles and functions of many ISGs are unknown. However a number of the key 
antiviral effectors have been studied for many years and their roles and functions are 
becoming better understood. Amongst these are protein kinase R (PKR), RIG-I and Mx. 
PKR directly recognizes and autophosphorylates viral dsRNA, contributes to autophagy 
(degradation process of cytoplasmic portions) and activates transcription factor, nuclear 
factor-kB (NFkB). PKR upregulation by IFN-β also phosphorylates host eukaryotic 
initiation factor 2α, eTF-2α, to allow non-specific translation initiation inhibition of both 
host and viral protein synthesis (Garcia et al., 2006).  
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Another ISG, RIG-I, is able to sense viral intracytoplasmic dsRNA, initiating a signalling 
cascade that results in phosphorylation and nuclear translocation of cytoplasmic IFN-
regulatory factor-3, IRF-3, to induce IFN production (Grant et al., 1995). A recent study 
established that RIG-I is probably absent from chickens (but not ducks) and, somewhat 
controversially, suggests that this may explain the relative vulnerability of these species 
to influenza viruses (Barber et al., 2010). 
 
Secreted IFN-α/β can be recognised in an autocrine or paracrine manner by the type I 
IFN-receptor, IFNAR, on producing and neighbouring cells, respectively. IFNAR 
associates with Janus kinase family, JAK-1, or tyrosine kinase-2, TYK-2, thus allowing 
regulation of Signal Transducers and Activators of Transcription (STAT) 1 or 2. 
Phosphorylated STAT1/2 forms a complex, known as ISG factor-3 (ISG3), with IRF9, 
which then translocates to the nucleus and binds to IFN-stimulated response elements, 
ISREs, to instigate ISG transcription (Haller et al., 2006). Antiviral ISGs include 2'-5' 
oligoadenylate synthetase (OAS), which synthesises short 2’-5’ oligoadenylates to 
activate another ISG, ribonuclease L (RNaseL), which in turn directly cleaves cellular 
and viral RNA.  
 
Another antiviral ISG is myxovirus resistance protein, Mx, hypothesised to block ssRNA 
and dsRNA viruses by endocytosis and vesicle transportation (Sen, 2001). In a mouse 
model, expression of Mx protein enhances resistance to influenza viruses both in vitro 
and in vivo (Suarez and Schultz-Cherry, 2000b). Microarray gene expression analysis by 
Sarmento et al. (2008) indicates high level expression of IFN-α and myxovirus resistance 
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protein-1, Mx-1, upon HPAI H5N1 strain A/chicken/Hong Kong/220/97 virus infection 
of chickens. However, induction of PKR, Mx protein and IL-6 (cytokines secreted by T 
helper lymphocytes type 2) shows an abortive protection against HPAI H5N1 (Daviet et 
al., 2009). The influence of Mx protein induction is arguable as it provides a different 
antiviral response depending on chicken breed (Ko et al., 2002).  
 
AIV NS1 protein, however, has the ability to antagonise IFN pathways in several ways, 
including: binding and sequestering dsRNA (Garcia-Sastre, 2001), interfering with the 
activation of IRF3 (Talon et al., 2000), NFkB (Wang et al., 2000), Jun N-terminal kinase 
and AP-1 transcription factors (Ludwig et al., 2002). NS1 may also form an IFN-β-
inhibition-complex with RIG-I and PKR (Guo et al., 2007; Mibayashi et al., 2007; Opitz 
et al., 2007) and obstruct activation of the 2'-5' oligoadenylate synthetase/RNAseL 
antiviral pathway (Min and Krug, 2006). IFN pathways and their inhibition by NS1 are 
illustrated in Figure 1.1. 
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Figure 1.1. Schematic showing points of antagonism of the IFN pathways by AIV NS1 protein. 
(A) NS1 forms an inhibition complex with PKR, RIG-I, IRF3 or NFkB to block IFN induction. 
(B) NS1 directly neutralises the antiviral products of the ISGs. Modified from Haller and Webber 
(2007). 
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1.2.3.2 Adaptive immune response 
Host adaptive immunity against AIV can be divided into humoral and cell-mediated 
responses. Humoral immune responses include systemic (IgM and IgY) and mucosal 
(IgA) antibody production. These antibodies bind to the virus thus preventing virus 
attachment and entry. In comparison to internal and non-structural proteins of AIV, the 
surface proteins, HA and NA, are the main antigens capable of inducing neutralizing 
antibody, thereby acting as protective determinants in chickens (Suarez and Shultz-
Cherry, 2000). However, recent findings show influenza viruses have recombined and 
mutated their HA and NA protein, indicating evolutionary variability of the viruses 
(Steinhauer and Skehel, 2002; Fiers et al., 2004).  The external domain of the M2 surface 
protein, M2e, has also been shown to induce a response that reduces influenza virus 
infectivity, morbidity and mortality in vivo, despite its failure to elicit a strong humoral 
response, in mice (Neirynck et al., 1999; Fan et al., 2004). In chickens, immunization 
with recombinant Salmonella expressing M2e peptide conjugated with a tumor necrosis 
factor ligand family member, CD154, increases IgY responses significantly. The vaccine 
also provides protection and reduces viral shedding after LPAI, but not HPAI, viral 
challenge (Layton et al., 2009).  
 
Limited characterization of the chicken mucosal immune responses upon AIV infection 
were undertaken. Nonetheless, IgA was detected in bile ducks upon infection with 
different influenza isolates (Higgins et al., 1987). 
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Cellular immunity involves: (i) activation of macrophages which can produce cytokines 
and engulf foreign particles through phagocytosis, (ii) antigen-specific cytotoxic T-
lymphocytes and (iii) natural killer (NK) cells, which can release granzymes and 
perforins to induce apoptosis upon recognition of receptors on virally infected cells 
(Cullen and Martin, 2008). Human macrophages infected with influenza A H5N1 virus 
express high levels of mRNAs encoding tumor necrosis factor-α, TNFα, RANTES, 
MIP1α/β and MCP-1 (Cheung et al., 2002).  
 
The virus also triggers secretion of IFN-γ-stimulated protein (IP-10), interleukin (IL)-6, 
and RANTES in primary human bronchial and alveolar epithelial cells (Chan et al., 
2005). In an animal model, susceptibility to a lethal H5N1 virus infection of mice that 
lacked chemokine (C-C motif) ligand-2 (CCL2), IL-6 or TNFα is equivalent to those of 
wild-type (Salomon et al., 2007). In another study in TNFα signalling cascade-disrupted 
mice, the mortality rate was not significantly reduced despite the decreased morbidity 
(Szretter et al., 2007). Host adaptive immune responses observed upon AIV infection are 
illustrated in Figure 1.2. 
 
Recent data suggest that a series of the chicken's major histocompatibility complex 
(MHC; haplotype B2, B12, B13, B19 and B21), has a different influence on resistance to 
HPAI viruses (Hunt et al., 2010). In fact, Sarmento et al. (2008) suggest the possibility 
that AIV might have evolved a mechanism(s) to inhibit MHC Class I expression.  
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Figure 1.2. Overview of host adaptive immune response upon AIV infection. (A) HA-specific 
antibodies bind to the viruses’ HA proteins thus prevent infection of cells. (B) M2e-specific 
antibodies bind to M2e on virus-infected cells and induce antibody-dependent cell-mediated 
cytotoxicity (ADCC). (C) NA-specific antibodies block enzymatic activity of viral NA thus 
prevent progeny viral release. (D) Pathogens and proteins are broken down into peptides within 
acidified endosomes and bind to MHC Class II. The complexes are subsequently transported to 
the cell surface for recognition by CD4+ T cells. (E) The role of NP-specific antibodies is poorly 
known. (F) The proteosome degrades influenza viral proteins into peptides in the cytosol of the 
infected cell. The peptides are subsequently translocated to the endoplasmic reticulum and bind to 
MHC Class I. The peptide-MHC complexes are transported to the cell surface for recognition by 
CD8+ T cells, which then induce lysis of the infected cells. Modified from Flint et al (2004) and 
Bodewes et al. (2010). 
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1.2.4 Current H5N1 panzootic and human infection 
In 1997, 1.4 millions of chickens and various numbers of other domestic birds in Hong 
Kong were affected (either died of infection or were slaughtered) by HPAI H5N1 (Capua 
and Mutinelli, 2001). The HA gene of the virus derived from A/goose/Guangdong/1/96, 
the first H5N1 virus isolated from sick geese in Guangdong province in China a year 
before. In fact, most of HA genes of HPAI H5N1 viruses belong to this lineage (reviewed 
by Neumann et al., 2010). The outbreak caused 18 cases of human infections, of which 6 
were fatal. The infections represent the first documented fatal cases of influenza 
transmitted directly from avian species to humans (Subbarao et al., 1998).  
 
There were no reported cases of H5N1 infections in poultry or human after 1997 until 
February 2003, when the H5N1 panzootic began in many S.E. Asian countries including 
Hong Kong, Japan, Laos, Malaysia, Korea, Thailand, Vietnam with still ongoing 
reappearance of human cases in China, Indonesia, Egypt and Cambodia (Peiris et al., 
2004; Zhou et al, 2007). It is believed that the outbreaks originated in Yunnan and 
Guangxi provinces in 2002, have spread the virus to Indonesia and Vietnam, and other S. 
E. Asian countries (Wang et al., 2008). HPAI H5N1 predominated in China in early 2004 
when ducks, geese and chickens were being infected in 16 provinces. Then, after a major 
outbreak in many species of wild, migratory waterfowl and wading birds at Qinghai Lake 
in 2005-2006, the virus spread widely to around 60 countries including several Europe 
states (Gall-Recule et al., 2008), Russia (Lipatov et al., 2007), India, Australia, New 
Zealand and Mongolia (Chen et al., 2006). A new sub-lineage of the virus detected in 
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2005, China's 'Fujian-like' viruses, caused epizootics in Russia (Lvov et al., 2008), Hong 
Kong, Laos, Malaysia and Thailand.  
 
Since the re-emergence of H5N1 in 2003, there have been many reported cases of human 
infection. Until 16
th
 March 2011, Indonesia has reported their 174
th
 case, Egypt 130
th
 and 
Vietnam 40
th
, with the last fatality case occurred in Indonesia on 13
th
 February 2006. A 
typical case is that of a recent H5N1 human infection, identified in February 2006, where 
a 36-year-old man died from several complications, including respiratory failure, liver 
failure, renal failure and disseminated intravascular coagulopathy (Zhou et al., 2007). 
Although human to human spread has not generally been observed, infections of H5N1 
HPAI in humans have been a major concern as humans also possess the ubiquitous 
protease, furin (Capua and Alexander, 2007). Recent reports have identified the 
significant levels of α2,3-linked sialic acid, which is the preferential binding site for 
influenza viruses in avian host, in human epithelial cells from respiratory tract (Nicholls 
et al., 2007). However, the cooler temperature of human proximal airways (32
o
C) 
compared to distal airways (37
o
C) may restrict avian influenza virus replication, which 
occurs at 40 to 42
o
C in the avian enteric tract (Scull et al., 2009), thus limiting avian-to-
human spread.  
 
1.2.5 H5N1 outbreaks in poultry in Malaysia 
The first report of the presence of HPAI H5N1 in Malaysian poultry was in August 2004. 
The outbreak occurred among a free-range chicken flock in the state of Kelantan, near the 
Thailand border (Figure 1.3). A few cases continued to re-emerge in September and 
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November 2004 (WHO, 2008). Sequence analysis of the HA gene revealed that viruses 
isolated from both scenes were clustered with Vietnam’s and Thailand’s 2003-2005 virus 
isolates. The group was phylogenetically most closely-related to viruses isolated from 
domestic and migratory birds in Hong Kong in 2002-2003 (Chen et al., 2006). The 
outbreak was suppressed until 2006, when free-range chicken flocks in Selangor and 
Perak were infected in February and March, respectively. Early detection and a stringent 
control strategy allowed Malaysia to eradicate the virus in April 2006, shortly after the 
onset (Webster et al., 2006a; WHO, 2008). According to phylogenetic study of the HA 
gene, the Malaysian 2006 virus isolates (A/Chicken/Malaysia/935/2006) formed an 
independent sublineage with viruses isolated from ducks in Fujian, China in 2005, and 
distinctly separated from the 2004 cluster (Boltz et al, 2006; Wu et al., 2008). This 
evidence suggests that instead of being due to recirculating viruses of the previous strain, 
the 2006 outbreak represented a new introduction into Malaysia.  
 
In June 2007, an H5N1 outbreak, which involved semi-free ranging chickens, reappeared 
in a village in Petaling, Selangor. In line with its response to the previous occurrence, 
Malaysian authorities implemented a policy to rapidly cull and safely dispose of all 
infected birds, and the birds within a 1 km-radius of the affected flock, and set up a 10 
km-radius quarantine zone. Three months later, the World Organization of Animal Health 
(OIE) declared Malaysian poultry free of H5N1 viruses. 
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Figure 1.3. Map of Peninsular Malaysia, denoting the locations of HPAI H5N1 outbreaks in 
Malaysian poultry.  The first outbreak was reported among a free-range chicken flock in the state 
of Kelantan, near the Thailand border in August 2004. In February and March 2006, free-range 
chicken flocks in Selangor and Perak were infected, respectively. In June 2007, the 
outbreak re-emerged in a village in Petaling, Selangor, infecting semi-free ranging 
chickens. The Veterinary Research Institute, VRI, Ipoh, Perak, is indicated by a rectangle ( ), 
Regional Diagnostic Veterinary Laboratories is represented by a star ( ), while the H5N1 
outbreaks are denoted by a circle ( ). 
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1.2.6 Avian influenza vaccines  
Essentially four different types of avian influenza vaccines have been developed for use 
in poultry, namely (i) inactivated whole influenza viruses, (ii) in vitro expressed AIV 
proteins, (iii) in vivo expressed AIV proteins and (iv) nucleic acid (DNA plasmid) 
vaccines. For the past 30 years, vaccines against HPAI have been developed based on 
inactivated whole-virus, by using strains of LPAI viruses (LPAIV) isolated from 
outbreaks in poultry or from surveillance of wild or domestic birds (Swayne et al., 2008). 
Such vaccines were proved to work, with the notable feature of offering broad cross-
protection against diverse field viruses (Swayne et al., 2000). Recently, heterologous 
inactivated vaccines (H5N2 and H5N9-based isolates) with low homology (as low as 
84%) between their HA1 amino acid sequence and the challenge strains (2003-2004 
Asian H5N1 HPAI viruses), were shown to be protective against flock morbidity and 
mortality (Swayne et al., 2006; Bublot et al., 2007). Despite the effectiveness, inactivated 
vaccines carry several disadvantages. The foremost is biosecurity during the production 
of inactivated AI vaccines, the risk of virus escape and spread being high as they are 
cultivated in embryonated chicken eggs. Secondly, the yield of total viral protein also 
may be lower than expected, resulting in difficulties in large scale vaccine preparations 
(Lipatov et al., 2004). Furthermore, it is difficult to identify infected birds compared to 
vaccinated birds by routine serological tests. The potency of the vaccine is also highly 
dependent on antigen quantity in each dose and adjuvant system (oil emulsification).  
 
In a second approach to vaccination, ample amount of AI proteins can be expressed in an 
in vitro system, using eukaryotic cell cultures, plants (Nemchinov and Natilla, 2007), 
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yeast (Saelens et al., 1999), bacteria (e.g. Davis et al., 1983; Horthongkham et al., 2007) 
or viral vectors, such as baculovirus (e.g. Crawford et al., 1999; Hu et al., 2006). The 
crude or purified proteins can be administered as vaccines. Although the production of 
this vaccine is safer compared to inactivated whole AI vaccines, it shares the same 
drawbacks of high cost, and dose and adjuvant system-dependence.  
 
Thirdly, AI gene sequences can be inserted into bacterial or viral vectors producing 
recombinant vectored-vaccines, and their in vivo expression in the host (such as chickens) 
can be driven by live administration. In poultry, a replicative fowlpox virus-based vector 
expressing H5 of AIV vaccine (Webster et al., 1991) and more recently, a recombinant 
Newcastle Disease Virus (NDV)-based vaccine (Ge et al., 2007), have been licensed. 
These viral-vectored vaccines offer many advantages over inactivated whole virus, 
including co-immunisation against the vector agent, though with several limitations 
(discussed in Section 1.3.7 and 1.3.8). 
 
Fourthly, vaccines based on DNA plasmids with cDNA inserts that code for AI proteins 
(also termed nucleic acid vaccines or DNA vaccines), have been shown to be efficacious, 
with HA gene inserts being the most immunogenic (van den Berg et al, 2008). The 
plasmids elicit immune response via their uptake and expression by antigen-presenting 
cells or myocytes (Suarez and Schultz-Cherry, 2000b). Rao and colleagues (2008) have 
shown that DNA vaccines using multivalent HA are able to protect chickens against 
HPAI H5N1 strain A/Vietnam/1203/2004.  Several advantages of this type of vaccine are 
(i) they are readily modifiable upon identification of circulating virus strain, and (ii) large 
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scale production is feasible (Hoare et al., 2005). The main problem of DNA vaccines is 
inefficient gene delivery and expression. An alternative way for its delivery is to use 
Shigella flexneri (Vecino et al., 2004) or Salmonella typhimurium (Qu et al., 2008), while 
the cellular uptake might be enhanced by using application of a short electrical pulse to 
muscle tissues (Liu et al., 2008).  
 
1.2.7. AI vaccination policy in Malaysia  
In Malaysia, as in Europe, vaccination against avian influenza among poultry is 
considered a last resort, as the virus may circulate undetected, resulting in endemicity 
(Veits et al., 2008). However, the Malaysian Government realizes the potential of 
vaccination as a complementary measure in the eradication of HPAIV.  
 
1.3 Poxvirus vectors 
The Poxviridae family is divided into two subfamilies, Chordopoxvirinae, and 
Entomopoxvirinae, which infect vertebrates and insects, respectively. The 
Chordopoxvirinae are subdivided into eight genera (Orthopoxvirus, Parapoxvirus, 
Avipoxvirus, Capripoxvirus, Leporipoxvirus, Suipoxvirus, Molluscipoxvirus and 
Yatapoxvirus) and are better characterized than Entomopoxvirinae (in which subdivided 
into three genera, Entomopoxvirus A, B and C).  
 
1.3.1 Vaccinia virus 
Vaccinia virus (VV) is a type-species of Orthopoxvirus. Most genes characterized from 
poxviruses are from VV. In addition, studies on host innate immunity response upon 
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poxviruses infection are also more ascertained on VV. Four morphologies are displayed 
by a VV, (i) intracellular mature virus (IMV), which have one or two surrounding 
membranes, (ii) intracellular enveloped virus (IEV), which derived from a second 
membrane wrapping event from the trans golgi, (iii) extracellular enveloped virus (EEV), 
and (iv) cell-associated enveloped virus (CEV), which attached to the cell surface to 
allow induction of actin tail formation to be force away from the infected cell (Smith and 
Law, 2004). 
 
1.3.2 Avipoxviruses 
According to International Committee on Taxonomy of Viruses, ICTV, Avipoxvirus is 
the only genus in Chordopoxvirinae which infect birds, not mammals. More than 232 
species of the approximately 9000 bird species reported by van Riper et al. (2007) have 
acquired natural poxvirus infections, including the endangered Southern giant petrel, 
Macronectes giganteus, a long-lived, large, pelagic bird found in the Antarctica (Shearn-
Bochsler et al., 2008).  
 
1.3.3 Fowlpox virus 
Possessing a large double stranded DNA genome up to 300 kb, Fowlpox virus (FWPV) is 
the best-studied and type species of the Avipoxvirus (Skinner et al., 2005). Using 
improved microscope and histological technique, FWPV was first detected in chicken 
cells by Bollinger in 1873. The observed large, intra-cytoplasmic inclusion bodies were 
now termed Bollinger's inclusion bodies (Bolte et al., 1999). To date, two FWPV 
sequences have been determined; a virulent US FWPV with 288 kb genome (Afonso et 
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al., 2000), and an attenuated vaccine strain, FP9 with 266 kb genome (Laidlaw and 
Skinner, 2004). FWPV causes a widespread, contagious disease of poultry and other 
galliform birds, resulting in reduced egg production, decreased growth rates in broilers, 
blindness and may cause death (Afonso et al., 2000; Skinner et al., 2005). The common 
form of fowlpox is cutaneous, involving spread by biting insects. It is milder than the 
diphtheritic form, which involves droplet or dust-borne infection of the mucous 
membranes resulting in higher mortality (Afonso et al., 2000; Skinner et al., 2005).  
 
Replication of FWPV occurs exclusively in the cytoplasm of infected cells and the 
virions are nonicosahedral (Drillien et al., 1987). Productive replication of FWPV is 
restricted to avian cells. Although FWPV enters into, and induces synthesis of proteins in, 
mammalian cells, the production of infectious progeny virus is abortive (Afonso et al., 
2000; Skinner et al., 2005; Mingxiao et al., 2006). Foreign proteins expressed by 
recombinant FWPV (rFWPV) are displayed on the cell membrane in the case of viral 
surface glycoproteins (Taylor and Paoletti, 1988; Taylor et al., 1988).  
 
Field isolate strains of FWPV are likely to carry a near full-length, infectious provirus of 
reticuloendotheliosis virus (REV), which can cause REV dissemination with implications 
for FWPV virulence (Hertig et al., 1997). Proviral sequences have only ever been found 
at a single genomic location in FWPV, suggesting a single ancestral insertion (Moore et 
al., 2000). A more recent survey, however, showed FWPV can retain viability and 
produce disease in wild birds and poultry even when REV inserts are absent (Davidson et 
al., 2008). Most FWPV vaccines have lost REV coding sequences and retain only partial 
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REV-long terminal repeats, except the Australia vaccine strain FWPV-S, which carries a 
nearly full-length REV sequence, leading to its discontinued usage as a vaccine (Singh et 
al., 2000).  
 
The morphogenesis of Avipoxviruses appears to differ from that elucidated for the 
Orthopoxviruses such as VV (Boulanger et al., 1998) (Section 1.3.1), in that IMV 
particles acquire their additional external membrane to form EEV by budding at the cell 
membrane rather than by wrapping with a double intracellular membrane at the trans-
golgi network or endosomes with subsequent loss of the outer of these two membranes by 
fusion at the cell membrane. 
 
1.3.4 Fowlpox virus strain FP9 
Following embryo passage then 438 serial passages of the European virulent FWPV 
strain HP-1 in chicken embryonic fibroblast cells (CEF), the derived, attenuated strain 
HP438 (Mayr and Malicki, 1966) was passaged twice further in CEF at a low multiplicity 
of infection (MOI) and plaque-purified twice to obtain the laboratory-adapted, highly 
attenuated FWPV strain FP9 (Mockett et al., 1992). The FP9 genome was mapped and 
compared with that of Vaccinia virus (VV), the type species of Orthopoxvirus genus 
(Mockett et al., 1992), and later its complete sequence was compared with pathogenic 
FWPV strains USDA and HP-1 (Laidlaw and Skinner, 2004). Passage-specific mutations,  
which are probably involved in FP9 attenuation, affect no more than 46 open reading 
frames (ORFs), especially members of protein families such as the Ankyrin repeat (a 
stretch of well-conserved 33 amino acids with protein-binding role) proteins, rather than 
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obvious immunomodulator genes. However, the specific determinants and mechanism of 
attenuation remains unclear (Laidlaw and Skinner, 2004).  
 
FP9 encodes 247 predicted ORFs, numbered as orthologues of FWPV USDA, e.g. 
fp9.002 (left) to fp9.259 (right), and contains 10.2 kbp inverted terminal repeats (ITRs; 
Laidlaw and Skinner, 2004). FWPV USDA encodes 260 putative genes and contains 9.5 
kbp ITRs (Afonso et al., 2000). Several genes non-essential for viral replication have 
been described, such as FP-SNAP, FP-CEL1 and FP-PC1, which are all homologues of 
cellular genes (Laidlaw et al., 1998). The nature of an immunodominant 39K core protein 
encoded by fp9.168 and an orthologue of VV A4L has been described (Boulanger et al., 
1998). FP9 carries only a partial long terminal repeat of REV (Laidlaw and Skinner, 
2004).  
 
1.3.5 Immune response to fowlpox virus infection 
1.3.5.1 Immune responses to abortive fowlpox virus infections in mice 
Recently, Lousberg et al. (2010) identified the role of plasmacytoid dendritic cells, pDCs, 
as major inducers of Type I IFNα/β upon FWPV infection, in mice. This finding 
corresponds to the known behaviour of FP9, which is to activate mammalian dendritic 
cells (Brown et al., 2000; Morse et al., 2005).  
 
VV-encoded IFN modulators have been described extensively. They include the VV E3 
intracellular protein, which binds and sequesters dsRNA thus inhibiting IFN induction 
(Davies et al., 1992) as well as preventing activation of PKR and 2’, 5’-OAS; the soluble 
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B18 protein which binds extracellular IFN (Symons et al., 1995) and a soluble 43 kD 
protein (B8R), which binds IFN-γ of human, cow, rabbit and rat hosts as well as that of 
chickens (Alcami and Smith, 1995).  
 
Three FWPV genes were identified as encoding the major immunodominant proteins in 
mice. They were fpv140 (encoding the FWPV 30/35 kD orthologue of VV H3), fpv168 
(encoding the FWPV 39 kD orthologue of VV A4) and fpv191 (encoding the FWPV 
orthologue of VV p4c) (Laidlaw and Skinner, 2004). The most highly immunogenic part 
of fpv168 is the central 131-amino acid repeat region (Boulanger et al., 1998).  
 
Several studies have addressed the FP9 ability to elicit CD4+ or CD8+ T-cell responses 
against antigens in mice, including Webster et al. (Webster et al., 2006b), in which FP9 
was shown to be immunogenic for CD8+ T cells and capable of inducing protective 
efficacy, with or without prime-boost combinations with pre-erythrocytic malaria antigen 
thrombospondin-related adhesion protein and a string of CD8+ epitopes (METRAP). FP9 
also confers higher cellular immunogenicity against recombinant antigens from 
Plasmodium berghei (circumsporozoite protein) or human immunodeficiency virus type 
1 (a Gag-Pol-Nef fusion protein), when given as a priming or boosting dose, compared to 
Webster FPV-M FWPV strain (Cottingham et al., 2006). The prime-boost approach 
relates to initial introduction of a specific antigen to develop immune response against 
that antigen, followed by secondary presentation of that same antigen using a different 
vector in order to focus the immune response on the shared antigen rather than on vector 
proteins. Frequently in experimental approaches, DNA plasmid expressing the antigen is 
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used as a prime, whilst a viral vector, for instance FWPV, expressing the same antigen is 
used as a boost (though different viral vectors may be used instead of, or in addition to, 
the DNA prime).  
 
1.3.5.2 Immune response to fowlpox virus infection in the permissive avian host 
Understanding of avian immune responses against FWPV is paradoxically still very 
limited in comparison to understanding of mammalian host responses. A study by Singh 
and Tripathy (2003) shows ex vivo supernatants of buffy coat cells from chickens 
infected by FWPV is able to promote a lymphoproliferative response lasting for 2-4 
weeks post-infection. The supernatants contain elevated levels of an approximately 48–
50 kD protein, able to stimulate naive, non-adherent cells of the buffy coat cultures, in a 
dose dependant manner, postulated to be a stimulatory cytokine such as IFN-α, IL-15 or 
IL-2. The proliferative effect was followed by anti-FWPV antibody production. Hghihghi 
et al. (2010) further demonstrated an early stimulation of Type I IFNs, TLRs (3 and 7), 
cytokines (IL-1β and IL-8) and beta-defensin genes after TROVAC-AIV H5 infection of 
cultured CEFs. Higher expression was also observed for IFN-γ and IL-10 in spleen cells 
from vaccinated chickens, compared to controls. TROVAC-AIV H5 is a commercial, 
recombinant fowlpox vaccine against AIV with H5 gene insert from H5N9 strain 
A/Turkey/Ireland/83. 
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1.3.6 Putative immunomodulators encoded by fowlpox virus 
Several putative orthologues of cytokines and chemokines, including TGF-β (fpv080), β-
nerve growth factor (fpv076) and CC-like chemokines (fpv060, fpv061, fpv116 and 
fpv121) of FWPV, have been identified (Afonso et al., 2000; Laidlaw and Skinner, 
2004). A potential NK cell receptor, C-type lectin, found in US FWPV is predicted to 
bind MHC Class I and modulate immune activity through intracellular signalling 
pathway (fpv198). IL-18 have also been predicted in both US FWPV and FP9, using in 
silico sequence analysis (Afonso et al., 2000; Laidlaw and Skinner, 2004). IFN- γ is a 
Type II IFN which activates macrophages and upregulates MHC Class II expression on 
cell surface. Based on studies of IL-18-binding protein from the host and from other 
poxviruses (Xiang et al., 1999), it was proposed that the FWPV IL-18-binding protein 
homologue might inhibit IL-18-dependent IFN-γ production in infected cells (Afonso et 
al., 2000).  
 
Banadyga et al. (2007) identified fpv039 as a mitochondria-localised, anti-apoptotic 
protein, which shares homology to the anti-apoptotic cellular protein Bcl-2. fpv039 is 
intact in FP9 (Laidlaw and Skinner, 2004). 
 
1.3.7 Recombinant fowlpox vaccines for poultry  
Live FWPV vaccines have been used successfully in the poultry industry since the 1920s; 
many such commercial vaccines are now available but in most cases there origins and 
extent of attenuation are not publicly known. Since the late 1980s, rFWPV based on these 
attenuated FWPV have been developed to express antigens from several important avian 
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pathogens, including: avian influenza virus (AIV) (e.g. Taylor et al., 1988; Bublot et al., 
2006), Newcastle disease virus (NDV) (e.g. Boursnell et al., 1990; Sun et al., 2006) and 
Marek’s disease virus (MDV) (e.g. Nazerian et al., 1992; Lee et al., 2003). rFWPV 
recombinants expressing H5 protein of AIV were initially marketed in Mexico against 
HPAI H5N2 in 1995, and now are being used in S.E. Asia against H5N1. To date, two 
billion doses of rFWPV-AIV H5 vaccine have been provided in Mexico alone (Swayne et 
al., 2008). The H5 gene inserts for these rFWPV-AIV are from A/Turkey/Ireland/83 
(H5N9), or A/Goose/Guangdong/96 (H5N1). rFWPV, and other viral vectored-vaccines 
(such as NDV-based vaccines), hold several advantages over the conventional inactivated 
influenza vaccines. Firstly, uninfected poultry vaccinated with recombinant vectors can 
be differentiated from infected animals in so-called DIVA (Differentiating Infected from 
Vaccinated Animals) assays using commercial anti-NP ELISA tests or agar gel 
precipitation (AGP), as the former do not demonstrate antibodies to NP and M (Suarez, 
2005; Mingxiao et al., 2006). The other obvious advantage is that the production of these 
vaccines in cell culture possesses less risk of accidental influenza virus release. 
Furthermore, NDV vectors were shown to induce a broad immunity, including humoral, 
cellular and mucosal responses (Ge et al., 2007). Moreover, the vectored-vaccines also 
were proven to provide bivalent vaccination (AI and FWPV or NDV, depending on the 
vector), though this is only of value to the industry in those regions where the vector 
virus is endemic (Steel et al., 2008).  Finally, the recombinant vectored-vaccine is safer 
for humans or for the poultry and reliable as it avoids use of the adjuvant which is a 
component of an inactivated vaccine (Swayne et al., 1997; Qiao et al., 2003; Mingxiao et 
al., 2006; Qiao et al. 2006). Although the purpose of adjuvants is to increase the immune 
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response to the vaccine, the absolute safety of adjuvants can never be guaranteed. There 
still can be an accidental stimulation of various mechanisms of the immune responses by 
the adjuvants (Edelman et al., 1980, Gupta et al., 1993).  
 
FWPV and NDV-based recombinant AI vaccines are designed to be inoculated in 1-day-
old chick at the hatchery. Advantages of hatchery vaccination are: (i) biosecurity at 
hatcheries are higher compared to farms, (ii) automatic or semi-automatic administration 
systems are possible, (iii) lower numbers of hatcheries than farms, thus vaccination 
controls are focused to particular area, (iv) different vaccines can be mixed 
simultaneously, and (v) vaccinated chicks at hatcheries are protected at a younger age 
compared to those vaccinated in farms (Bublot et al., 2005; van den Berg et al., 2008).  
 
1.3.8 Limitations of viral-vectored vaccines against avian influenza virus 
Use of rFWPV vaccines, as with other viral-vectored vaccines (especially NDV-based), 
is only effective in chickens without prior vaccination and exposure to field strains of 
FWPV or the other respective viral-vectors (Swayne et al., 2000). Pre-existing immunity, 
whether humoral (which may be maternally-derived) and/or cell-mediated, may restrict 
infection by, and expression from, the vaccine vector. This might be expected to limit the 
efficacy of the vaccine (Skinner et al., 2005). Nevertheless, limited field evidence 
suggests that the presence of maternal antibodies to FWPV and AIV or NDV, does not 
interfere with the immunity induction by rFWPV (Bublot et al., 2005; Taylor et al., 
1996). 
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Vaccination with rFWPV requires introduction to poultry via scarification (Boyle and 
Heine, 1994). This is more labour intensive for mass vaccination than is application in 
drinking water or by aerosol, but is aided by semi-automatic vaccinators and is more 
reliable (Skinner et al., 2005). Moreover, it is not an additional burden in those parts of 
the world where FWPV vaccination is already required due to endemic fowlpox. An 
alternative approach for mass application is in ovo vaccination. A field trial for 
multivalent in ovo vaccination, which included a rFWPV expressing Newcastle disease 
virus F and HN genes, demonstrated that the method was successful in the protection 
against both FWPV and Newcastle disease virus (Sharma et al., 2002). NDV-based 
vaccines can be administered via eye drop (Jeon et al., 2008) but this too is labour-
intensive. The mass vaccination technique of aerosol application is more appropriate but 
the need to use day-old chicks means that maternal immunity becomes a major problem. 
 
A recent study by Wambura et al. (2010) described the possibility of mass oral 
vaccination using thermostable live FWPV (strain TPV-1) coated on oiled rice, as the 
protective efficacy is equivalent to the conventional wing web stab route. However, the 
specified vaccine strain is used against field FWPV antigens; hence more study is needed 
to manipulate the vaccine virus genome to carry different viral antigens. 
 
Approaches to explore ways of improving the efficacy of rFWPV, for laboratory-based 
studies, would include co-expression of some host-derived immunomodulators, such as 
cytokines (discussed in the next section). However, there are concerns about this 
approach. For instance, it might conceivably lead to inappropriate responses against other 
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infectious agents. Moreover, there is still considerable sensitivity over experiments 
conducted in Australia in which recombinant Ectromelia (mousepox) virus expressing IL-
4 were shown to be more pathogenic, even breaking through genetic resistance and 
partially overcoming protective immunity (Jackson et al., 2001) This is of particular 
concern should the immunomodulator genes transfer to wild type strains via 
recombination during coinfections of wild type and vaccine viruses. Therefore, it is still 
doubtful whether licenses will be granted for commercial rFWPV vaccines co-expressing 
host immunomodulator genes (Skinner et al, 2005). 
 
1.4 Cytokines 
Cytokines are small, soluble proteins secreted especially by cells of immune system 
immediately after infection or vaccination. The proteins mediate and regulate the 
intensity and duration of responses comprised of a multitude of effects ranging from 
activation and differentiation of immune or nonimmune cells, to enhancing immune 
function (Hilton et al., 2002; Degen et al., 2004). In 1986, Mosmann and Coffman first 
divided cloned, murine helper T lymphocytes, Th, into two functional subsets based on 
their secreted immunomodulator cytokines. The terms Th1 and Th2 were used for IFN-γ 
and IL-4-secreting Th lymphocyte clones, respectively. However, the existence of a 
broad spectrum of cytokine secreting cells, including multiple other haematopoietic cells 
and even non-haematopoietic cells, has required new terminologies, Th1-like and Th2-
like, which are more suitable for in vivo immune dysregulation diseases and conditions 
(Lucey et al., 1996). Table 2 shows several Th1-like and Th2-like cytokines produced by 
primary cultures of all leukocyte types. 
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Table 1.1. Leukocyte sources of Th1-like and Th2-like cytokines 
Leukocyte 
 cell type                                  Secreted cytokine (s) 
 Th1-like Th2-like 
Lymphocyte   
    CD4+ T cell IL-2, IFN-γ, IL-12, IL-15, TNF-β IL-4, IL-5, IL-6, IL-10, IL-13, IL-17 
    CD8+ T cell IL-2, IFN-γ, IL-15 IL-4, IL-5, IL-10, IL-17 
    B cell IL-12, TNF-β IL-6, IL-10 
    NK cell IFN-γ, TNF-β  
Monocyte IL-12 IL-6, IL-10 
Macrophage IL-12, IL-18 IL-6, IL-10 
Dendritic cell IL-12, IL-18  
Neutrophil IL-12  
Mast cell  IL-4, IL-5, IL-6 
Eosinophil  IL-4, IL-5, IL-6 
Basophil  IL-4 
* Modified and updated from Lucey et al., 1996 
 
Th1 cytokines, for instance IL-2, IFN-γ and TNF, are principally involved in the 
activation of cell-mediated immunity, while Th2 cytokines (e.g. IL-4, IL-5 and IL-6) 
generally affected in B cells stimulation to regulate humoral immunity (Hilton et al., 
2002; Degen et al., 2004). In general, cell-mediated immunity is postulated to be more 
critical in viral clearance, during primary infection, as host defence against infections are 
principally mediated by Th1 cells (Ada and Jones, 1986; Bender et al., 1992; Doherty et 
al., 1997).   
 
1.4.1 Cytokines as vaccine adjuvants 
Some cytokines have been proven to perform as effective immunomodulators in animal 
models or clinical tests, for instance IL-1 to IL-8, IL-12, IL-18, type 1 IFN, colony-
stimulating factor and tumour necrosis factor, TNF (Mingxiao et al., 2006). These 
cytokines have been used extensively in mammalian models as vaccine adjuvants, 
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including in tumour immunotherapy (e.g. Dredge et al., 2002, Hance et al., 2009), DNA 
vaccines (e.g. Hartoonian et al., 2009, Wei et al., 2009), bacterial vaccines (Kajikawa et 
al., 2010), and live viral vaccines (e.g. Kittel et al., 2005).  
 
In contrast to extensive studies of mammalian cytokine genes, chicken cytokine gene 
identification, cloning and characterization has lagged considerably. Moreover, almost all 
of the cytokines that have been successfully cloned in chicken are Th1-like. Recent 
discovery and characterization of avian cytokines including IL-1β and IL-6 (Kaiser et al., 
2004), IL-2 (Sundick and Gill-Dixon, 1997; Zhou et al., 2005), IL-10 (Rothwell et al., 
2004), IL-12β (Balu and Kaiser, 2003), IL-12 (Degen et al., 2004), IL-15 (Choi et al., 
1999; Lillehoj et al., 2001), IL-18 (Schneider et al., 2000) and IL-19 (Kim et al., 2009), 
has triggered their development as vaccine co-immunostimulators and have allowed the 
study of their effectiveness. For instance, Yang et al. (2009) have demonstrated a novel 
method of incorporating bioactive chicken IL-2 and chicken granulocyte-macrophage 
colony-stimulating factor (GM-CSF) on the surface of killed influenza virus particles. In 
another report, cell-cultured NDV vaccine co-administered with chicken IL-18, which 
was expressed in either prokaryotic or eukaryotic system, was shown to augment 
proliferation of peripheral blood mononuclear cells (PBMC), CD8+ to CD4+ ratios and 
haemagglutination inhibition (HI) titres, compared to chickens vaccinated with NDV 
alone. Although the innate immune response of avians is not well-characterized, their 
immune system is closely comparable to that of mammals, with few clear differences. 
Unlike mammals, chickens do not have lymph nodes and the site for antigen presentation 
is still questionable. Chickens do have a unique organ called the bursa of Fabricius, 
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which filled with numerous polyhedral follicles composed of lymphatic tissue and critical 
for development of B cells (William et al., 2006). Chickens also have a different antibody 
repertoire (IgM, IgA and IgY) and mechanism of generating antibody diversity, 
compared to mammals (Reynaud et al., 1994). Moreover, chickens have a minimal 
essential MHC with the size and content is much reduced than that of mammals 
(Kaufman et al., 1999). 
 
1.4.2 IL-15 
Sharing structural and functional characteristics with IL-2, IL-15 is another T cell growth 
factor that plays crucial roles in cell-mediated immunity, for instance in inducing B cell 
proliferation and promoting CTL memory (Min et al., 2002; Stevceva et al., 2006). While 
IL-2 is selectively expressed in activated T cells, IL-15 mRNA is distributed widely in 
many tissues and cell types (Grabstein et al., 1994). IL-2 and IL-15 also elicit 
overlapping immune functions in activation of cytotoxic effector cells and monocytes, 
and B cell immunoglobulin (Ig) synthesis via co-stimulation. In synergy with IL-12, IL-
2R-bound IL-15 was found to enhance the production of IFN-γ by up-regulating natural 
killer (NK) cells (Carson et al., 1994). NK cells offer direct or indirect lytic activity 
against intracellular pathogens, and aid the immune system to build an adaptive immune 
system to eliminate the pathogen. Thus, in virus invasion, any defect in NK cells may 
weaken the host defence mechanism (Fawaz et al., 1999; Perera et al., 2001).  
 
Chicken IL-15 was first characterized by Choi and colleagues in 1999. They 
demonstrated that chicken IL-15 expressed in E. coli and CHO cells confers growth 
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promoting activity. It shares highest sequence homology with bovine IL-15 (31% 
identity, 43% similarity) compared to other mammals. Although the homology was 
relatively low, the putative chicken IL-15 sequence conserved four essential cysteine 
residues for the biological activity of mammalian IL-15. It was later verified that the 
chicken IL-15 gene possesses 187 amino acid ORF encoding a predicted 22 kD protein 
with two potential N-linked glycosylation sites that can stimulate spleen lymphoblast cell 
proliferation and enhance NK cell activity in vitro, activities similar to those of 
mammalian IL-15 (Lillehoj et al., 2001). 
 
1.4.2.1 Use of IL-15 as co-immunostimulatory molecule in vaccines 
In mice, recombinant Vaccinia virus (rVV) co-expressing gp160 of human 
immunodeficiency virus (HIV) and hIL-15 has been shown to provide a stronger and 
more enduring response than rVV expressing gp160 alone (Oh et al., 2003). Integration 
of human IL-15 into rVV Wyeth strain and modified VV Ankara, MVA, also resulted in 
better survival rate of athymic nude mice (Perera et al., 2007) and an enhanced in vivo 
viral clearance (Zielinski et al., 2010) upon lethal intranasal challenge with virulent VV, 
or intravenous challenge with monkeypox virus strain Zaire 79, respectively. Against 
bacterial infection, the group illustrated highly persistent protective immune responses, 
induced upon vaccination with recombinant MVA co-expressing IL-15 and five 
Mycobacterium tuberculosis antigens, in a homologous prime boost regime study against 
tuberculosis (Kolibab et al., 2010). Enhanced CD4 and CD8 T cell memory responses, 
along with reduction in lung mycobacterial load in lungs, were also observed in mice 
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infected with Bacille Calmette-Gue´rin (BCG) vaccine, supplemented with IL-7 and IL-
15 recombinant proteins, but not IL-1, IL-6 and IFN-α (Singh et al., 2010).  
 
In limited avian model studies, in ovo plasmid DNA vaccination against an intestinal 
coccidial parasite parasite, Eimeria acervulina, using gene 3-1E coexpressed with 
chicken IL-15, has been shown to induce higher serum antibody response than 
immunization with 3-1E alone. Following challenge with the homologous parasite, 
chickens vaccinated with 3-1E and IL-15 showed a significant decreased in oocyst 
shedding and had an increased body weight, compared to chickens vaccinated with 3-1E 
alone (Ding et al., 2004; Lillehoj et al., 2005). Similar results were obtained when the 
construct was given subcutaneously (Min et al., 2001) or intramuscularly (Ma et al., 
2011). The effect in poultry of co-expression of IL-15 by rFWPV has not been previously 
studied. 
 
1.4.3 IL-12 
Functional IL-12 (IL-12 p70) is a heterodimeric protein (70 kD in mass), consisting of 
two disulphide-linked subunits, p35 (or IL-12α) and p40 (or IL-12β); heterodimerization 
being important for the manifestation of IL-12 bioactivity. IL-12 is produced by 
mononuclear cells, macrophages, dendritic cells and B lymphocytes (Stevceva et al., 
2006). In mammals, IL-12 was showed to mediate diverse effects on T cells and NK 
cells, including T cell proliferation and differentiation, and induction of IFN-γ production 
by NK cells (Trinchieri et al., 2003). Expression of mRNA for IL-10, which is a crucial T 
cell regulator and potential Th1 pathway modulator, was also increased in IL-12-treated 
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mice (Lynch et al., 2003). Chicken IL-12 was first isolated and characterized by Degen 
and co-workers in 2004 (Degen et al., 2004). Although chicken IL-12 subunits showed 
restricted sequence homology (21% to 41% amino acid identity) to mammalian IL-12, 
the study indicated they share many functional similarities. For instance, in order to 
stimulate chicken cell proliferation, the chicken IL-12 p40 subunit has to be combined 
with the p35 subunit. Expression of bioactive chicken IL-12 has been achieved in 
eukaryotic systems, such as baculovirus and COS cells (Degen et al., 2004), E. coli 
(Thomas et al., 2008) and plant systems (Medrano et al., 2010).  
 
Neonatal mice demonstrate a reduction in peripheral expression of IL-12 compared to 
adult mice. Upon exposure to antigens, neonates treated with IL-12 within 24 hours of 
birth were shown to increase IFN-γ and IL-10 mRNA expression in their spleens. Higher 
IgG2a and IgG2b antibody levels were observed upon adulthood challenge of treated 
mice, compared to untreated mice, suggesting the potential use of IL-12 to enhance early 
immunity and memory antibody responses against childhood pathogens (Arulanandam et 
al., 1999).  
 
1.4.3.1 Use of IL-12 as co-immunostimulatory molecule in vaccines 
Many studies involving recombinant IL-12 have been performed in mouse models. 
Although IL-12 is predicted to direct the early host immune defence against Influenza A 
virus infection (Hama et al., 2009), reports from studies of influenza virus infection offer 
contradictory results, as administration of recombinant IL-12 to influenza virus-infected 
mice either enhanced (Tsurita et al., 2001) or delayed (Kostense et al., 1998; van der 
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Sluijs et al., 2006) the virus clearance. Van der Sluijs and co-workers (2005) also 
observed augmented virus clearance for influenza virus-infected IL-18-deficient mice. 
This result was in contrast to results observed by Gherardi et al. (2003) and Denton et al. 
(2007).  
 
Upon bacterial infection with Streptococcus pneumoniae, previous coadministration of 
murine IL-12 as adjuvant for pneumococcal polysaccharide conjugate vaccines, enhances 
IFN-γ mRNA expression, IgG2a antibody levels (Buchanan et al., 2001; Lynch et al., 
2003), IL-10 mRNA expression and opsonic activity (Lynch et al., 2003; a process by  
which opsonins make foreign molecules more susceptible to phagocytosis). Similar 
observations were made when murine IL-12 was used as adjuvant for conjugate vaccines 
against Neisseria meningitidis meningococcus (Buchanan et al., 2001), while 
coadministration of exogenous IL-12 with live, attenuated Francisella tularensis vaccine 
enhanced the protective efficacy of the latter in mice upon lethal intranasal challenge 
(Baron et al., 2007). However, there are concerns about adverse effects in human subjects 
upon co-administration of recombinant human IL-12 in pneumococcal polysaccharide 
vaccine, indicated by injection site pain, injection site reaction, fever, headache, myalgia, 
general pain, asthenia, chills and increased cough (Hedlund et al., 2001). 
 
1.5 Use of host cytokines in recombinant fowlpox vaccines 
A recombinant fowlpox vaccine co-expressing HA of AIV H5N1 and chicken IL-18 
(Mingxiao et al., 2006) has been described. The result showed that all chickens 
vaccinated with rFWPV-HA-IL-18 had higher levels of cellular immunity compared to 
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those vaccinated with rFWPV-HA alone. Similar outcomes were observed in a study to 
protect chickens against a birnavirus, infectious bursal disease virus (IBDV), using 
rFWPV co-expressing IL-18 and an IBDV structural protein (Eldaghayes, 2005). Pigs 
inoculated with a rFWPV co-expressing GP5/GP3 of porcine reproductive and 
respiratory syndrome virus (PRRSV) with swine IL-18 were also endowed with a 
stronger immune response and better protection compared to rFWPV-GP5/GP3 alone 
(Shen et al., 2007). More recently, chickens vaccinated with rFWPV co-expressing the 
VP2 protein of IBDV and IL-12 alone, or IL-12 co-administered with mineral oil, have 
demonstrated enhanced levels of IFN-γ in serum and splenocyte cultured supernatant, as 
well as serum neutralizing antibodies against IBDV, than those vaccinated with mineral 
oil alone (Su et al., 2011). 
 
1.6 Project aims 
The general aim of the project is to evaluate the potential adjuvant effects of chicken IL-
12 and IL-15, coexpressed with AI genes in rFWPV, with the hope of possible 
improvements to current H5N1-rFWPV vaccines. The cytokines were chosen mainly due 
to their ability to induce IFN-γ, which might be postulated to enhance cell-mediated 
immunity, and their novelty as immunostimulatory molecules in recombinant virus 
vaccines. Co-expression of IL-18 was not pursued as part of this project, as such studies 
were already underway within the Skinner group at Imperial College London in 
collaboration with scientists at the Institute for Animal Health, Compton.  
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This present investigation may enable several key questions pertinent to the role and 
function of avian cytokines to be answered: 
1) Do IL-15 and IL-12 confer any significantly enhanced cellular immune response in 
chickens, as has been extensively demonstrated in mice? 
2) Does co-expression of IL-12 in rFWPV-AI vaccines stimulate adverse toxicity effects 
in chickens, as was shown when it was coadministered with pneumococcal 
polysaccharide vaccine? 
3) How appropriate would the cytokines be as adjuvants in readily available rFWPV-
influenza vaccines?  
 
1.6.1 Project objectives 
In order to address the general aim, the following specific objectives were envisaged: 
 (i) to generate rFWPV expressing avian influenza H5, N1 and NP genes 
(ii) to insert into these rFWPV recombinant genes encoding chicken IL-12 or IL-15 
(iii) to vaccinate poultry using these recombinants and monitor any adverse clinical signs 
and 
(iv) to elucidate the vaccine potential of the cytokines in enhancing humoral and cellular 
responses in poultry, post-vaccination. 
 
1.7 Thesis summary 
Co-expression of avian cytokines IL-15 and IL-12, by recombinant rFWPV already 
expressing AI antigens, may add to the limited laboratory studies on cytokine effects in 
avian model.  
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Chapter 2 describes the general methodology used in this study. 
Chapter 3 describes the cloning strategy and construction method to generate the 
recombinant vaccines. 
Chapter 4 describes the results of animal studies involving vaccination with rFWPV-AI 
co-expressing IL-15. 
Chapter 5 describes the results of animal studies involving vaccination with rFWPV-AI 
co-expressing IL-12. 
Chapter 6 describes the effect on host body weight of chicken IL-15 or IL-12 co-
expressed from recombinant fowlpox viruses. 
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CHAPTER 2 
Materials and Methods 
 
2.1 Plasmid vectors 
2.1.1 pCR2.1-TOPO 
Vector pCR2.1-TOPO is a TA cloning vector, 3931 bp in length. It contains ampicillin 
and kanamycin resistance genes and a multiple cloning site (MCS) downstream of the 
Lac promoter which drives expression of, a LacZ gene. An insertion within the MCS 
interrupts the coding sequence of β-galactosidase, allowing recombinant clones to be 
identified as white colonies compared to blue colonies containing the parental plasmid 
The T7 promoter permits in vitro RNA transcription/translation and sequencing (Figure 
2.1). 
 
2.1.2 pGEM-T Easy 
Vector pGEM-T Easy (3015 bp) contains T7 and SP6 RNA polymerase promoters 
flanking the MCS within a lacZ gene. It is a TA cloning vector and encodes a β-
lactamase for selection with ampicillin (Figure 2.2).  
 
2.1.3 pCDNA3.1(-) 
Vector pCDNA3.1(-) is 5427 bp in length and contains ampicillin and neomycin as 
selectable marker. Genes inserted in the MCS can be expressed from the T7 promoter by 
co-expression of T7 polymerase (Figure 2.3).  
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Figure 2.1. A simple map of pCR2.1-TOPO with MCS, reproduced from Invitrogen. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. A simple map of vector pGEM-T-Easy with MCS, courtesy of Promega. 
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2.1.4 pEFL29 
Plasmid pEFL29 (11557 bp) is a recombination plasmid for the insertion of selectable 
expression cassettes into FWPV. FWPV sequences in the plasmid (not shown), derived 
from FP9 and containing ORFs 1, 2 and 3 (equivalent to FWPV genes fpv002, 003 and 
004), target the expression cassette to non-essential open reading frames in the inverted 
terminal repeat regions (ITRs) of FWPV. It was derived from pEFL10 by inserting the 
FWPV 4b promoter (Binns et al., 1989) upstream of the lacZ gene before incorporating 
the VACV P7.5 promoter upstream of the P4b promoter and in the opposite orientation 
(Qingzhong et al., 1994). The vector has a unique SmaI site (downstream of the p7.5 
promoter and within ORF1/fpv002) used for gene insertion. A kanamycin resistance gene 
(Kan
R
) is the bacterial selectable marker for this vector (Figure 2.4).  
 
2.1.5 pEFgpt12S 
Vector pEFgpt12S (6362 bp) contains a synthetic (S) hybrid early/late promoter upstream 
of an MCS. Kan
R
 and E. coli gpt genes are present as selectable markers for use in 
bacteria and eukaryotic cells, respectively (Figure 2.5). FWPV sequences in the plasmid 
(not shown) target the expression cassette to non-essential open reading frame fpv002. 
FWPV sequences in the plasmid (not shown), derived from FP9, target the expression 
cassette to non-essential open reading frame ORF 1 (equivalent to fpv002) in the FWPV 
ITRs. The EcoGPT cassette is embedded within the FWPV recombination sequences so 
that stable MPA
R
 rFWPV can be isolated. 
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Figure 2.3. A simple map of vector pCDNA3.1 (-) with MCS, reproduced from 
Invitrogen. 
 
 
 
Figure 2.4. Map of vector pEFL29 with a unique SmaI (CCCGGG) site. 
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2.1.6 pPC1.X 
Vector pPC1.X (5584 bp in length) was used for the construction of recombination 
plasmids that would insert expression cassettes for chicken interleukin genes into the 
FWPV genome by transdominant selection (Laidlaw et al., 1998). It contains an 
ampicillin resistance gene and an E. coli gpt gene as selectable markers for use in bacteria 
and eukaryotic cells, respectively. The E. coli gpt gene is located outside the FWPV 
recombination sequences, allowing it to be used as a selectable marker for transdominant 
selection. FWPV recombination sequences are derived from the FWPV orthologue of the 
PC1 gene (fpv030; Laidlaw and Skinner, 2004) allowing it to be used to insert genes at 
this locus even when other genes are inserted at the fpv002 locus. A large part of the gene 
was deleted by digestion with XbaI followed by religation then one of the remaining 
HindIII restriction sites was deleted, leaving a unique HindIII site towards the C-terminus 
of fpv030 to facilitate cloning of inserts (Figure 2.6).  
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Figure 2.5. Map of vector pEFgpt12S, 6361 bp, with unique enzyme sites, EcoRI 
(GAATTC), XbaI (TCTAGA), SacII (CCGCGG) and PstI (CTGCAG). 
 
 
 
 
 
 
Figure 2.6. Map of vector pPC1.X, 5584 bp, with unique enzyme sites, SmaI (CCCGGG) 
and HindIII (AAGCTT). 
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2.2 Construction of recombinant plasmids containing influenza and cytokine 
genes 
2.2.1 Cloning of AIV genes into pEFL29 
cDNA copies of H5, N1 and NP genes of avian influenza (AI) from strain 
A/Chicken/Malaysia/5858/2004 had been cloned in pCR2.1-TOPO vector and sequenced 
in Malaysia by Nurul Hidayah Abdullah Zawawi from Universiti Putra Malaysia.  
 
2.2.2 Bioinformatics analysis 
The polybasic cleavage site of the H5 gene of the Malaysian HPAI virus strain 
A/Chicken/Malaysia/5858/2004 was identified using CLC Combined Workbench 3 
software (CLC bio). The deduced H5 amino acid sequences, with and without the 
polybasic cleavage site, were aligned with sequences in the databases using BLAST 
(http://www.ncbi.nlm.nih.gov/blast/). Restriction enzyme maps and coding sequences of 
genes or plasmid vectors of interest were generated using the same software to facilitate 
cloning strategies and primer design. Cloning strategies for AIV and cytokine genes were 
designed on the basis of restriction enzyme maps generated in bioinformatics analysis. 
For insertion into expression vectors, AIV genes were produced as PCR products (with 
appropriate sequences added to facilitate sub-cloning), while cytokine genes were 
digested from their respective plasmid vectors. 
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2.2.3 Preparative Polymerase Chain Reaction (PCR) of AIV genes for sub-cloning 
Three primer sets were generated to amplify the full coding sequences of H5, N1 and NP 
gene, with either EcoRV or SspI sites incorporated at the termini (Appendix 1). Removal 
from the H5 gene of sequence encoding the polybasic sequence and the mutation of 
nucleotide 1022 from G to C, to change an arginine to a threonine, were done using 
mutagenic primers S(2-F) and S(1-R). Primers H5-F and S(1-R) were used to generate 
the first H5 fragment, while H5-R and S(2-F) were used to generated the second H5 
fragment. The full length modified H5 gene, designated H5 S, was obtained through PCR 
overlap extension mutagenesis using 50 ng of each first round PCR product as template. 
The reaction mixture contained 10X Pfx buffer (5 µL; Sigma), Accuprime Pfx DNA 
polymerase (2 U), oligonucleotide primers (0.75 µL of each 10 µM stock) and template 
DNA (50 to 260 ng) in a final volume of 50 µL. PCR was performed using the protocol 
in Section 2.2.5, but the extension temperature was changed from 72 
o
C to 68 
o
C 
following guidance from the manufacturer of Accuprime Pfx DNA polymerase. 
Amplification of the N1 gene, using primers N1-F and N1-R, and the NP gene using 
primers NP-F and NP-R, was carried out with the same reaction mixture and protocol. 
 
2.2.4 Analytical PCR reaction mixture 
The reaction mixture for a small scale PCR checking contained 10X PCR buffer (2 µL; 
Sigma), JumpStart Taq DNA polymerase (0.5 U; Sigma), dNTPs (0.5 µL of 10 mM) and 
oligonucleotide primers (0.5 µL of each 10 µM stock), in a total volume of 20 µL.  
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2.2.5 PCR protocol 
PCR was conducted according to the following programme: 
(i) Initial denaturation at 95 
o
C for 3 minutes.  
(ii) 4 cycles of denaturation at 95 
o
C for 30 seconds, annealing at 50 
o
C for 30 
seconds and extension at 72 
o
C for 1.5 minutes. 
(iii) 26 cycles of denaturation at 95 
o
C for 30 seconds, annealing at 59 
o
C for 30 
seconds and extension at 72 
o
C for 1.5 minutes.  
(iv) Final extension was operated at 72 
o
C for 10 minutes.  
 
2.2.6 Purification of PCR products  
DNA from PCR and other enzymatic reactions was purified when necessary using the 
QIAquick PCR Purification Kit, supplied by QIAGEN. Buffer PB (5 volumes) was first 
added to 1 volume of the reaction, mixed and placed in a 2 ml collection tube. The 
sample was then applied to QIAquick column and centrifuged at 10,000 rpm for 1 
minute. Buffer PE was used to wash the column before centrifuged for 1 minute. The 
buffer in the collection tube was discarded before centrifuged again for 1 minute. DNA 
was eluted with of nuclease free water (50 l). 
 
2.2.7 Small-scale preparation of plasmid vectors  
Small-scale isolation of plasmid vector DNA, based on adsorption of DNA onto silica in 
the presence of high salt after alkaline lysis of bacteria (Vogelstein and Gillespie, 1979), 
was performed using the QIAprep Spin Minipreparation Kit, supplied by QIAGEN. A 
single bacterial colony was picked from a freshly streaked selective plate and 
 72 
resuspended in Luria Bertani (LB; 5 mL) broth containing the appropriate antibiotic (100 
μg/mL ampicillin or 50 μg/mL kanamycin), before overnight vigorous agitation at 37 oC. 
Bacteria were harvested by centrifugation (13,000 rpm; 5 minutes). Buffer P1 containing 
100 μg/mL RNase A (250 μL) was added and pellets were resuspended then transferred 
into a microcentrifuge tube. The bacteria were lysed under alkaline conditions in Buffer 
P2 (250 μL). After less than 5 minutes of thorough mixing, the lysate was neutralized 
with Buffer N3 (350 μL). Cell debris, proteins, chromosomal DNA and SDS were 
precipitated under the high salt concentration in the buffer. The solution was subjected to 
centrifugation at 13,000 rpm for 10 minutes. The supernatant was decanted to a QIAprep 
spin column before subsequent centrifugation (13,000 rpm, 1 minute). Adsorbed plasmid 
DNA was then washed with Buffer PE (750 μL) and an additional centrifugation was 
applied to remove residual wash buffer, before elution of DNA with DNAse free water 
(50 μL). 
 
2.2.8 Restriction enzyme digestion 
Restriction enzymes (restriction endonucleases) recognize and cut specific sequence in 
double-stranded DNA to produce sticky or blunt ends. In this study, restriction enzyme 
digestions were used: to produce compatible ends after PCR before cloning into plasmid 
vectors, to excise inserts from vector plasmids, to check the size of plasmid vectors and 
to determine the orientation of inserts. Reactions were allowed to proceed for 3 hours or 
overnight, in appropriate 10X Buffer (NEB). The requirement for BSA and the 
temperature for incubation depended on the enzyme. In preparation for sub-cloning, 2 to 
10 μg of plasmid vectors were digested with 40 U of suitable restriction enzymes in total 
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volumes of 50 μL or 100 μL while for analytical purposes, 100 to 200 ng of plasmid 
vectors were digested with 10 to 20 U of appropriate restriction enzyme(s) in 20 μL of 
total volume. Restriction enyme digest products were analyzed by agarose gel 
electrophoresis 
 
2.2.9 Phosphatase treatment of cut vectors 
To prevent self-ligation of plasmid vector DNA linearized with single restriction 
enzymes, the 5’ phosphate groups were removed by phosphatase treatment. Unpurified 
restriction enzyme digestion mixture (10 µL), which contained the plasmid vector of 
interest, was mixed with Antarctic phosphatase (25 U) in 10X reaction buffer in a final 
volume of 100 µL. The mixture was incubated at 37 
o
C for 30 minutes then the enzyme 
was inactivated by heating at 65 
o
C for 5 minutes. Purification of the digested vector was 
performed using QIAprep Spin Minipreparation Kit, before size confirmation by gel 
elecrophoresis. 
 
2.2.10 Agarose gel electrophoresis 
Agarose gel electrophoresis was used to analyze all PCR or restriction enzyme digestion 
samples. Agarose (1 %) was dissolved in 1X Tris-Borate-EDTA (TBE) buffer containing 
1 µg/µL ethidium bromide. Samples were mixed with equal volume of loading dye 
before loaded into gel wells. A DNA marker with bands ranging from 100 bp to 10 kb 
was always included. Gels were electrophoresed in 1X TBE at 90 V for 30 to 60 minutes 
or until the dye was about one third from the bottom of the gel. Gels were visualized 
under ultraviolet light using a GelDoc 2000 system (BioRad) for detection and recording. 
 74 
2.2.11 Ligations 
Ligation reactions involved 20 U of T4 DNA ligase (20 U), ATP (1 µL of each 0.05 mM 
stock) and 10x NEB Buffer 4 (1 µL) in a total volume of 10-15 µL. In this study, two 
types of ligation were used. ‘Sticky-end’ ligations were set up with 1:1 ratio (usually 50 
ng each) between the plasmid vector and DNA insert. The ligation mixture was left at 16 
oC overnight. ‘Blunt-end’ ligations required vector to insert ratios of 1:2 to 1:10, with an 
incubation temperature of 4
  o
C (overnight).  
 
2.2.12 Transformation  
Transformation of chemically competent bacteria with plasmid DNA was performed 
using the method described by Mandel and Higa (1970). Plasmid vector (1 µL) or 
ligation mixture (5 µL) was added to a bijou containing of 5-alpha F´I
q 
competent E. coli 
(25 µL; NEB) and incubated on ice for 30 minutes. The cells were heat-shocked at 42 C 
for 90 seconds and immediately placed on ice again for 2 minutes. SOC medium (1000 
µL; Invitrogen) was added and the tube was incubated at 37 C with shaking at 200 rpm 
to allow expression of antibiotic resistance. After 1 hour, the mixture (50 to 200 µL) was 
plated onto an LB agar plate containing either ampicillin or kanamycin antibiotics (50 
µg/µL). The plate was incubated at 37 
o
C overnight. Single colonies were picked into 
antibiotic-supplemented media to be grown overnight for subsequent plasmid 
minipreparation. 
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2.2.13 Selection for positive transformants 
Several approaches were taken to select for positive transformants. A method using 
restriction enzyme digestion has been described in Section 2.2.8. 
 
2.2.13.1 Culture PCR 
Colonies that were picked after transformation were grown in LB (15 mL) supplemented 
with appropriate antibiotic(s) (15 µL of 50 µg/µL) at 37 
o
C overnight. The culture (0.5 
µL) was used to provide templates for analytical PCR (Section 2.2.4).  
 
2.2.13.2 Sequencing 
Plasmid transformants which were predicted to be positive after restriction enzyme 
digestion or culture PCR were sent for sequencing. In a tube with 10 µL of total volume, 
3.2 pmole of primer with a Tm of 50 – 55 °C were mixed with 200-500 ng (per 3 kb) of 
the plasmid DNA sample. The tube was then forwarded to Clinical Sciences Centre 
(CSC), a division of the Faculty of Medicine of Imperial College London, which is 
located in the Hammersmith Hospital Campus in London, United Kingdom, to be 
analysed. The sequencing data were assembled and evaluated using CLC Combined 
Workbench 3 software described in the early part of this chapter.  
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2.2.14 Cloning of chicken cytokine genes 
Plasmid pGEMT-Easy and pCDNA3.1(-) with cytokine IL-15 and IL-12 genes 
incorporated, respectively, were supplied by Dr Pete Kaiser from  the Institute for Animal 
Health, Compton. A sub-cloning strategy was designed on the basis of the restriction 
maps of IL-12 or IL-15 and the vectors used, pEFgpt12S and pPC1.X.  
 
2.2.14.1 Cloning of chicken cytokine genes into pEFgpt12S  
Plasmid pGEMT-Easy/IL-15 (5 µg) and pEFgpt12S (5 µg) were digested using PstI and 
SacII (40 U), separately, in 10X NEB buffer 2 (5 µL) and 100X BSA (0.5 µL), in a total 
volume of 50 µL. Plasmid pCDNA3.1(-)/IL-12 (10 µg) was digested using PmeI (40 U), 
while pEFgpt12S (4 µg) was digested using XbaI (40 U), in 10X NEB buffer 4 (5 µL) 
and 100X BSA (0.5 µL) in a total volume of 50 µL. The four individual digestion 
mixtures were incubated at 37 
o
C for 3 hours. Digested IL-15 and IL-12 gene fragments 
were purified by QIAquick Gel Extraction Kit after being electrophoresed, while 
restricted pEFgpt12S was purified by QIAquick PCR Purification Kit. The purified DNA 
samples were ligated before transformed into competent E. coli strain. 
 
2.2.14.2 Cloning of chicken cytokine genes into pPC1.X 
Plasmid pEFgpt12S/IL-15 (5 µg) was digested using PstI and HindIII (40 U), while 
pPC1.X (5 µg) was digested using NsiI and HindIII (40 U), in separate reaction mixtures 
of 10X NEB buffer 2 (5 µL) and 100X BSA (0.5 µL), in a total volume of 50 µL. 
Plasmid pEFgpt12S/IL-12 (5 µg) and pPC1.X (5 µg) was also restricted independently 
using HindIII (40 U) in 10X NEB buffer 2 (5 µL) in a total volume of 50 µL. The 
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digestion mixtures were incubated at 37 
o
C for 3 hours and purified using either 
QIAquick Gel Extraction Kit after being electrophoresed, or by QIAquick PCR 
Purification Kit. Ligations and transformations were applied to the DNA samples after 
the purification procedure.  
 
2.2.14.3 End repair 
Sticky ends of pEFgpt12S generated by digestion with XbaI (0.5 µg) were ‘polished’ 
using Klenow DNA Polymerase enzyme (1 U) in a reaction mixture which contained 
dNTP mix (10 µL of each 1mM stock) and 10X NEB buffer 2 (10 µL) in a total volume 
of 100 µL. The mixture was incubated at 25
 o
C for 15 minutes before the DNA was 
purified by QIAquick PCR Purification kit. 
 
2.2.14.4 QIAquick gel extraction kit  
The QIAquick gel extraction kit was used to extract and purify DNA fragments after 
agarose gel electrophoresis using the protocol provided by the manufacturer. The cassette 
of interest digested from the plasmid vector was excised from the gel using a clean 
scalpel under short exposure of long wave UV light. The gel slice was then weighed in a 
microcentrifuge tube. Three volumes of Buffer QG were added to one volume of gel (100 
mg ~ 100 μL) and incubated at 50 °C for 10 minutes or until the gel slice dissolved 
completely. One gel volume of isopropanol was mixed with the sample and the mixture 
was applied onto a column with the provided 2 mL collection tube underneath, and 
centrifuged. Buffer QG allowed DNA to be adsorbed onto the membrane while 
isopropanol increased the yield. Buffer PE (750 μL) was then added to wash the column. 
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An additional spin was carried out after the flow-through was discarded to remove 
residual wash buffer. A clean 1.5 mL microcentrifuge tube was positioned under the 
column. Elution of DNA was with 30 to 50 μL of water. All centrifugation steps were 
performed at 13,000 rpm for 1 minute. 
 
2.3 Construction of recombinant FWPV co-expressing influenza and cytokine 
genes 
2.3.1  Virus and media 
The initial stock of wild type FP9 was from Skinner laboratory stocks. The derivation of 
FP9 via 438 serial passages of the wild-type fowlpox virus HP-1, followed by plaque 
purification, has been described (Mockett et al., 1992). All media for tissue culture works 
were warmed at 37 °C before used. The media constituents are described in Appendix 2. 
 
2.3.2 Preparation of chick embryo fibroblast (CEF) primary cell cultures 
CEFs for this project were either prepared from 9 to 10-day-old embryonated eggs using 
standard methods or provided by the Institute for Animal Health, Compton, Berkshire, 
UK. CEFs were cultured in either tissue culture dishes or different sizes of tissue culture 
flask and incubated in 10 % NBBS in DMEM media at 37 
o
C in 5 % CO2  until used. 
 
2.3.3 Fluid overlay 
Growth medium in either a well or a flask was removed before an inoculum (virus stock 
diluted in serum free DMEM) with enough volume just to cover the cells, was added.  
The virus was allowed to adsorb for 1 to 2 hours at 37 
o
C. After aspiration, an appropriate 
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volume of 2 % NBBS in DMEM was added and the cells were placed again in 37 
o
C 
incubator with 5 % CO2. When a good cytopathic effect (CPE) was observed under a 
microscope within 4 to 5 days (the cells changed from elongated to more circular shape), 
both supernatant and cells were harvested. Freeze/thawing at -80 
o
C was done three times 
to ensure intracellular virus release.  
 
2.3.4 Agarose overlay 
Growth medium was discarded then an appropriate volume of inoculum was added to the 
cells and left for 1 to 2 hours at 37 
o
C. The inoculum was then aspirated. Agarose 
medium (Appendix 2) was gently overlayed and left for 10 to 15 minutes at room 
temperature to solidify. The cells were incubated in 37 
o
C incubator with 5 % CO2 again 
until plaques could be seen by holding the dish up to the light (4 to 6 days). To ease 
viewing of plaques of viruses containing LacZ gene, X-Gal could be added at the fourth 
day post infection. 
 
2.3.5 Recombination/Transfection using lipofectin 
T12.5 flasks containing 50 to 80 % confluent CEF cells were selected for infection of 
FP9 and transfection of recombinant plasmids. The medium from each flask was first 
discarded before addition of 500 µL of FP9 in pre-warmed serum free DMEM medium. 
The flasks were incubated at 37 C in 5 % CO2 for 2 hours to allow the virus to adsorb to 
cells, with a gentle rocking every 30 minutes. Pre-warmed 2 % NBBS DMEM media (2.5 
mL) was then added to each flask and reincubated for a further 2 hours. For each 
transfection, two solutions were prepared in a separate bijou. One solution contained 
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plasmid DNA (5 µg) in serum free DMEM (50 µL), and another one contained of 
lipofectin reagent (10 µL) in serum free DMEM (50 µL). The two solutions were 
subsequently combined and incubated at room temperature for 10 to 15 minutes. In the 
meantime, flasks were rinsed twice with 3 mL serum free DMEM. The second rinse was 
left inside the flasks while awaiting the plasmid DNA-lipofectin complex. After the 
incubation period, 2 % NBBS DMEM media (1.5 mL) was added to each bijou with 
plasmid DNA-lipofectin complex and gently mixed. This solution was then added to the 
washed cells in the flasks after the second rinse had been discarded, and incubated at 37 
C in 5 % CO2 overnight before replaced with 2.5 mL of 2 % NBBS DMEM. The 
addition of mycophenolic acid (MPA) (25 μg/mL),  xanthine (250 μg/mL) and 
hypoxanthine (25 μg/mL) for gpt selection could be done at this step. The transfected 
cells were then incubated further for 4 to 5 days until CPE was observed. The cells and 
the supernatant were harvested into a bijou and freeze/thawed three times. 
 
2.3.6 Selection of viruses  
2.3.6.1 Selection of viruses containing LacZ gene 
Agar overlay solution containing X-Gal at a final concentration of 0.4 mg/mL was 
pippetted onto the agar-overlaid cells at the fourth day post-infection. Successful 
recombination/transfection of recombinant plasmids carrying a LacZ gene into FP9 was 
demonstrated by blue plaques observed from the next day. Single plaques were picked, 
diluted in 500 µL serum free DMEM and freeze/thawed three times. This protocol was 
repeated six times to obtain plaque-purified virus. 
 
 81 
2.3.6.2 Selection and resolution of viruses containing gpt gene  
At the stage of recombination/transfection, the viruses were incubated in 2 % NBBS 
DMEM in the presence of MPA. Three serial viral passages were performed by infecting 
200 µL of the virus in T12.5 flask. Virus from the third passage was sequentially diluted 
(10
-3
 to 10
-6
) using serum free DMEM before being subjected to agar overlay infection in 
the presence of MPA. Single plaques were picked into 500 µL of serum free DMEM and 
freeze/thawed three times. The clones were subjected to further (three to six times) 
plaque purifications in non-selective gpt media.  
 
2.3.7   Verification of recombinant viruses 
2.3.7.1 PCR after genomic extraction 
DNA was isolated from infected tissue culture cell lysates using Wizard SV Purification 
Kits (Promega). Using an equal volume of Wizard SV Lysis Buffer, 150 µL of harvested 
lysates from at least 1x10
4
 cells to a maximum of 5x10
6
 cells were lysed. Total sample 
lysates were then transferred onto spin columns. Centrifugation occurred at 13 000 x g 
for 3 minutes and the flow-through was decanted. To wash, 650 µL of Wizard SV Wash 
Solution was added into the column and centrifuged for 1 min. The liquid was discarded 
and the column was centrifuged for another 2 minutes to dry the binding matrix. The 
DNA was then eluted with 250 µL of nuclease free water. An aliquot (3 µL) from the 
total yield was used in small scale PCR screening. 
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2.3.7.2 Western blotting 
For protein expression analysis, we utilized CEF infected with RG14 lysate supplied by 
Prof Wendy Barclay (Imperial College London), as positive control, while wild type FP9 
protein lysate and lysates of CEF, DF1 and/or QT35 served as negative controls. RG14 is 
a reference vaccine virus strain derived from A/Vietnam/1194/2004, and was developed 
by NIBSC using reverse genetics technology to transfer the H5 (modified to remove the 
polybasic cleavage site sequence) and N1 segments into a PR8 background. The 
recombinant protein lysates were prepared by infecting CEFs, with the recombinant 
viruses at a multiplicity of infection (MOI) of 3 in a 12-well plate, for 48 hours. The cell 
pellet was harvested by adding 250 μL RIPA buffer (50 mM Tris pH 8.0, 0.1 % SDS, 1 
% NP-40, 0.05 % w/v sodium deoxycholate and 150 mM NaCl) and squirting the pipette 
until total cell pellet was detached. Protease inhibitor (0.01 %) was included to minimize 
protein degradation.   
 
Standard Sodium Dodecyl Sulphate-Polyacrylamide gel electrophoresis (SDS-PAGE) 
was used to separate proteins expressed by the infected cells (Sambrook et al, 1989). A 
stacking gel (130 mM Tris-HCl pH 6.8, 0.1 % SDS, 0.1 % ammonium persulphate, 5.1 % 
acrylamide and 0.1 % TEMED) was poured on top of a resolving gel (375 mM Tris-HCl, 
0.1 % SDS, 0.1 % ammonium persulphate, 9.9 to 15 % acrylamide and 0.04 % TEMED) 
and allowed to solidify. A 10 or 15 well comb was added prior to setting. Protein samples 
from either lysed cells or supernatant (10 to 30 µL) were mixed with 1X Laemmli 
Loading Buffer (15 % β-mercaptoethanol, 15 % SDS, 1.5 % w/v bromphenol blue and 50 
% glycerol, diluted in distilled water), and heated for 1 minute at 60 to 100 °C. 
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Electrophoresis was conducted in SDS-PAGE running buffer (190 mM glycine, 20 mM 
Tris-Base and 0.1 % SDS) initially at 100 V, switching to 200 V when the samples 
reached the resolving gel. Protein size markers (BioRad Precision Plus Protein Standards) 
were run alongside. The resolved proteins and controls were transferred onto a 
nitrocellulose membrane, at 100 V for 1 hour at room temperature, in Transfer Buffer 
mix (20 % methanol, 10 % Transfer Buffer : 20 mM Tris-Base, 192 mM glycine and 0.01 
% SDS, diluted in distilled water). The membrane was subsequently immersed at 4 °C 
overnight in 5 % skimmed milk in Phosphate Buffered Saline, PBS (200 mM phosphate 
and 150 mM NaCl). The solution was then removed and the membrane was incubated 
with primary antibody, diluted with PBS containing 2 % skimmed milk, at its respective 
ratios (1:500, 1:1000 or 1:2000) for 1½ hours at room temperature, with slow rotation. 
The membrane was then washed with PBS, five times for five minutes. Secondary 
antibody, conjugated with horseradish peroxidase and diluted with PBS/2 % skimmed 
milk, was added at an appropriate dilution, and the container was placed on a rotator for 
another 1.5 hours. Excess conjugate was removed and rinsed with PBS. The membrane 
was then developed using Amersham ECL Plus Detection Reagent (GE Healthcare). The 
exposure time of the membrane to autoradiograph film varied from 5 to 20 minutes.  
 
2.3.7.3     Indirect immunofluorescence assay (IFAT) 
CEF were grown in 6-well plates containing two round coverslips (1.2 cm in diameter) in 
each well, until the monolayer reached 80 % confluency. Each well was infected with 
virus stock at 0.3 MOI, while one well was left uninfected. The infection was left to 
proceed overnight in 2 % NBBS DMEM medium. Cells were washed twice with 5 mL 
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pre-warmed 1X PBS. Each coverslip was transferred into individual wells of a 12-well 
plate. Each was incubated with specific primary antibodies diluted in PBS, for 2 hours, 
with a gentle shake every 30 minutes. After three washes with 1 mL PBS, cells were 
incubated with secondary antibodies, conjugated with FITC, for 1 hour, before being 
washed again three times. All FITC procedures were conducted in dim light. Coverslips 
were gently placed onto glass slides, air-dried and viewed under a fluorescent microscope 
(model Leica DMRA II). 
 
2.4 Characterization of immune response by in vivo experimental study  
2.4.1 Chickens  
Layer chickens of the White Leghorn breed used in all the animal experiments were 
imported from SPAFAS Australia Pty Ltd by Malaysian Vaccines and Pharmaceuticals 
Sdn Bhd (www.mvp.com.my). They were tested and declared free from specific 
pathogens (SPF) by Charles River Laboratories (www.criver.com).  
 
Chickens were kept in separate cages by group, fed twice a day using commercial 
chicken feed (brand Gold Coin) and provided with water, ad libitum. 
 
Table 2.1. Composition of chicken feed in commercial brand, Gold Coin, of Malaysia 
Composition Percentage, % 
Crude protein, minimum 21.2 
Crude fibre, maximum  5.0 
Crude fat, minimum 5.0 
Moisture, maximum 13.0 
Ash, maximum 8.0 
Calcium 0.8 – 1.2 
Phosphorus 0.6 – 1.0 
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2.4.2  Animal experimental design 
All animal experiments were conducted at Animal Experimental House of the Faculty of 
Veterinary Medicine, Universiti Putra Malaysia (UPM), Malaysia, in compliance with the 
international Guide for the Care and Use of Laboratory Animals (ILAR, 1996), under the 
approval of the local Institutional Animal Care and Use Committee (IACUC) of UPM 
(Reference No.: UPM/FPV/PS/3.2.1.551/AUP-R72).  
 
2.4.2.1 Animal experimental  1 
Fifty four 1-day-old chicks were randomly assigned into six groups, nine in each group as 
follows: 
(i)  Control (mock-vaccinated with 100 μL PBS). 
(ii)  Parental FWPV FP9 (WT FP9). 
(iii) rFWPV expressing H5 gene (rFWPV/H5). 
(iv) rFWPV coexpressing H5 and IL-15 genes (rFWPV/H5/IL-15). 
(v)  rFWPV expressing N1 gene (rFWPV/N1). 
(vi) rFWPV expressing N1 and IL-12 genes (rFWPV/N1/IL-12). 
 
The viral vaccine inoculation dose was 10
5
 PFU, diluted in PBS to a total volume of 100 
μL. Within one hour upon preparation, the viral inoculum was inoculated subcutaneously 
at the scruff of the neck of each bird, using a 27-gauge needle. Clinical signs were 
observed twice daily post inoculation (p.i.) for two weeks.  
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Blood sampling (for serum) of each chicken was done on a weekly basis. At Week 2 and 
5, whole blood (0.2 mL) of each chicken in each group of nine was sampled and 'pooled' 
into 3 groups (0.6 mL in total), for lymphocyte isolation for flow cytometry analysis 
(Section 2.4.7).  
 
All chickens were weighed at Week 1 until Week 4. The chickens were left until Week 7 
to distinguish their sexes before being euthanized. 
 
2.4.2.2 Animal experiment 2 
Thirty 1-day-old chicks were randomly assigned into six groups (five chickens in each 
group). Vaccine groups and inoculation design were similar to Section 2.4.2.1. Blood 
sampling (for serum) of each chicken was done on a weekly basis. At Week 2 and 4, 
whole blood (0.5 mL) of each chicken in each group of five was sampled for lymphocyte 
isolation for flow cytometry analysis (Section 2.4.7). The chickens were left until Week 7 
before being euthanized. 
 
2.4.3 Serum collection 
Collected whole blood (0.2 to 1 mL, according to chicken size) was left in the syringe, 
horizontally, at room temperature, for five hours (no longer than six hours) to allow 
clotting. The transparent, yellowish liquid (serum) was gently transferred into 1.5 mL 
tubes and centrifuged at 1200 rpm for 10 minutes. The supernatant was collected into 
new clean tubes and kept in -20 
o
C until further used. 
 
A 
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2.4.4 Red blood cell isolation 
Chicken whole blood, 1.5 to 2 mL, was collected into vacutainers containing EDTA as 
anti-coagulant and 500 μL PBS. The blood was transferred into 50 mL tubes containing 
30 mL cold PBS and mixed gently. The tube was centrifuged at 2000 rpm, 4 
o
C for 10 
minutes. Supernatant was inspected to be completely yellowish, without reddish 
particulates (lysed red blood cells, RBC), and slowly discarded. Cold PBS, 20 mL, was 
added to the tube which was centrifuged again at 2000 rpm, 4 
o
C for 10 minutes. The 
clearer yellowish colour of the supernatant was noted before being discarded. Cold PBS 
(20 mL) was added and this step was repeated further until the supernatant was 
colourless. Packed RBC at the bottom of the tube were pipetted gently into a clean tube, 
labelled as 100 % concentrated, and kept at 4 
o
C no longer than two days.  
 
2.4.5  Haemagglutination test 
PBS (25 μL) was aliquoted into 12 wells (one row) of U-bottomed 96-well plates. 
Inactivated, low pathogenic H5 AIV (50 μL; A/Malaysia/Duck/8443/04 H5N2), provided 
by the Veterinary Research Institute, VRI, Ipoh, Malaysia, was added into the first well. 
The virus was serially diluted (twofold) into the second well until the eleventh well. The 
remaining 25 μL was discarded. Freshly prepared RBC (50 μL, 100 % concentration) 
were diluted to 0.8 % in PBS and aliquotted into all 12 wells. The minimum virus 
concentration that caused complete agglutination of RBC was taken as the virus titre. 
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2.4.6  Haemagglutinin inhibition assay 
Using a U-bottomed 96-well plate, 25 μL PBS was aliquotted into the second to twelfth 
wells. Sample serum (50 μL) was added into the first well and half of it was serially 
diluted (twofold) until the eleventh well. The remaining 25 μL was discarded. H5N2 
virus strain A/Malaysia/Duck/8443/04, titrated to 4 HA units, was added into the diluted 
sera and gently mixed. The plate was incubated at room temperature for one hour. 
Washed chicken RBC (25 μL of 0.8 %) was added to each of the wells and incubated for 
30 minutes before viewing. HI titers were determined as the reciprocal of the highest 
serum dilution that completely inhibited haemagglutination. 
 
2.4.7 Isolation of lymphocytes  
Fresh, non-coagulated whole blood was diluted to 1 mL using cold PBS and was 
carefully layered on BD Biosciences Ficoll-Paque PLUS (2 mL) and centrifuged using a 
swing rotor, at 400 x g for 30-40 minutes at 4 °C. The lymphocyte layer was removed 
into a clean centrifuge tube and washed with 2 mL of PBS before re-centrifuging under 
the same conditions for 10 minutes. The supernatant was discarded. If RBC particulates 
were observed at the bottom of the tube, 2 mL of lysis buffer (7.56 g ammonium chloride 
and 2.42 g tris in total 1 L water) was added and the tube was kept in 4 
o
C for 30 minutes. 
Centrifugation was carried out as above and the step was repeated until no RBC were 
observed. PBS (2 mL 1X) was added to the pellet and the tube was re-centrifuged. The 
washing step was repeated twice. The lymphocytes pellet was resuspended in 0.2 to 0.5 
mL PBS for cell counting and transferred into amber tubes. The lymphocytes were kept 
at 4 
o
C and used within one day.  
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2.4.8 Preparation of paraformaldehyde solution 
Paraformaldehyde (2 % w/v) was prepared as a stock by adding 2 g of the powder to 100 
mL 1X PBS and heating at 56 
o
C in a waterbath until fully dissolved. The solution was 
allowed to cool to room temperature. The pH was adjusted to 7.4 using 0.1 M sodium 
hydroxide or 0.1 M hydrochloride acid. The solution was stored at 4 
o
C and used no later 
than two weeks. A 0.5 % working solution of paraformaldehyde was prepared by adding 
10 mL of 2 % stock into 30 mL 1X PBS. The solution was kept at 4 
o
C and was stable for 
one week. 
 
2.4.9 Staining and fixing of lymphocytes 
Mouse anti-chicken CD8a-PerCP-Cy5-conjugated (0.1 mg, working concentration was 1 
µg/mL), mouse anti-chicken CD3-PE-conjugated (0.1 mg, working concentration was 0.5 
µg/mL) and mouse anti-chicken CD4-FITC-conjugated (0.5 mg, working concentration 
was 0.5 µg/mL) monoclonal antibodies (all from Southern Biotech) were each added into 
an amber tube containing approximately 10
6 
cells. The cells were resuspended and 
incubated at 4 
o
C in a 100 rpm shaker for 3 hours, with tapping every hour. The 
antibodies were then washed three times with 1 mL cold 1X PBS, centrifuging at 250 x g 
for 10 minutes at 4 °C. Supernatants were discarded each time. Cold paraformaldehyde 
(0.3 mL of 0.5 %) was added to the stained cell pellets, which were vortexed 
immediately. The stained and fixed cells were kept at 4 
o
C in the dark no longer than 
three days. The cells were transferred into Flow tubes for analysis using a BD 
FACSCalibur flow cytometer. 
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2.4.10  ELISA assays  
ID Screen Influenza N1 Antibody Competition kits, purchased from ID VET, France, 
were used for specific detection of anti-influenza N1 antibodies in chicken sera. The kits, 
comprised of flat-bottom, 96-well microplates coated with N1 antigen (inactivated, whole 
H1N1 virus of 2009 pandemic, isolated from Brescia, Italy), 10X concentrated conjugate 
(anti-N1-peroxidase), positive and negative controls, dilution buffers, 20X wash 
concentrate, TMB as substrate solution and sulphuric acid as stop solution were stored at 
4 
o
C. Reagents were allowed to cool to room temperature and homogenized by vortexing 
before use. Dilution buffer 8 (50 μL) was loaded into each well of the microplates. 
Positive control (50 μL) was added into wells A1 and B1, with negative control into wells 
C1 and D1. Samples (50 μL each) were added to the remaining wells and the plate was 
incubated for 1.5 h at 37 
o
C.  Using an automatic ELISA plate washer, each well was 
emptied and washed three times using 300 μL of wash solution. Drying of the wells 
between washings was avoided. Conjugate (100 μL of 1X) prepared by diluting the 10X 
concentrated conjugate in dilution buffer 3, was added to each well and the plate was 
incubated for a further 30 minutes. Using an automated microplate washer (BioRad 
model 1575), each well was emptied and washed three times using 300 μL of wash 
solution. Substrate solution (100 μL) was added to each well before incubation for 10 
minutes at 21 
oC in the dark. Stop solution (100 μL) was added before the plate was read 
using a microplate reader (BioRad model 680) at 450 nm optical density, OD. The test 
was validated if the mean value of the negative control OD was greater than 0.700 and 
the mean value of the positive control was less than 30 % of the negative control OD. 
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Once the test was validated, competition percentage of antibodies from the samples was 
calculated using the equation below: 
                OD of sample              X 100 
       OD of negative control    
 
N1 antibodies were considered to be present in the sample if the competition percentage 
of the sample was less than 60 %, and absent if the percentage was equal to or more than 
60 %. 
 
In principle, N1 antibodies if present in the serum samples formed an antibody-antigen 
complex with N1 antigen coated on the microplates. Subsequent addition of anti-N1-
peroxidase conjugate bound to the remaining free epitopes of N1 antigen, forming an 
antigen-antibody-peroxidase complex. Addition of substrate solution, TMB, after 
elimination of the excess conjugate, later resulted in colouration based on the quantitity 
of specific antibodies present in the serum; no colour changes in the presence of 
antibodies, or blue colour which turned to yellow after addition of stop solution indicated 
the absence of antibodies.      
 
2.4.11 Statistical analysis 
Differences between groups of chicken were analyzed by One-Way ANOVA (if more 
than two groups) or Paired-samples T test (if two groups were compared) using SPSS 
Version 15 software. Results were expressed as the mean ± standard error of the mean 
(SEM). P values less than 0.05 were considered statistically significant in all cases.  
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CHAPTER 3 
Construction of recombinant FWPV coexpressing influenza virus and cytokine 
genes 
 
3.1 Introduction 
All of the sub-cloning of AIV and chicken cytokine genes into FWPV recombination 
vectors as well as the generation, characterisation and initial bulk preparation of 
recombinant FWPV (rFWPV) was conducted during the first half of the project in the 
laboratory of Dr M. A. Skinner at Imperial College London. Construction and use of the 
rFWPV in London was conducted according to HSE guidelines, under the approval of the 
local Genetic Modification Safety Committee, at Category 1 (elsewhere known as 
biosafety level, BSL, 1).   
 
The cloning strategy to construct recombinant FWPV, rFWPV, coexpressing AIV genes 
and chicken cytokine genes is summarized in Figure 3.1. 
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Figure 3.1. Overview of cloning strategy of AIV and cytokine genes. A) AIV genes (H5, with 
deleted polybasic sequence, N1 and NP) were amplified by PCR and inserted into recombination 
vector pEFL29 at a unique SmaI site. The first homologous recombination occurred at ORF 002 
of FWPV and clones were isolated by 6 fold plaque purification with X-gal screening and PCR. 
B) Cytokine genes IL-15 and IL-12 were excised from pCDNA3.1(-) and pGEMT-Easy, 
respectively, into vector pEFgpt12S carrying the S promoter. Expression cassettes were sub-
cloned into recombination vector pPC1.X. The second homologous recombination occurred into 
rFWPV already carrying AIV genes. The Ecogpt gene external to the recombination cassette in 
pPC1.X allowed trans-dominant selection of unstable intermediate viral clones subsequently 
allowed to resolve into stable AIV-rFWPV either having or not having cytokine genes. Final the 
presence of the inserted genes was verified by PCR, western blotting and IFAT.  
 
 
 94 
3.2 Construction of recombinant FWPV expressing influenza virus genes  
3.2.1 PCR amplification of AIV genes (including primer design and removal of 
polybasic sequence) 
Three primer sets to be used to generate the full length H5, N1 and NP sequences were 
designed with either EcoRV or SspI restriction enzyme sites incorporated (Appendix 1). 
The restriction enzymes were chosen to create blunt-end PCR products. 
 
The HPAIV haemagglutinin (HA) gene of the H5 virus contains multiple basic amino 
acids, arginine and lysine, that allow cleavage by ubiquitous proteases (furin and PC6) 
(Wood et al., 1994; Horimoto et al., 1994). To maintain compatibility with recombinant, 
killed H5N1 influenza vaccines (personal communication, Dr John Wood at NIBSC, 
Potters Bar, UK), and to reduce any potential biosafety issues, the polybasic region was 
removed. The sequence of the polybasic region is S-P-Q-R-E-R-R-R-K-K-R. Based on 
the sequence of the cleavage site of a low pathogenic Mexican lineage H5N2 AIV isolate 
(Garcia et al., 1996; Ito et al., 2001; Lee et al., 2004), it was decided to delete the 
tetrabasic peptide motif and also to replace one of the remaining arginines (R) with 
threonine (T), resulting in S-P-Q-R-E-T-R. BLAST searches 
(http://www.ncbi.nlm.nih.gov/blast/) were undertaken to compare the newly deduced 
amino acid sequence of the H5 with other influenza virus sequences. The most significant 
BLAST score is a modified haemagglutinin sequence of Influenza A virus 
(A/Vietnam/1203/2004) which shares 97% amino acid identity.  
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Deletion of the R-R-K-K motif and introduction of a point mutation at nucleotide 
position 1022, changing the arginine codon (AGA) to a threonine codon (ACA) were 
made using mutagenic primers S(2-F) and S(1-R). Use of primer pair H5-F and S(1-R) 
led to successful generation of the first H5 fragment (1036 bp), while use of primers H5-
R and S(2-F) allowed generation of the second H5 fragment (684 bp). Full length 
mutated H5 gene, designated H5 S (1695 bp in length), was obtained through PCR 
overlap extension mutagenesis using 50 ng of each DNA fragment as templates (Figure 
3.2). Later sequencing confirmed the presence of the mutated sequence: 
ATGLRNSPQRETRGLFGAIAG. 
 
PCR amplification of the N1 gene using N1-F and N1-R primers created a product of 
approximately 1353 bp, which corresponds to the expected N1 size of 1350 bp. Primers 
NP-F and NP-R were used to produce the NP gene. The product ran as a band between 
1353 bp and 2027 bp, which matched the expected size (1497 bp) of the NP gene (Figure 
3.2). 
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Figure 3.2. Amplification of AIV genes using PCR, including removal of multibasic sequence 
from H5 gene. A) Full length HA H5 gene, 1707 bp, is shown in Lane 1. Fragment 1, 1036 bp, 
and Fragment 2, 684 bp, of H5 were generated using mutagenic primers (Lanes 2 and 3, 
respectively). Re-assembled full length H5 sequence, lacking the polybasic region, 1695 bp, was 
obtained using PCR overlap extension mutagenesis (Lane 4). Lanes 5 and 6 show N1 (1350 bp) 
and NP (1497 bp) gene products, respectively. M is a ladder marker. B) Diagram showing the 
positions of primers used to amplify the genes and the predicted size of PCR products. 
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3.2.2 Introduction of influenza gene expression cassettes into the FWPV genome 
In this thesis, the term ‘positive transformants’ is used to refer to bacterial clones carrying 
plasmid vectors with the desired DNA correctly inserted in the appropriate orientation. 
To select for positive transformants carrying pEFL29 with inserted AIV genes, several 
single colonies were picked from an LB plate after the transformations and grown 
overnight. Culture PCR using a flanking primer (annealing to the vector) and an internal 
primer (annealing to the inserted gene) was generally used to confirm the presence and 
orientation of the insert (Figure 3.3a, Figure 3.3b).  
 
 
 
 
 
 
 
 
Figure 3.3a. Primer locations for PCR analysis to confirm the presence of the insert and its 
orientation. Two sets of primers were used, flanking primers F1 and F2, annealing to the parental 
vector, and internal primers I1 and I2, annealing to the 5' and 3' ends, respectively, of the inserted 
gene. 
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Figure 3.3b. Typical culture PCR analysis to confirm the presence of the insert and its orientation. 
A) Two sets of primers were used, flanking primers pEFL29-F and pEFL29-R, annealing to the 
parental vector, and internal primers H5-F and H5-R, annealing to the 5' and 3' ends, respectively, 
of the inserted gene. B) Example of culture PCR products. In this figure, pEFL29 and H5 primer 
sets were used to confirm the presence of H5 gene insert in pEFL29, in four cultures of single 
colonies. The size of the expected product is 1800 bp for both sets. Products of pEFL29-F and 
H5-R primers are shown in Lanes 1, 3, 5, and 7. Products of pEFL29-R and H5-F primers were 
indicated at Lane 2, 4, 6 and 8. Lane 1 and 2 represent culture number 1, Lane 3 and 4, culture 
number 2, Lane 5 and 6, culture number 3, Lane 7 and 8, culture number 4. M is a ladder marker. 
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Cultures that yielded positive PCR products (Figure 3.3) were subjected to plasmid DNA 
isolation using QIAGEN Minipreparation Kit. The extracted plasmid DNAs were 
digested using restriction enzymes SphI or NcoI for pEFL29 predicted to have H5/NP or 
N1 gene inserts, respectively (Figure 3.4). Plasmid DNA from positive transformants was 
then sent for sequencing (Figure 3.5a,b,c). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. Agarose gel showing the size of plasmid pEFL29 carrying AIV genes after restriction 
enzyme digestion. pEFL/H5 was digested with SphI to give 1296 bp, 4962 bp and 7000 bp 
fragments. pEFL29/N1 was digested with NcoI to give 1743 bp and 11170 bp fragments. 
pEFL29/NP was digested with SphI to give 2740 bp and 10314 bp. M is a ladder marker. 
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GAATTCCCATC 
ATGGAGAAAATAGTGCTTCTTTTTGCAATAGTCAGTCTTGTTAAAAGTGATCAGATTTGCATTG
GTTACCATGCAAACAACTCGACAGAGCAGGTTGACACAATAATGGAAAAGAACGTTACTGTT
ACACATGCCCAAGACATACTGGAAAAGACACACAACGGGAAGCTCTGCGATCTAGATGGAGT
GAAGCCTCTGATTTTGAGAGATTGTAGTGTAGCTGGATGGCTCCTCGGAAACCCAATGTGTGA
CGAATTCATCAATGTGCCGGAATGGTCTTACATAGTGGAGAAGGCCAATCCAGTCAATGACCT
CTGTTACCCAGGGGATTTCAATGCCTATGAAGAATTGAAACACCTATTGAGCAGAATAAACCA
TTTTGAGAAAATTCAGATCATCCCCAAAAGTTCTTGGTCCAGTCATGAAGCCTCATTAGGGGT
GAGCTCAGCATGTCCATACCAGGGAAAGTCCTCCTTTTTCAGAAATGTGGTATGGCTTATCAA
AAAGAACAGTACATACCCAACAATAAAGAGGAGCTACAATAATACCAACCAAGAAGATCTTT
TGGTACTGTGGGGGATTCACCATCCTAATGATGCGGCAGAGCAGACAAAGCTCTATCAAAAC
CCAACCACCTATATTTCCGTTGGGACATCAACACTAAACCAGAGATTGGTACCAAGAATAGCT
ACTAGATCCAAAGTAAACGGGCAAAGTGGGAGGATGGAGTTCTTCTGGACAATTTTAAAACC
GAATGATGCAATCAACTTCGAGAGTAATGGAAATTTCATTGCTCCAGAATATGCATACAAAAT
TGTCAAGAAAGGGGACTCAACAATTATGAAAAGTGAATTGGAATATGGTAACTGCAACACCA
AGTGTCAAACTCCAATGGGGGCGATAAACTCTAGTATGCCATTCCACAATATACACCCTCTCG
CCATCGGGGAATGCCCCAAATATGTGAAATCAAACAGATTAGTCCTTGCGACTGGGCTCAGA
AATAGCCCTCAAAGAGAGACAAGAGGATTATTTGGAGCTATAGCAGGTTTTATAGAGGGAGG
ATGGCAGGGAATGGTAGATGGTAGGTATGGGTACCACCATAGCAATGAGCAGGGGAGTGGGT
ACGCTGCAGACAAAGAATCCACTCAAAAGGCAATAGATGGAGTCACCAATAAGGTCAACTCG
ATCATTGACAAAATGAACACTCAGTTTGAGGCCGTTGGAAGGGAATTTAACAACTTAGAAAG
GAGAATAGAGAATTTAAACAAGAAGATGGAAGACGGGTTCCTAGATGTCTGGACTTATAATG
CTGAACTTCTGGTTCTCATGGAAAATGAGAGAACTCTAGACTTTCATGACTCAAATGTCAAGA
ACCTTTACGACAAGGTCCGACTACAGCTTAGGGATAATGCAAAGGAGCTGGGTAACGGTTGTT
TCGAGTTCTATCATAAACGTGATAATGAATGTATGGAAAGTGTAAGTAACGGAACGTATGACT
ACCCGCAGTATTCAGAAGAAGCAAGACTAAAAAGAGAGGAAATAAGTGGAGTAAAATTGGA
ATCAATAGGAATTTACCAAATACTGTCAATTTATTCTACAGTGGCGAGTTCCCTAGCACTGGC
AATCATGGTAGCTGGTCTATCCTTATGGATGTGCTCCAATGGGTCGTTACAATGCAGAATTTG
CATTTAA* 
 
Figure 3.5a. Confirmed sequence of the H5 gene as inserted in vector pEFL29. Half of the unique 
SmaI cloning site is shown in bold. Half of an EcoRV site (italic), inserted to facilitate blunt-end 
ligation, is also shown. The sequence flanking the point mutation at nucleotide position 1022, 
which changes arginine (AGA) to threonine (ACA), is underlined and in bold. The sequencing 
primer positions are highlighted, while their orientations are indicated by arrows. P7.5 early/late 
promoter is not shown. 
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GAATTCCCATT 
ATGAATCCAAATAAGAAGATAATAACCATCGGATCAATCTGTATGGTAACTGGAATGGTTAG
CTTAATGTTACAAATTGGGAACTTGATCTCAATATGGGTCAGTCATTCAATTCACACAGGGAA
TCAACACAAAGCTGAACCAATCAGCAATACTAATCTTCTTACTGAGAAAGCTGTGGCTTCAGT
AAAATTAGCGGGCAATTCATCTCTTTGCCCCATTAATGGATGGGCTGTATACAGTAAGGACAA
CAGTATAAGGATCGGTTCCAAGGGGGATGTGTTTGTTATAAGAGAGCCATTCATCTCATGCTC
CCACTTGGAATGCAGAACTTTCTTTTTGACTCAGGGAGCCTTGCTGAATGACAAGCACTCCAA
TGGGACTGTCAAAGACAGAAGTCCTCACAGAACATTAATGAGTTGTCCTGTGGGTGAGGCTCC
CTCCCCATACAACTCAAGGTTTGAGTCTGTTGCTTGGTCAGCAAGTGCTTGCCATGATGGCAA
CAGTTGGTTGACAATTGGAATTTCTGGCCCAGACAATGGGGCTGTGGCTGTATTGAAATACAA
TGGCATAATAACAGACACTATCAAGAGTTGGAGGAATAACATACTGAGAACTCAAGAGTCTG
AATGTGCATGTGTAAATGGCTCTTGCTTTACTGTAATGACTGACGGACCAAGTAATGATCAGG
CATCACATAAGATCTTCAAAATGGAAAAAGGAAAAGTGGTTAAATCAGTCGAATTGGATGCT
CCCAATTATCACTATGAGGAATGCTCCTGTTATCCTGATGCCGGCGAAATCGCATGTGTGTGC
AGGGATAATTGGCATGGCTCAAATCGGCCATGGGTATCTTTCAATCAAAATTTGGAGTATCAA
ATAGGATATATATGCAGTGGAGTTTTCGGAGACAATCCACGCCCCAATGATGGAGCAGGTAG
TTGTGGTCCGGTGTCCTCTAACGGGGCATATGGGGTAAAAGGGTTTTCATTTAAATACGGCAA
TGGTGTCTGGATCGGGAGAACAAAAAGCACTAATCCCAGGAGCGGCTTTGAAATGATTTGGG
ATCCAAATGGGTGGACTGAAACGGACAGTAGCTTTTCAGTGAAACAAGATATCGTAGCAATA
ACTGATTGGTCAGGATATAGCGGGAGTTTTGTCCAGCATCCAGAACTGACAGGACTAGATTGC
ATAAGACCTTGTTTCTGGGTTGAGTTGATCAGAGGGCGGCCCAAAGAGAGCACAATTTGGACT
AGTGGGAGCAGCATATCTTTTTGTGGTGTAAATAGTGACACTGTGGGTTGGTCTTGGCCAGAC
GGTGCTGAGTTGCCATTCACCATTGACAAGTAG* 
 
Figure 3.5b. Sequencing of N1 gene in vector pEFL29. Unique SmaI site is shown in bold. SspI 
site (italic) was incorporated to facilitate blunt-end ligation. The sequencing primer positions are 
highlighted, while their orientations are indicated by arrows. P7.5 early/late promoter is not 
shown. 
 
 
 
 
 
 
 
 
 102 
GAATTCCCATC 
ATGGCGTCTCAAGGCACCAAACGATCTTATGAACAGATGGAAACTGGTGGGGAACGCCAGAA
TGCTACTGAGATCAGGGCATCTGTTGGAAGAATGGTTAGTGGCATTGGGAGGTTCTACATACA
GATGTGCACAGAACTCAAACTCAGTGACTATGAAGGGAGGCTGATCCAGAACAGCATAACAA
TAGAGAGAATGGTACTCTCTGCATTTGATGAAAGAAGGAACAGATACCTGGAAGAACACCCC
AGTGCGGGAAAGGACCCGAAGAAAACTGGAGGTCCAATTTATCGGAGGAGAGATGGGAAAT
GGGTGAGAGAGCTAATTCTGTACGACAAAGAGGAGACCAGGAGGATTTGGCGTCAAGCGAAC
AATGGAGAGGACGCAACTGCTGGTCTCACCCACCTGATGATATGGCATTCCAATCTAAATGAT
GCCACATATCAGAGAACGAGAGCTCTCGTGCGTACTGGAATGGACCCAAGGATGTGCTCTCTG
ATGCAAGGGTCAACTCTCCCGAGGAGATCTGGAGCTGCCGGTGCAGCAGTAAAGGGGGTAGG 
GACAATGGTGATGGAGCTGATTCGGATGATAAAACGAGGAATCAACGACCGGAATTTCTGGA
GAGGCGAAAATGGAAGAAGAACAAGGATTGCATATGAGAGAATGTGCAACATCCTCAAAGG
GAAATTCCAAACAGCAGCACAAAGAGCAATGATGGATCAAGTGCGAGAGAGCAGAAATCCT
GGGAATGCTGAAATTGAAGATCTCATTTTTCTGGCACGGTCTGCACTCATCCTGAGAGGATCA
GTGGCCCATAAGTCCTGCTTGCCTGCTTGTGTGTACGGACTTGCGGTGGCCAGTGGATATGAC
TTTGAGAGAGAAGGGTACTCTCTGGTTGGAATAGATCCTTTCCGCCTGCTTCAAAACAGCCAG
GTCTTTAGTCTCATTAGACCAAATGAGAATCCAGCACATAAGAGTCAATTAGTGTGGATGGCA
TGCCACTCTGCAGCATTTGAGGACCTTAGAGTCTCAAGTTTCATCAGAGGGACAAGAGTGGTC
CCAAGAGGACAGCTATCCACCAGAGGGGTTCAAATTGCTTCAAATGAGAACATGGAGGCAAT
GGACTCCAACACTCTTGAACTGAGAAGCAGATATTGGGCTATAAGAACCAGAAGCGGAGGAA
ACACCAACCAGCAGAGGGCATCTGCAGGACAGATCAGCGTTCAGCCCACTTTCTCGGTACAG
AGAAACCTTCCCTTCGAAAGAGCGACCATTATGGCAGCATTTACAGGAAATACTGAGGGCAG
AACGTCTGACATGAGGACTGAAATCATAAGAATGATAGAAAGTGCCAGACCAGAAGATGTGT
CATTCCAGGGGCGGGGAGTCTTCGAGCTCTCGGACGAAAAGGCAACGAACCCGATCGTGCCT
TCCTTTGACATGAATAATGAAGGATCTTATTTCTTCGGAGACAATGCAGAGGAATATGACAAT
TGA* 
 
Figure 3.5c. Sequencing of NP gene in vector pEFL29. Unique SmaI site is shown in bold. EcoRV 
site (italic) was inserted to facilitate blunt-end ligation. The sequencing primer positions are 
highlighted, while their orientations are indicated by arrows. P7.5 early/late promoter is not 
shown. 
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Clones of recombinant viruses were produced by transfection of 80% confluent primary 
chicken embryo fibroblasts (CEFs), infected with FWPV, with pEFL29/inserts using 
lipofectin. The completely sequenced, highly attenuated FP9 strain of FWPV (Laidlaw 
and Skinner, 2004) was used as the recipient vector. The expression cassette was inserted 
into the viral genome by recombination at the fpv002 locus. Expression of the gene was 
driven by a copy of the Vaccinia virus p7.5 early/late promoter. A copy of the LacZ gene, 
transcribed from the fowlpox P4b late promoter in the opposite direction, served as a 
marker for selection of recombinant viruses. After isolations by six fold plaque 
purification on CEFs using X-Gal selection (blue plaque selection), recombinants were 
checked for presence of the inserted genes by PCR of extracted FWPV genomic DNA 
(Figure 3.6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6. Agarose gel showing the presence of AIV genes incorporated into FWPV FP9 
genome confirmed by PCR, using internal primers, after genomic DNA extraction. Recombinant 
FP9 carrying the H5 gene gave a 1695 bp PCR product, FP9 carrying the N1 gene gave a 1350 bp 
product, while FP9carrying the NP gene gave a 1497 bp product. M is a ladder marker. 
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3.3 Construction of recombinant FWPV co-expressing influenza and cytokine 
genes 
3.3.1 Deletion of one HindIII site of pPC1.X vector  
Vector pPC1.X has two HindIII sites located 1274 bp apart from one another. The 
HindIII site located external to the PC-1 (fpv030) open reading frame (ORF) was 
removed so as to obtain a unique HindIII site for cloning inserts within the PC-1 ORF. 
This was achieved by partial digestion of pPC1.X. Firstly, as a trial, 1 μg of pPC1.X was 
digested with 1 U of HindIII, sampling at sequential time intervals (from 5 to 85 minutes) 
prior to agarose gel electrophoresis. Analysis of the products of partial digestion (Figure 
3.7) indicated that 75 minutes offered the optimal yield of singly-cut, linearised product 
so a further 2 μg of pPC1.X was digested  for 75 min using 2 U of HindIII in a total 
volume of 50 μL.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7. Pattern of vector pPC1.X after partial digestion with HindIII at time intervals. The 
band size of interest is 5.6 kbp. M is a ladder marker. Lanes correspond to pPC1.X pattern at 
specifies time intervals (in minutes). 
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After gel electrophoresis, a 5.6 kbp band, which corresponded to the required product, 
was extracted (Figure 3.8). The product was subjected to end repair using Klenow 
polymerase before blunt-end religation to eliminate one HindIII site. Twelve colonies 
were picked after transformation of the product; plasmid DNA was isolated and doubly 
digested with HindIII and NsiI to enable selection of clones with the correct HindIII site 
knocked-out (Figure 3.9). Correct knock-outs displayed 789 bp and 4802 bp products on 
gel electrophoresis, while incorrect knock-outs gave 502 bp and 5098 bp products. Based 
on the figure, recovery of clones digested at the desired site predominated (ten out of 
twelve gave positive knock-outs).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8. Pattern of vector pPC1.X after incomplete digestion with HindIII for 75 minutes. 
Band size of interest is 5.6 kb. M is a ladder marker.  
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Figure 3.9. Screening of vector pPC1.X for the desired HindIII knockout by restriction enzyme 
digestion using HindIII and NsiI. Lanes 1 to 12 are from partially-digested and religated pPC1.X 
clones. The desired knockout gives fragments of 789 bp and 4802 bp in size, while knockout of 
the other site results in 502 and 5098 bp products. M corresponds to a ladder marker. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 107 
3.3.2 Transdominant selection for recombinant FWPV carrying cytokine genes 
A procedure for eliminating the selectable marker, in this case the Ecogpt gene (E. coli 
guanine phosphoribosyltransferase), from the final recombinant virus was established by 
Falkner and Moss in 1990. It was termed ‘transient dominant selection’ (TDS). They 
showed that, under nonselective condition, ten out of ten vaccinia virus plaques became 
gpt- after only three cycles of plaque picking, and five of these were the required 
recombinants.  The procedure has been used successfully to knockout many FP9 genes 
(Boulanger et al., 1998; Laidlaw et al., 1998; S. Laidlaw and M. A. Skinner, personal 
communication) and to introduce genes for expression (Jeshtadi et al., 2005; M. A. 
Skinner, personal communication). In brief, recombinant viruses containing Ecogpt gene 
were selected in the presence of mycophenolic acid (MPA). In this study, the gene 
marker was incorporated into FP9 genome by homologous recombination with 
derivatives of vector pPC1.X contains inserted IL-15 or IL-12 expression cassettes to the 
FWPV PC1 gene corresponds to ORF 030 of the viral genome (Laidlaw et al., 1998; 
Laidlaw and Skinner, 2004). MPA inhibits inosine monophosphate dehydrogenase, 
leading to arrest of the de novo purine metabolism pathway, and thus wild type FP9 
replication. However, in recombinant FP9 containing Ecogpt, the expression of this gene 
(in the presence of exogenous xanthine and hypoxanthine) permits purine metabolism via 
the salvage pathway, allowing replication. Removal of the gpt marker is desirable, and it 
is achieved spontaneously when MPA selection is lifted, resulting in the production of 
stable viruses, half of which will carry the cytokine genes (S. Laidlaw and M. A. Skinner, 
personal communication). The TDS strategy used in this study is illustrated in Figure 
3.10.  
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Figure 3.10. Transdominant selection strategy for recombinant FWPV. A first recombination 
occurs between the flanking sequence of the FWPV PC1 (fpv030) ORF encoded by vector 
pPC1.X and those in parental FP9. MPA was used to select the unstable intermediate viruses 
containing gpt gene. Removal of MPA selection led to resolution of the recombinants with loss of 
the gpt gene by a second crossover event. The final result was viruses containing either wild type 
PC1 or mutant PC1 with a cytokine gene insert. 
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Refer to page 3.10c       Refer to Figure 3.10b  
3.3.3 Generation and selection of cytokine gene-positive transformants  
The overall strategy of cytokine gene cloning is illustrated in Figure 3.11a, 3.11b and 
3.11c. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11a. Cloning of chIL-15 and chIL-12 into vector pEFgpt12S. Vector pGEMT-
Easy/ChIL-15 possessed ampicillin resistant gene, AmpR, pCDNA3.1/ChIL-12 contained 
ampicillin and neomycin resistance genes, AmpR and NeoR, respectively, while pEFgpt12S 
contains kanamycin resistance gene, KanR. IL-15 and IL-12 inserts were cloned upstream of a 
synthetic promoter (S prom) Wittek. VAC P7.5 e/l served as a promoter for the expression of a 
selectable marker, Ecogpt gene. 
PstI/SacII 
PmeI-digested 
IL-12 fragment 
into XbaI end 
repaired-
pEFGPT12S 
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Figure 3.11b. Cloning of chIL-15 with S promoter into vector pPC1.X. Vector pEFgpt12S/ChIL-
15 possessed kanamycin resistant gene, KanR, while pPC1.X contained ampicillin resistant gene, 
AmpR. IL-15 and a synthetic promoter (S prom) Wittek were cloned into vector pPC1.X which 
contained recombination sequences of FWPV PC1 gene (fpv030). VAC P7.5 e/l served as a 
promoter for the expression of a selectable marker, Ecogpt gene. 
 
 
 
 
 
 
 
Note: PstI and 
NsiI have 
compatible ends 
page …. 
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Figure 3.11c. Cloning of chIL-12 with S promoter into vector pPC1.X. Vector pEFgpt12S/ChIL-
12 possessed kanamycin resistant gene, KanR, while pPC1.X contained ampicillin resistant gene, 
AmpR. IL-12 and a synthetic promoter (S prom) Wittek were cloned into vector pPC1.X which 
contained recombination sequences of FWPV PC1 gene (fpv030). VAC P7.5 e/l served as a 
promoter for the expression of a selectable marker, Ecogpt gene. 
Note: The p35 and 
p40 subunit of IL-12 
were fused as p70 in 
the cloning and 
expression strategy 
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Chicken cytokine genes IL-15 and IL-12 were first individually inserted downstream of a 
synthetic/hybrid promoter (a kind gift of the late Dr Rico Wittek) in vector pEFgpt12S, 
by sticky-end or blunt-end cloning, respectively. The promoter–gene cassettes were 
subcloned into recombination vector pPC1.X (see Chapter 2). A 737 bp NsiI to XmaI 
fragment from pPC1.X/IL-12 was excised to achieve balanced lengths for the left and 
right flanks of the PC-1 homology region (data not shown). This was to ensure equivalent 
efficiencies of recombination between both flanks of the insert and the FWPV genome, 
so that progeny of the trans-dominant selection method had equal chances of bearing the 
cytokine expression cassette or not, with no bias for the parental phenotype. All positive 
transformants were confirmed by gel electrophoresis after restriction digests (Figure 
3.12) before being sent for sequencing (Figure 3.13a and 3.13b). 
 
 
 
Figure 3.12. Confirmation of insertion of cytokine genes into vectors pEFgpt12S and pPC1.X by 
restriction enzyme digestion. A) pEFgpt12S carrying IL-15 was digested with EcoRV, giving 
1407 bp and 5794 bp fragments. pEFgpt12S carrying IL-12 was digested with HindIII, giving 
1598 bp and 6312 bp fragments. B) pPC1.X carrying IL-15 and IL-12 were digested with EcoRI. 
IL-15-positive recombinant clones of pPC1.X were identified by products of 460 bp, 1810 bp and 
2825 bp; IL-12-positive clones by 418 bp, 2925 bp and 3195 bp fragments. A 737 bp fragment 
from pPC1.X/IL-12 had been removed previously. M is a ladder marker. 
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AGCTTCCCCGATAAAAATATAGTAGAATTTCATTTTGTTTTTTTCTATGCTATAAATAGGATCC
GATAAAGTGAAAAATAATTCTAATTTATTGCACGGTAAGGAAGTAGAATCATAAAGAATCGA
ATTGCGGCCGCTCCAGAATTCTAGAGCGGCCGCCACCGCGGGAATTCGATT 
ATGCTGGGGATGGCACAGCCAACACAAAACTCTGCCGGAGCACGGAGAAGGCCGGAGAGTC
AGAAAACACATGTGAAAAGTATTTGTCTCCAGTACCAACTGTATCTACTTTTGAACAGCCATT
TCTTTTGCCTTTTAAAGAATAAGACTGGACTAACCATCTTCTTCCTATGTGCTTATGTACCAAA
GACAGAAGCAAATCACTGTAAGTGGTCAGACGTTCTGAAAGATTTGGAGCTGATCAAGACAT
CTGAAGACATTGATGTCAGTTTATATACTGCAAACACATACGAGGATATAGAATGCCAGGAA
CCTGTAATGAGATGTTTTTTTTTAGAGATGAAAGTGATTCTTCACGAATGTGATATCAAAAAA
TGTAGTAGGAAGCATGATGTACGGAACATATGGAAAAATGGAAATGCAAGATTTGCAACTTA
CCAGTTGAATTCCACAACAGCAAAAAAATGCAAAGAATGTGAAGAGTATGAAGAAAAAAATT
TTACAGAATTTATACAGAGTTTTGTAAAGGTTATACAGAGGGAATGCAAAAAATACGCTAACT
AA*AATCACTAGTGAATTCGCGGCCGCCTGCATTCTTTAGATTCTTCTTTTACAGGATACAATG
TATAATTATCACTGTGTATAGACATATCTTCATCGGACTGATATCCATGATCCATAGTGGTACT
ATTTTTCATAGACATTCGTATAAACTAATTACTTAATCCATCATTTTTATTATATATTATTGTTT
GAAAGAAAAAAATACGCGATAAAATAACAATTATTATACTTGATACGAGTTTGAATTCTTATT
TTTCAACAATATCACGT 
 
Figure 3.13a. Sequencing of the IL-15 gene inserted into a derivative of vector pPC1.X. HindIII 
(AGCTT) and NsiI (CACGT) partial restriction sites used for cloning are shown in bold and 
italic. The sequencing primer positions are highlighted, while their orientations are indicated by 
arrows. Forward and reverse primers complementary to pPC1.X are not shown. S promoter 
sequences are highlighted in a darker shade. The AUG start codon is indicated by double 
underlining; the UAA stop codon by an asterisk (*). 
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AGCTTCCCCGATAAAAATATAGTAGAATTTCATTTGTTTTTTTCTATGCTATAAATAGGATCCG
ATAAAGTGAAAAATAATTCTAATTTATTGCACGGTAAGGAAGTAGAATCATAAAGAATCGAA
TTGCGGCCGCTCCAGAATTCTAGAAACGGGCCCTCTAGACTCGAGCGGCCGCC 
ATGTCTCACCTGCTATTTGCCTTACTTTCATTACTTTCCTTTGCTGCCCTTCTGGAAGCACAGTG
GAAACTTAGAGAGAATGTGTATGTCATAGAATCTGAGTGGAACGATGAGACACCAGCTAAAA
AAGTGAAGCTCACCTGTGACACATCTGATGAAGCACTGCCAGTTTACTGGAAAAAGGGAACA
GAACTGAAAGGAACTGGAAAGACTCTGACCACCGAAGTGAAGGAGTTCCCAGATGCTGGCAA
CTACACCTGCCTGTCTGCTAAGACCCACGAGATTATCAGCTACAGTTTCTTTCTCATAACTAAA
GTAGACTCCAATGGGCAAATGATACGGTCAATTCTGAAAAGCTATAAAGAGCCAAGCAAGAC
GTTCTTAAAATGTGAGGCAAAGAACTACTCTGGAATTTTCACATGTTCATGGATGACAGAAAA
TGAGAGTCCAAGTGTGAAGTTCACAATTAGGAGCCTAAAAGGCTCTCAAGGAGATGTAACCT
GCAGCAGCCCTGTGGCTCGCACTGATAAATCTGTGACTGAATACACTGCCCAGTGCCAGAAGG
AAAACTACTGTCCATTTGCCGAAGAGCACCAGCCGACTGAGATGTTCCTGGAGGTCATTGATG
AGGTGGAATATGAGAACTACACTAGTAGCTTCTTCATCAGAGATATCATAAAGCCAGACCCAC
CTCAATGTCAGTATGCAAGCACAAATGGAACTGTGACCTGGACATATCCCAAGACCTGGAGC
ACACCGAAGTCCTACTTCCCTTTGACTTTCAGGGTCAAAGTTGAAAGCACAAAGAAATACAAA
AGCAAGGTTTATGATGCTGATGAGCAGTCTATTCAGATTCCAAAGACTGGGCCAAAAGACAA
GATCTCTGTGCAGGCCAGGGATCGCTATTACAACTCATCCTGGAGTGAGTGGTCCACGCTTTG
CAGA  GGTGGCGGTGGCTCGGGCGGTGGTG 
GATCCGGTGGCGGCGGATCTCTGCCACTTCCTGCCCACAACCTGGCCAAGGGACTCAACTGCT
CCAGGGCGCTGCTGGCCGCTGCAAACGAGGCACTCCTGAAGGTGCAGAAGCAGAGGACGCTG
GGGTTTGAGTGCACCCTTGAAGAGGTCGATCTTGAAGACGTCACCAACAGTCAGAGCAACAC
AATAAAGTCCTGCACGTCTCACGATCCGGGGCCTGGAAACTGCCCCGTACTGGAAAGTTCTAC
TTTAGATATGAGCAAATGCCTGCAGGGGATCTACGAAGACCTGAAAACCTACAAGGCAGAGC
TGGGGAACCTCAAGGATCTGAGGGTGCTGACATCCATTGATGACATGATGCAAGCCCTGCAG
CCCCGCAGCCCAGCCATGCCGCAGCCCTCGCCCAGCACCACCCTTGGCTCCTTCCAGGGCCGC
ATGCGGCTCTGCGGGGTCCTGCACGCCTTCTGCCTGCGCGCAGTCACCATCGGCAGGATGCTG
GGCTACCTGAGTGCCCTCACTGCAGAGATGTAA*AAGCT 
 
Figure 3.13b. Sequencing of the fusion IL-12 (p70) gene inserted into a derivative of vector 
pPC1.X. IL-12β (p40) subunit is separated from IL-12α (p35) by 25 nucleotides, displayed in 
italic. HindIII (AGCTT) and NsiI (CACGT) partial restriction sites used for cloning are shown in 
bold and italic. The sequencing primer positions are highlighted, while their orientations are 
indicated by arrows. Forward and reverse primers complementary to pPC1.X are not shown. S 
promoter sequences are highlighted in a darker shade. The AUG start codon is indicated by 
double underlining; the UAA stop codon by an asterisk (*). 
 
 
 115 
3.3.4 Introduction of cytokine expression cassettes into rFWPV 
The cytokine expression cassettes, driven by the S promoter obtained from the 
pEFgpt12S vector, were inserted into rFWPV already carrying avian influenza genes by 
recombination at a second non-essential site, the PC1 locus (fpv030; Laidlaw et al., 1998; 
Skinner, unpublished). Following three rounds of passage in CEFs, in the presence of 
mycophenolic acid (MPA), recombinant viruses carrying the gpt gene (driven by a copy 
of the Vaccinia virus p7.5 early/late promoter) were isolated. Dilutions of viruses from 
the third passage were plaqued onto 60 mm dishes in the absence of MPA. Ten plaques 
were picked into serum free DMEM (500 μL). Plaque-purification, using ten plaques 
each time, was repeated several times until the originally gpt+ recombinant clones had 
lost the gpt gene spontaneously. This was verified by failure of the virus (at high 
concentration) to replicate in the presence of MPA.  
 
When intermediate gpt+ recombinant viruses lose the gpt gene, they resolve either to the 
desired recombinant virus or revert back to parental virus (losing the cytokine inserts) so, 
PCR analysis of their viral DNA genomes was carried out after every stage of plaque-
purification, to assay for retention of the cytokine gene. A flanking primer set was 
applied to screen IL-12-recombinant clones.  Recombinant FP9/AIV genes showed a 984 
bp PCR product, while introduction of IL-12 into the genome generated a 1934 bp 
product (Figure 3.14). 
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Figure 3.14. Screening extracted FP9 virus genome for the incorporated IL-12 gene using PCR. 
Primers used were pPC1.X-F and pPC1.X-R. Intermediate viruses demonstrate two fragments, 
984 bp (without IL-12) and 1934 bp (IL-12 integrated). Recombinant FP9 viruses which lost the 
IL-12 insert was indicated by a single 984 bp fragment. Resolved recombinant FP9 to mutant 
carrying IL-12 was illustrated by a single 1934 bp fragment, alongside the IL-12 positive control 
product. M is a ladder marker. 
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In contrast to the IL-12 screening, the use of flanking primer sets was inappropriate for 
IL-15-clone screening, as the PCR product size for IL-15-positive clones was not 
sufficiently different to that for clones without inserts (Figure 3.15). Therefore, the 
screening of IL-15-carrying clones used primers external (pPC1.X-F) and internal (IL-15-
R) to the inserted genes (the latter resulting in PCR products of 700 bp, exclusively for 
recombinant clones). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15. Screening of extracted FP9 virus genome for the incorporated IL-15 gene using 
PCR. Primers used were pPC1.X-F and IL-15-R. No PCR product was observed for recombinant 
FP9 clones lacking the insert. Recombinant FP9 clones with IL-15 gene integrated showed a 700 
bp PCR fragment, correspond to the IL-15 positive control product, obtained using plasmid 
template. M is a ladder marker. 
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Despite the rapid loss of gpt as described by Falkner and Moss (1990) (Section 3.3.2), 
only two of the putative recombinant viruses, FP9/H5/IL-15 and FP9/N1/IL-12, 
successfully resolved after five and three plaque purifications, respectively. The other 
putative recombinant viruses (FP9/H5/IL-12, FP9/N1/IL-15, FP9/NP/IL-15 and 
FP9/NP/IL-12) were still in their intermediate forms even after the sixth plaque 
purification. The reasons for this were not further explored. It is possible that the original 
insertion was aberrant, occurring via non-homologous recombination at a non-specific 
site. Consequently, the wild-type insertion site would always remain; the intermediate 
recombinant can never be resolved by the normal second round of homologous 
recombination shown in Figure 3.10. The disrupted insertion site (bearing the cytokine 
expression cassette), carried on the aberrantly inserted recombination plasmid, could 
either be lost at the same time as gpt was lost, or (as appears to be the case) might remain, 
especially if the aberrant insertion was at a non-essential site. Screening the initial 
intermediate recombinants to demonstrate bona fide insertion at the correct site before 
progressing to isolate resolvants might have precluded this problem.  
 
Time constraints precluded restarting the selection process so, as there were indications 
that the unresolved clones were stable, they were allowed to grow in the presence or 
absence of MPA (+MPA or –MPA) so that their stability could be assessed. Stocks of the 
recombinant viruses were prepared and titrated. The final virus titres are shown in Table 
3.1. 
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Table 3.1. Titration of constructed recombinant viruses 
Virus Final concentration (PFU/mL) 
WT FP9 1.50 x 10E6 
FP9/H5 1.48 x 10E6 
FP9/N1 1.45 x 10E7 
FP9/NP 3.45 x 10E6 
FP9/H5/IL-15 1.58 x 10E6 
FP9/H5/IL-12gpt +MPA 8.80 x 10E5 
FP9/H5/IL-12gpt –MPA 4.60 x 10E5 
FP9/N1/IL-15gpt +MPA 3.03 x 10E6 
FP9/N1/IL-15gpt –MPA 3.50 x 10E5 
FP9/N1/IL-12 3.46 x 10E6 
FP9/NP/IL-15gpt +MPA 2.07 x 10E6 
FP9/NP/IL-15gpt –MPA 6.20 x 10E5 
FP9/NP/IL-12gpt +MPA 6.20 x 10E6 
FP9/NP/IL-12gpt –MPA 9.70 x 10E5 
 
3.3.5 Expression of avian influenza (AIV) and cytokine gene inserts by rFWPV 
In order to analyze expression of the AIV and cytokine genes, SDS-PAGE and western 
blotting were carried out for lysates of CEFs infected with the recombinant viruses. 
Additional indirect immunofluorescence test, IFAT, was performed to ascertain AIV H5 
and N1 expressions. One polyclonal antiserum for H5, one polyclonal antiserum for N1 
and three antibodies for NP were used as probes for the proteins in western blot, while 
one polyclonal antiserum each was used for H5 and N1 in IFAT. The list of antibodies is 
in Table 3.2.  
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Table 3.2. Polyclonal or monoclonal antibodies used in this study 
Name Analysis Description Dilution Antigen Source 
ab62587  Western 
blot 
Goat 
polyclonal 
1:1000 Avian Influenza A 
haemagglutinin 5 
(synthetic peptide 
corresponding to 12 amino 
acids near the amino 
terminus) 
Abcam 
ab70077 Western 
blot, 
IFAT 
Rabbit 
polyclonal 
1:1000 Avian Influenza A 
haemagglutinin 5 
(synthetic peptide 
corresponding to 14 amino 
acids near the centre of 
H5N1 strain, 100% 
homology to 
A/China/GD01/2006)   
Abcam 
ab36566  Western 
blot 
Rabbit 
polyclonal 
1:1000 Avian Influenza A 
neuraminidase 1 (synthetic 
peptide, corresponding to 
15 amino acids at the C 
terminal) 
Abcam 
ab70759 Western 
blot, 
IFAT 
Rabbit 
polyclonal 
1:1000 Avian Influenza A 
neuraminidase of 
A/H5N1/Vietnam/1203/20
04 
Abcam 
ab25921  Western 
blot 
Rabbit 
polyclonal 
1:500 Avian Influenza 
nucleoprotein (synthetic 
peptide corresponding to 
amino acids 58-77) 
Abcam 
2F6C9  Western 
blot 
Mouse 
monoclonal 
1:2000 Avian Influenza 
nucleoprotein  
Barclay, 
Imperial 
College 
5D8  Western 
blot 
Mouse 
monoclonal 
1:500 Avian Influenza 
nucleoprotein  
Santa 
Cruz 
HC8  Western 
blot 
Mouse 
monoclonal 
1:1000 Avian interleukin 12  Kaiser, 
IAH 
β-
galactosi
dase 
Western 
blot 
Mouse 
monoclonal 
1:5000 E. coli β-galactosidase near 
the C terminal 
Promega 
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3.3.5.1 Analysis of nucleoprotein expression by rFWPV. 
Nucleoprotein (NP) accumulates in the nucleus upon AIV infection. Therefore, a strong 
buffer, RIPA (which contains three types of detergent), was used for cell lysis so as to 
lyse the nuclear membrane to release nuclear proteins. Initially 2F6C9, a monoclonal 
antibody provided by Prof Barclay, was used as a primary antibody at a dilution of 
1:1000. A band of ~56 kD (as expected based on the predicted molecular weight of native 
NP) was observed for all the samples, including the negative controls (uninfected and 
parental FP9-infected CEFs). Indeed it was faintest in the positive control (RG14 
recombinant influenza virus). No such band was observed in the Marker lanes (Figure 
3.16). The same outcome was observed when 5D8 antibody, purchased from Santa Cruz 
Biotechnology, was used at dilution of 1:500 (Figure 3.17).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16. Western blot analysis of a mouse anti-nucleoprotein monoclonal antibody, 2F6C9 
(kindly supplied by Prof Barclay). Lanes showed lysates of uninfected CEF, or CEF infected with 
different viruses. M is a protein marker. 
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Figure 3.17. Western blot analysis of a mouse anti-nucleoprotein monoclonal antibody, 5D8 
(Santa Cruz Biotechnology). Lanes showed lysates of uninfected CEF, or CEF infected with 
different viruses. M is a protein marker. 
 
As the observed band would seem to be a cross reacting chicken protein, the specificity 
of the 5D8 monoclonal antibody was investigated further. Three different avian cell lines, 
CEF, DF1 and QT-35, were cultivated for 48 hours without any infection. DF1 is an 
immortal chicken embryo fibroblast cell line developed using conventional passage 
techniques by Douglas Foster in 1998 (Schaefer-Klein et al., 1998), while QT-35 is a 
continuous cell line of Japanese quail origin. Three different types of sera, new-born 
bovine serum (GIBCO), fetal bovine serum (Autogen BioClear) and fetal bovine serum 
(BioSera), were included in the cell medium (DMEM), separately. The supplemented 
cells were compared with cells grown in DMEM without any serum. The aim of this 
experiment was to evaluate the band pattern of other uninfected avian cells treated with 
the same primary antibody, and to investigate whether a serum plays a role in blocking 
detection of the band by the antibody. All of these uninfected samples generated a ~56 
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kD protein band, although two minor bands (possibly degradation products) with sizes of 
less than 50 kD were evident with QT-35 lysates. The constant level of labelling suggests 
that the nature of the cultivation sera does not affect detection of the band by each 
antibody (Figure 3.18), suggesting that the protein is unlikely to be a serum protein and is 
more likely to be a cellular protein. As yet, the comparison has not been extended to non-
avian cell lines. 
 
 
 
 
 
 
 
 
 
 
Figure 3.18. Western blot analysis of a mouse anti-nucleoprotein monoclonal antibody, 5D8 
(Santa Cruz Biotechnology). Lanes 1 showed particular cells grown in DMEM without serum. 
Lanes 2 showed particular cells grown in DMEM with NBBS (GIBCO). Lanes 3 showed 
particular cells grown in DMEM supplemented with FBS of Autogen Bioclear. Lanes 4 showed 
particular cells grown in DMEM with FBS from BioSera. M is a protein marker. 
 
A further experiment was performed using ab25921 (diluted at final concentration of 1 
μg/mL), acquired from Abcam. Immunogen for this antibody is a synthetic peptide 
corresponding to amino acids 58-77 of AIV NP. However, the result was a relatively 
consistent band pattern, including several strong bands (at ~95 kD & ~63 kD) observed 
across the recombinants as well as positive or negative controls. No band unique to the 
recombinants was observed, though there was a band at ~60 kD common only to lanes 
carrying lysates infected with FP9 (WT or recombinant) (Figure 3.19). The ~56kD band 
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seen with 5D8 was not prominent. Once again, the pattern was not seen in the Marker 
lanes, though some faint, diffuse bands were present.  
 
These results were unexpected and are not easy to explain. In none of these cases has a 
second antibody-only control yet been performed, to ascertain whether the cross 
reactivity is due to the primary or secondary antibody. A simple explanation for these 
results might be a failure to block adequately, or to wash adequately, so that low affinity 
cross-reactions are observed. Clearly ab25921 can distinguish between FP9-infected and 
uninfected cell lysates (via the ~60 kD band; Figure 3.19), even though the antiserum is 
claimed to be specific for an NP peptide. A different cross-reactive band was seen with 
DF1, at ~120 kD.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.19. Western blot analysis of a mouse anti-nucleoprotein monoclonal antibody, ab25921 
(Abcam). Lanes showed lysates of uninfected CEF, DF1 and QT35, or CEF infected with 
different viruses. M is a protein marker. 
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3.3.5.2 Analysis of H5 expression by rFWPV. 
In order to detect H5 expression by the recombinants, ab62587 (Abcam) was used as a 
primary antibody at a final concentration of 1 μg/mL. The immunogen for this antibody 
was a synthetic peptide corresponding to 12 amino acids near the amino terminus (N-
terminus) of the AIV HA protein. While the predicted size of unglycosylated H5 protein 
is 64 kD, the positive control (RG14-infected CEF cells) displayed a distinct protein size 
of ~80 kD, the difference probably being due to glycosylation (though this was not 
checked by the use of inhibitors or glycosidases). No such expression was observed for 
any of the rFWPV (Figure 3.20).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.20. Western blot analysis of a goat anti-haemagglutinin polyclonal antibody, ab62587 
(Abcam). Lanes showed lysates of uninfected CEF, DF1 and QT35, or DF1 infected with 
different viruses. M is a protein marker. 
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A subsequent analysis was performed using Abcam's ab70077, diluted to a final 
concentration of 1 μg/mL. The immunogen for this rabbit polyclonal primary antibody 
was a synthetic peptide corresponding to 14 amino acids near the middle of AIV H5 
strain A/China/GD01/2006. A commercial kit using the chromogenic substance, 
WesternBreeze (Invitrogen) was used to replace the conventional western blot procedure. 
A faint band at ~50 kD was observed for H5 recombinant, none for uninfected cell lysate 
and negative control (Figure 3.21). Reproducibility was difficult due to limited virus 
stock. As an alternative approach, IFAT was performed using the same antibody. 
Fluorescent signals were detected only for CEF infected with H5 recombinant, no 
reactivity was observed for uninfected or negative control (WT FP9)-infected CEF 
(Figure 3.22).  
 
 
Figure 3.21. Western blot analysis using a rabbit anti-haemagglutinin polyclonal antibody, 
ab70077 (Abcam). Lanes showed lysates of uninfected CEF, CEF infected with wild type FP9 
and CEF infected with recombinant FP9/H5. M is a protein marker. Blot was presented in an 
original version (A) or an edited version, to increase the contrast (B). Blot of cell lysates was 
darker than the Marker due to the final staining procedure using a chromogenic reagent (purple).  
 
(A) (B) 
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A(i) 
B(i) B(ii) 
C(i) C(ii) 
A(ii) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.22. Indirect immunofluorescence assay, IFAT, of H5 recombinant. CEF cell cultures 
were grown until 80% confluent on coverslips, and either remained uninfected (A), infected with 
wildtype FP9 (B) or infected with recombinant FP9 carrying H5 gene (C). After 19 hours, the 
cells were incubated with Abcam's ab70077 primary antibody for 2 hours, before counterstained 
with a fluorescein-labeled anti-rabbit antibody, for an hour. (i) showed CEF under visible light, 
while (ii) showed cells under UV light. Positive fluorescence was observed only in C(ii). The 
images did not represent 80 % of cell confluency due to repeated washing of the cells (without 
fixing) in IFAT procedure. 
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3.3.5.3 Analysis of N1 expression by rFWPV. 
To examine the expression of N1, we used the ab36566 primary antibody (Abcam). The 
immunogen for this antibody was a synthetic peptide, corresponding to 15 amino acids at 
the C terminus of AIV NA. The predicted size of the unglycosylated N1 protein is 49 kD, 
based on its deduced amino acid sequence. However, a faint, diffuse ~60 kD band, 
instead of 49 kD, was present in the positive control, suggesting a glycosylated product. 
Besides the band seen in the positive control, the analysis revealed no unique  protein 
band among the recombinant virus lysates. Lysates from DF1s infected with FP9 (both 
WT and recombinant), but not from uninfected DF1s, generated two strong bands of ~65 
kD and ~70 kD (presumably FWPV proteins), with no sign of the N1 band (Figure 3.23). 
A band at about 42 kD was present in all samples, infected or uninfected, CEF, DF1 or 
QT35 (in which it was stronger and accompanied by an equally strong band at 45 kD), 
but not in the Marker lanes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.23. Western blot analysis of a rabbit anti-neuraminidase polyclonal antibody, ab36566 
(Abcam). Lanes showed lysates of uninfected CEF, DF1 and QT35, or DF1 infected with 
different viruses. M is a protein marker. 
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  M 
M 
Further western blot analysis was performed using WesternBreeze (Invitrogen). Abcam's 
rabbit polyclonal, ab70759, was diluted at a final concentration of 1 μg/mL. Immunogen 
for this primary antibody is a neuraminidase of influenza A/H5N1/Vietnam/1203/2004. A 
prominent band was observed at ~48 kD, which corresponding to the predicted 
unglycosylated size, 49 kD (Figure 3.24). Using the same primary antibody in IFAT, 
fluorescent signals were detected only for N1 recombinants, not for the negative controls 
(Figure 3.25). 
 
 
 
 
Figure 3.24. Western blot analysis of a rabbit anti-neuraminidase polyclonal antibody, ab70759 
(Abcam). Lanes showed lysates of uninfected CEF, CEF infected with wild type FP9 and CEF 
infected with recombinant FP9 carrying N1 gene. M is a protein marker. Blot was presented in an 
original version (A) or an edited version, to increase the contrast (B). Blot of cell lysates was 
darker than the Marker due to the final staining procedure using a chromogenic reagent (purple).  
 
 
 
 
(A) (B) 
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A(i) 
B(i) B(ii) 
A(ii) 
C(i) C(ii) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.25. Indirect fluorescent antibody test of N1 recombinant. CEF cell cultures were grown 
until 80% confluent on coverslips, and either remained uninfected (A), infected with wildtype 
FP9 (B) or infected with recombinant FP9 carrying N1 gene (C). After 19 hours, the cells were 
incubated with Abcam's ab70759 primary antibody for 2 hours, before counterstained with a 
fluorescein-labeled anti-rabbit antibody, for an hour. (i) showed CEF under visible light, while 
(ii) showed cells under UV light. Positive fluorescence is observed only in C(ii). The images did 
not represent 80 % of cell confluency due to repeated washing of the cells (without fixing) in 
IFAT procedure. 
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In conclusion, expression of H5 and N1 by rFWPV has been detected using a commercial 
western blotting kit and IFAT.  However, the RG14 positive control was not available for 
these analyses. It is not clear whether the difficulties experienced in AIV protein 
detection were a function of the antigens used to produce the primary antibody, affecting 
specificity, or a technological issue relating to the sensitivity of detection method.  
 
There are several possible reasons for the inability to detect expression of H5 and N1 by 
the recombinants using conventional western blotting procedures. Firstly, the viruses 
might not actually be recombinant. This possibility was excluded by western blotting 
with an antibody against β-galactosidase protein (Promega), expressed by the LacZ 
selectable marker carried on pEFL29 (into which the AIV genes were inserted). A band 
of ~130 kD, similar to the predicted size of β-galactosidase expressed by pEFL29 (120 
kD), was detected in FP9 recombinant for H5, N1 and NP. No band was observed for 
FP9 WT nor for uninfected CEF (Figure 3.26). Confirmation of the presence of the 
respective AIV genes by PCR therefore confirms that the viruses are actually 
recombinant and have integrated the respective expression cassettes from the 
corresponding pEFL29 derivatives. Naturally it does not per se demonstrate the function 
of the expression cassettes. 
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Figure 3.26. Western blot analysis of a mouse anti-β-galactosidase monoclonal antibody 
(Promega). Lanes showed lysates of uninfected CEF or CEF infected with different viruses. M is 
a protein marker. 
 
 
 
The second possibility, and most likely, is that the actual level of expression (or, more 
precisely, the steady state level) was below the detectable limit. This would be somewhat 
surprising, given that the VACV p7.5 promoter used to express recombinant proteins  in 
pEFL29 is, though not the strongest poxvirus promoter available, tried and tested with a 
good ‘track record’ of success for many diverse proteins. Increasing the MOI of the 
recombinant viruses might possibly should boost the expression to a level that could be 
detected. 
 
Thirdly, mutations in the PCR-generated AIV gene inserts might lead to missense or 
frame-shift mutations, leading to truncation, loss of recognition, altered glycosylation or 
folding of the polypeptides. The resulting products might then have been masked by the 
cross-reacting bands seen in the western blot for N1, or might have become unstable 
leading to rapid turnover and undetectable steady-state levels. However, sequencing 
demonstrated that the genes’ start codons were in-frame, that there were no insertion or 
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deletion mutations in the sequences that could disturb the reading frames and that there 
were no non-coding changes. Hence, these possible explanations could be rejected. 
 
In the case of nucleoprotein detection, the specificity of the assay remains to be 
established, with cross-reactivity towards a protein of unknown nature and source 
obscuring the position expected for NP.  Curiously the presence of NP in the positive 
control sample (RG14 in CEF) has not been unambiguously demonstrated.  
 
3.3.5.4 Analysis of chicken IL-12 expression by rFWPV. 
Monoclonal antibody HC8, specific for the chicken IL-12 p70 heterodimer (provided by 
Dr Pete Kaiser; Institute for Animal Health, Compton), was used to monitor for the 
presence of the soluble secreted chicken IL-12 protein 70 kD fusion protein in 
supernatants from infected and uninfected CEF.  A doublet of bands (the upper band 
being fainter) was observed at about 70 kD for five recombinants (two H5/IL-12, one 
N1/IL-12 and two NP/IL-12) but not for uninfected CEF nor for FP9 WT (Figure 3.27). 
There were differences between the levels of IL-12 observed for the recombinants; it is 
not yet known how reproducible this is. 
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Figure 3.27. Western blot analysis of a mouse anti-chicken IL-12 monoclonal antibody, HC8 (Dr 
Kaiser, IAH). Lanes showed supernatants of uninfected CEF or CEF infected with different 
viruses. M is a protein marker.  
 
 
 
3.3.5.5 Analysis of chicken IL-15 expression by rFWPV. 
Although one resolved (FP9/H5/IL-15) and two unresolved recombinants containing IL-
15 (FP9/N1/IL-15 and FP9/NP/IL-15) have been obtained, we have so far been unable to 
screen for expression of IL-15 protein as no antibodies are currently available. However, 
bioactive recombinant chicken IL-15 expression has
 
been described (Lillehoj et al., 
2001), where the observed protein size corresponds to the deduced size of the studied 
chicken IL-15 (22 kD).  
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3.4  Summary 
Recombinant FWPVs coexpressing AIV genes, H5 or N1, and chicken cytokine genes, 
IL-15 or IL-12, have been constructed using homologous recombination at two non-
essential sites in the genome of FWPV strain FP9. Antibodies against chicken IL-15 are 
unavailable but expression of H5, N1 and IL-12 proteins was verified using western 
blotting and IFAT. The available recombinants after the verifications are FP9/H5 
(rFWPV/H5), FP9/N1 (rFWPV/N1), FP9/H5/IL-15 (rFWPV/H5/IL-15) and FP9/N1/IL-
12 (rFWPV/N1/IL-12). These recombinants were prepared ready to be inoculated into 
chickens to evaluate host immune responses. 
 
Initial plans to include NP recombinants in animal trials were aborted due to the inability 
to specifically detect NP expression in avian cells, and failure to obtain resolved NP 
recombinants carrying either IL-15 or IL-12, during the time that recombinants were 
being constructed at Imperial College London. 
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CHAPTER 4 
Co-immunostimulatory effect of IL-15 co-expressed in H5-recombinant fowlpox 
viruses on host immune responses 
 
4.1 Introduction  
Cell-mediated immune (CMI) responses of mice against viral infections have been 
widely described. However, the functional significance of CD4+ and CD8+ T cells as 
antiviral effectors in chickens needs more elucidation. In general, T cells displaying CD4 
membrane glycoprotein at their surface, CD4+, are T helper (Th) cells, while those 
presenting CD8 marker, CD8+, function as T cytotoxic (Tc) cells. Th cells differentiate 
into memory cells or effector cells that enable or "help" the activation of B cells, Tc cells, 
macrophages and various other immune cells.  Effector Th cells are divided into Th1 and 
Th2. While Th1 produce IFN-γ, which activates macrophages for CMI responses, the 
Th2 cell response results in the activation of B cells to produce antibodies that are able to 
neutralise (direct effect) or to opsonise (indirect effect) antigens, leading to humoral 
immune responses. 
 
In in vivo studies conducted at Animal Experimental House, Faculty of Veterinary 
Medicine, UPM, Malaysia, two recombinant vaccines, rFWPV/H5 and rFWPV/H5/IL-
15, the construction of which (at Imperial College London), has been described in 
Chapter 3, were inoculated into one-day-old SPF chicks, with parental, wild type (WT) 
FWPV strain FP9 and PBS-mock inocula implemented as controls. The experiments were 
carried out according to the international Guide for the Care and Use of Laboratory 
Animals (ILAR, 1996), under the approval of the local Institutional Animal Care and Use 
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Committee (IACUC) of UPM (Reference No.: UPM/FPV/PS/3.2.1.551/AUP-R72). Use 
of the rFWPV in laboratory of UPM was in accordance to guidelines from the local 
Biosafety Department, at Category 1 (elsewhere known as biosafety level, BSL, 1). 
 
 Upon inoculation of rFWPV carrying the H5 gene, infection of host cells will result and 
H5 will be expressed, along with FWPV proteins. Antigen presenting cells such as 
macrophages are responsible for identifying and engulfing virus-infected cells. These will 
then be lysed and then digested and peptides from the digested proteins will be 
transported to the cell surface by Class II MHC proteins for display to T or B lymphocyte 
cells. Presentation of H5 to T cells activates B cells to induce specific H5 antibodies 
which can be measured by haemagglutination inhibition test.  
 
IL-15 is an immune-enhancing cytokine with profound effects on CD8 memory T cells, 
NK cells, B cells, mast cells and cytokine-chemokine networks. The ability of IL-15 to 
induce the expression of IFN-γ in both NK and T cells emphasizes its significant role in 
promoting Th1 response. Although chicken IL-15 was cloned and characterized in 1999 
(Choi et al., 1999), no subsequent study has been reported since.  It therefore seemed 
valid to investigate the effect of IL-15 co-expressed in rFWPV/H5 on host CMI response, 
in comparison to rFWPV expressing H5 gene alone, as a major aim of this study. 
Although the level of IL-15 was not assessed, populations of CD4+ and CD8+ cells was 
measured as indicator of CMI response elicited by the cytokine. 
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Wing web puncture and brushing of chicken's exposed-follicles with the vaccine have 
been universally accepted in commercial FWPV vaccination (Mockett et al., 1990; Boyle 
and Heine, 1994). However, we inoculated our vaccines (10
5
 PFU in 100 μL) 
subcutaneously at the nape of the chicks, without any booster. This approach standardizes 
the vaccine dose as well alleviates inoculation of one-day-old chicks. Qiao et al. (2009) 
have demonstrated that rFWPV carrying HA and NA genes given by this subcutaneous 
route can induce HI antibodies and protect chickens against challenge with a pathogenic 
H5N1 strain A/Goose/Guangdong/1/96 (GS/GD/96), as efficiently as if they were given 
by wing web puncture or intramuscular injection. 
 
4.2 Results 
4.2.1 Humoral immune responses following rFWPV/H5 and rFWPV/H5/IL-15 
vaccination 
To measure H5 antibody levels in host serum samples post vaccination, the 
haemagglutination inhibition (HI) test was performed using influenza virus H5N2 strain 
A/Duck/Malaysia/8443/2004 as a heterologous antigen. The nucleotide (89.0 %) and 
amino acid (91.1 %) identities between HA genes of the agglutinating antigen virus and 
the vector insert strain (A/Chicken/Malaysia/5858/2004) were determined by pair-wise 
sequence alignment using BioEdit Version 7.0.5.3 (Figure 4.1).  
 
As presented in Table 4.1, none of the nine control chickens inoculated with PBS or WT 
FP9 showed any evidence of HI antibody responses. Four chickens vaccinated with 
rFWPV/H5 started to develop HI antibody titre at 3 weeks post inoculation (p.i.), ranging 
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from a low log2 1 to log2 32. A week later, the titres had decreased in two birds (log2 32 
to 0, and log2 32 to log2 16), and increased in one bird (log2 1 to log2 8). Another bird 
elicited a constant HI titre of log2 8 at both timepoints. No antibodies were detected at 
Week 5. 
 
In the rFWPV/H5/IL-15-vaccinated group, two chickens developed antibodies as early as 
2 weeks post-vaccination (log2 1 and log2 4). At Week 3, six other birds elicited HI 
antibody titre ranging from log2 1 to log2 16. A week later, the titre in one bird remained 
constant at log2 16. Three birds demonstrated a decrease in titre to log2 4, while titres in 
another four birds dropped to undetectable levels. At Week 5, no HA-specific antibodies 
were detected for any birds.  
 
Mean HI titres, in log2, of all groups were calculated for general comparison (Table 4.2). 
The data showed that H5 antibodies are induced at the highest level at Week 3 in both 
recombinant vaccine-treated chickens. However, the antibodies were undetectable at 
Week 5 onwards. In summary, fewer chickens in rFWPV/H5 elicited H5 antibodies 
compared to rFWPV/H5/IL-15. Moreover, contrary to expectations, chickens vaccinated 
with rFWPV/H5 developed antibodies one week later than those vaccinated with 
rFWPV/H5/IL-15. 
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                 10        20        30        40        50        60            
            ....|....|....|....|....|....|....|....|....|....|....|....| 
Duck/H5N2   MEKIVPLLAIISLVKGDQICIGYHANNSTEQVDTIMEKNVTVTHAQDILEKTHNGKLCSL  
ΔH5N1       .....L.F..V....S..........................................D.  
 
                 70        80        90       100       110       120         
            ....|....|....|....|....|....|....|....|....|....|....|....| 
Duck/H5N2   NGVKPLILGDCSVAGWLLGNPMCDIFLNVPEWSYIVEKDKTVNGLCYPGDFNDYEELKHL  
ΔH5N1       D.......R...............E.I...........ANP..D........A.......  
 
                130       140       150       160       170       180      
            ....|....|....|....|....|....|....|....|....|....|....|....| 
Duck/H5N2   LSSTNHFEKIQIIPRNSWSNHDASSGVSAACPYNGKSSFYRNVVWLIKKQNVYPTIKRSY  
ΔH5N1       ..RI..........KS...S.E..L...S....Q.....F.........NST........  
 
                190       200       210       220       230       240      
            ....|....|....|....|....|....|....|....|....|....|....|....| 
Duck/H5N2   NNTNQEDLLVLWGIHHPNDAAEQTKLYQNPNTYVSVGTSTLNQRSVPEIATRPKVNGQSG  
ΔH5N1       ..............................T..I..........L..R....S.......  
 
                250       260       270       280       290       300      
            ....|....|....|....|....|....|....|....|....|....|....|....| 
Duck/H5N2   RMEFFWTILKPNDAINFESSGNFIAPEYAYKIVKKGDSAIMKSELEYGNCNTKCQTPMGA  
ΔH5N1       ...................N..................T.....................  
 
               310       320       330       340       350       360      
            ....|....|....|....|....|....|....|....|....|....|....|....| 
Duck/H5N2   INSSMPFHNIHPLTIGECPKYVKSDRLVLAKGLRNVPQRETR----GLFGAIAGFIEGGW  
ΔH5N1      .............A..........N.....T....S......----..............  
 
               370       380       390       400       410       420      
            ....|....|....|....|....|....|....|....|....|....|....|....| 
Duck/H5N2   QGMVDGWYGYHHSNEQGSGYAADKESTQKAIDGITNKVNSIIDKVNTQFEAVGKEFNNLE  
ΔH5N1       ......R..........................V..........M........R......  
 
               430       440       450       460       470       480      
            ....|....|....|....|....|....|....|....|....|....|....|....| 
Duck/H5N2   RRIENLNKKMEDGFLDVWTYNAELLVLMENERTLYFHDSNVKNLYDKVRLQLRDNAKELG  
ΔH5N1       ..................................D.........................  
 
               490       500       510       520       530       540      
            ....|....|....|....|....|....|....|....|....|....|....|....| 
Duck/H5N2   NGCFEFYHKCDNECMESVRNGTYNYPQYSEEARLNREEISGVKLESMGTYQILSIYSTVA  
ΔH5N1      .........R........S....D..........K...........I.I...........  
 
               550       560        
            ....|....|....|....|....| 
Duck/H5N2   SSLALAIMVAGLSFWMCSNGSLQCR  
ΔH5N1      .............L...........  
 
 
Figure 4.1. Haemagglutinin (HA) amino acid identities between the studied, mutated H5 of   
A/Chicken/Malaysia/5858/2004, denote ΔH5N1, and H5N2 strain A/Duck/Malaysia/8443/2004, 
represented by Duck/H5N2. Duck/H5N2 is used as heterologous antigen for haemagglutination 
inhibition (HI) test. The sequences were determined by pair-wise sequence alignment using 
BioEdit Version 7.0.5.3. Nucleotide identities between both sequences are not shown. 
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Table 4.1. HI titre, log2, of serum samples obtained from chickens immunized by different 
vaccines, in one week interval, for seven weeks. 
 
Vaccines Number 
of 
chickens 
Day, post inoculation 
7 14 21 28 35 42 49 
PBS-treated 
control 
group 
1 0 0 0 0 0 0 0 
2 0 0 0 0 0 0 0 
3 0 0 0 0 0 0 0 
4 0 0 0 0 0 0 0 
5 0 0 0 0 0 0 0 
6 0 0 0 0 0 0 0 
7 0 0 0 0 0 0 0 
8 0 0 0 0 0 0 0 
9 0 0 0 0 0 0 0 
WT FP9 1 0 0 0 0 0 0 0 
2 0 0 0 0 0 0 0 
3 0 0 0 0 0 0 0 
4 0 0 0 0 0 0 0 
5 0 0 0 0 0 0 0 
6 0 0 0 0 0 0 0 
7 0 0 0 0 0 0 0 
8 0 0 0 0 0 0 0 
9 0 0 0 0 0 0 0 
rFWPV/H5 1 0 0 32 0 0 0 0 
2 0 0 32 16 0 0 0 
3 0 0 1 8 0 0 0 
4 0 0 8 8 0 0 0 
5 0 0 0 0 0 0 0 
6 0 0 0 0 0 0 0 
7 0 0 0 0 0 0 0 
8 0 0 0 0 0 0 0 
9 0 0 0 0 0 0 0 
rFWPV/H5/ 
IL-15 
1 0 1 16 4 0 0 0 
2 0 0 16 16 0 0 0 
3 0 0 16 4 0 0 0 
4 0 4 8 4 0 0 0 
5 0 0 8 0 0 0 0 
6 0 0 1 0 0 0 0 
7 0 0 8 0 0 0 0 
8 0 0 0 0 0 0 0 
9 0 0 16 0 0 0 0 
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Table 4.2. Mean of haemagglutination inhibition (HI) titre, log2, of sera from immunized 
chickens upon weekly bleeding. 
ND indicates undetected titre. Each value represents the means ± SEM. 
*The proportion of individual chickens which induce detectable HI antibody titre, to total 
chickens in each group. 
 
 
 
 
 
 
 
 
 
 
 
 
Group Day, post immunization 
 7 14 21 28 35 42 49 
Control ND 
(0/9)* 
ND 
(0/9) 
ND 
(0/9) 
ND 
(0/9) 
ND 
(0/9) 
ND 
(0/9) 
ND 
(0/9) 
WT FP9 ND  
(0/9) 
ND 
(0/9) 
ND 
(0/9) 
ND 
(0/9) 
ND 
(0/9) 
ND  
(0/9) 
ND 
(0/9) 
rFWPV/H5 ND  
(0/9) 
ND 
(0/9) 
8.11±4.60 
(4/9) 
3.56±1.94 
(3/9) 
ND 
(0/9) 
ND  
(0/9) 
ND 
(0/9) 
rFWPV/H5/IL-
15 
ND  
(0/9) 
0.56±0.44 
(2/9) 
9.89±2.16 
(8/9) 
3.11±1.74 
(4/9) 
ND 
(0/9) 
ND  
(0/9) 
ND 
(0/9) 
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4.2.2 Cell-mediated immune response following rFWPV/H5 and rFWPV/H5/IL-15 
vaccination 
Immune competence of a host can be evaluated from several parameters, including 
circulating T lymphocyte populations. Typical CD4+ and CD8+ T lymphocyte cell 
enumeration is via flow cytometric analysis, using fluorescent-conjugated monoclonal 
antibodies that recognise expressed cell surface markers. In our immunophenotypic flow 
cytometry analysis, isolated lymphocytes were triple-stained with anti-chicken CD3 (R-
Phycoerythrin(PE)-conjugated), anti-chicken CD4 (Fluorescein(FITC)-conjugated) and 
anti-chicken CD8 (Peridinin Chlorophyll Protein Complex (PerCP)-Cy5-conjugated) 
monoclonal antibodies, allowing eight cell subsets to be characterized concurrently; 
CD3-CD4-, CD3-CD4+, CD3+CD4-, CD3+CD4+, CD3-CD8-, CD3-CD8+, CD3+CD8-, 
CD3+CD8+. The estimation of CD4+ and CD8+ T cells captured by the cytometer, in 
percentages, was determined by the measurement of T cells having CD3+CD4+ or 
CD3+CD8+ receptors. We assume that mature and functional CD4+ and CD8+ T cells 
are constantly bound to T-cell receptor-CD3 complex. A typical flow cytometric pattern 
of CD4+ and CD8+ T cell that present positive signals is shown in Figure 4.2. 
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Figure 4.2. Typical flow cytometric pattern of chicken CD4 and CD8 cell expression in a single 
tube of 10000 captured cell events. Cells were gated using forward and side scatter to distinguish 
physical properties of cells and cellular contaminants (A). Percentages of CD3+CD4+ (B) and 
CD3+CD8+ (C) T cells amongst chicken PBMC were calculated from the upper right quadrant. 
The upper left quadrant represents CD3+ T cells which were  CD4- (B) or CD8- (C). Anti-
chicken CD3 monoclonal antibodies were conjugated with R-Phycoerythrin (PE), CD4 with 
Fluorescein (FITC) and CD8 with Peridinin Chlorophyll Protein Complex-Cy5 (Cy5).  
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In the first animal experiment, three pools of whole blood were established for each 
group of nine birds (n=3), each pool representing three individual chickens. This practise 
was selected to facilitate the ficoll gradient-isolation of lymphocytes from fresh 
peripheral blood mononuclear cells (PBMC). A minimal blood volume (will be discussed 
in Section 7.2) was drawn from birds to reduce overall stress and prevent anaemia. CD4 
and CD8 T cell phenotypes were determined at Weeks 2 and Week 5. In the second 
animal experiment, whole blood was sampled from five individual chickens (n=5) at 
Weeks 2 and 4. 
 
To present the difference, which is either an increment or reduction of a particular cell 
population, a fraction of 100 (percentage) is calculated in equation as below:  
   Final population percentage – initial population percentage         X 100 
                             Initial population percentage  
 
In the equation, ‘initial population percentage’ refers to flow cytometry values of a 
particular T cell population at two weeks post-vaccination, while ‘final population 
percentage’ refers to values at Weeks 5 or 4, post-vaccination, for Experiments 1 or 2, 
respectively.    
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4.2.2.1    PBMC CD4+ T cell population 
In the first animal experiment, in which n=3, the levels of CD4+ in the control group 
remained relatively constant at Weeks 2 (15.64 ± 1.75 %) and 5 (16.54 ± 3.33 %), 
showing an increase of only 0.9 % points, or 5.75 %. Samples from groups vaccinated 
with WT FP9 or rFWPV/H5/IL-15 demonstrated increases in CD4+ levels of 10.99 % 
(18.75 ± 2.53 % to 20.81 ± 0.84 %; 2.06 % points) and 21.97 % (14.38 ± 0.70 % to 17.54 
± 3.48 %; 3.16 % points), respectively. However, the rFWPV/H5 vaccinated group 
showed a higher CD4+ population at Week 2 (23.67 ± 1.11 %), than at Week 5 (16.09 ± 
2.72 %), a fall of 7.58 % points, or 32.02 %. The level of the CD4+ population in the 
rFWPV/H5 group at Week 2 was significantly higher (P≤0.05) compared to the control. 
No statistically significant difference was observed for other groups at either sampling 
point (Table 4.3, Figure 4.3(A)).  
 
In the second animal experiment (in which n=5), the CD4+ cell population increased only 
in the WT FP9-vaccinated group (from 9.94 ± 1.17 % to 10.93 ± 0.89 %, an increase of 
0.99 % points or 9.96 %). The CD4+ population in the control group decreased from 
10.49 ± 1.29 % to 7.37 ± 0.91 % (by 3.12 % points, or 29.74 %), while those in the 
rFWPV/H5 and rFWPV/H5/IL-15 groups decreased from 10.37 ± 0.82 % to 9.65 ± 0.71 
% (0.72 % points, or 6.94 %) and from 13.05 ± 1.05 % to 8.44 ± 0.62 % (4.61 % points, 
or 35.32 %), respectively. The 48.3 % difference of CD4+ cell population between WT 
FP9 and control at Week 4 was the only statistically significant comparison (Table 4.3, 
Figure 4.3(B)). 
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Overall, the pattern of results is similar for pooled and individual samples, except for 
control and rFWPV/H5/IL-15. The relative levels, and direction of change, of CD4+ in 
the rFWPV/H5/IL-15 group compared to the rFWPV/H5 were different in the two 
experiments.  However, the data obtained from the individual samples in experiment 2 
may be more reliable since they represented a larger sample size (n) and lower standard 
deviations (SD). The only significant change in CD4+ T cells observed during the time 
course in either experiment was the decrease observed for the rFWPV/H5/IL-15 group in 
experiment 2.  Therefore, it could be assumed that IL-15 co-expression does not induce a 
persistent Th1 response in chickens.  
 
 
Table 4.3. CD4+ T cell immunophenotyping of lymphocytes from chickens after mock-
treatment with PBS (Control), or vaccination with WT FP9, rFWPV/H5 or rFWPV/H5/IL-15. 
 Animal experiment 
Vaccine 1 (n=3) 2 (n=5) 
 Week 2 Week 5 Week 2 Week 4 
Control 15.64 ± 1.75   16.54 ± 3.33 10.49 ± 1.29   7.37 ± 0.91 
Wild Type FP9 18.75 ± 2.53    20.81 ± 0.84   9.94 ± 1.17 10.93 ± 0.89* 
rFWPV/H5 23.67 ± 1.11* 16.09 ± 2.72 10.37 ± 0.82   9.65 ± 0.71 
rFWPV/H5/IL-15 14.38 ± 0.70   17.54 ± 3.48 13.05 ± 1.05^   8.44 ± 0.62^ 
 
Animal experiment 1 represents PBMC samples of nine chickens pooled in threes (n=3), sampled 
at Weeks 2 and 5. Animal experiment 2 represents individual PBMC samples of five chickens 
(n=5), sampled at Weeks 2 and 4. 
Each value represents the means ± SEM (error bars). Significant differences between vaccinated 
and control groups, indicated by asterisks (*), were determined by one-way ANOVA (P≤0.05). 
Significant differences within the same group at different points, indicated by a caret (^), were 
determined by paired-samples T-test (P≤0.05). 
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Figure 4.3. CD4+ T cell immunophenotyping of lymphocytes from chickens after mock-treatment 
with PBS (Control), or vaccination with WT FP9, rFWPV/H5 or rFWPV/H5/IL-15. A) PBMC 
samples of nine chickens pooled in threes (n=3), sampled at Weeks 2 and 5. B) Individual PBMC 
samples of five chickens (n=5), sampled at Weeks 2 and 4. 
Each value represents the means ± SEM (error bars). Significant differences between vaccinated 
and control groups, indicated by asterisks (*), were determined by one-way ANOVA (P≤0.05). 
Significant differences within the same group at different points, indicated by a horizontal line, 
were determined by paired-samples T-test (P≤0.05). 
A 
B 
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4.2.2.2 PBMC CD8+ T cell population 
In experiment 1, pooled blood samples at Weeks 2 and 5 revealed relatively constant 
CD8+ populations for unimmunized control (8.54 ± 0.55 % and 8.17 ± 1.15 %, 
respectively) and WT FP9-vaccinated (12.71 ± 0.82 % and 13.28 ± 1.06 %, respectively) 
chickens, rising 4.3 % and falling 4.5 %, respectively. The population in rFWPV/H5/IL-
15 group demonstrated decreases in CD8+ levels of 7.82 % (10.49 ± 1.17 % to 9.67 ± 
2.51 %; 0.82 % points). A remarkable fall of 42.44 % (or 6.91 % points) of CD8+ cell in 
rFWPV/H5-vaccinated group from 16.28 ± 1.58 % to 9.37 ± 1.32 % is surprisingly not 
statistically significant. This is due to the small sample size (n=3), which needed a greater 
difference in the value and a smaller standard deviation (SD), to be considered as 
statistically significant (Table 4.4, Figure 4.4(A)).  
 
In the second animal experiment (n=5), the levels of CD8+ T cell in control group, 
rFWPV/H5 and rFWPV/H5/IL-15 decreased 34.61 % (or 2.89 % points; 8.35 ± 0.99 % to 
5.46 ± 0.69 %), 22.91 % (or 2.68 % points; 11.70 ± 0.61 % to 9.02 ± 0.51 %) and 45.78 
% (or 4.94 % points; 10.79 ± 0.67 % to 5.85 ± 0.87 %), respectively. The CD8+ T cell 
population increased only in WT FP9-vaccinated group (from 8.36 ± 0.73 % to 11.01 ± 
1.21 %; an increase of 31.70 % or 2.65 % points), although not statistically significant 
(Table 4.4, Figure 4.4(B)).  
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Overall, chicken IL-15 co-expression in rFWPV/H5 did not promote a higher CD8+ cell 
percentage significantly, in comparison to rFWPV carrying H5 alone. In fact, it appears 
that the CD8+ population in rFWPV/H5/IL-15-vaccinated birds diminished relative to 
those in birds vaccinated with WT FP9 (significant) or FWPV/H5 (insignificant) at Week 
4, though only in Experiment 2. 
 
 
Table 4.4. CD8+ T cell immunophenotyping of lymphocytes from chickens after mock-
treatment with PBS (Control), or vaccination with WT FP9, rFWPV/H5 or rFWPV/H5/IL-15. 
 Animal experiment 
Vaccine 1 (n=3) 2 (n=5) 
 Week 2 Week 5 Week 2 Week 4 
Control 8.54 ± 0.55 8.17 ± 1.15 8.35 ± 0.99 5.46 ± 0.69 
Wild Type FP9 12.71 ± 0.82*    13.28 ± 1.06* 8.36 ± 0.73 11.01 ± 1.21* 
rFWPV/H5 16.28 ± 1.58*   9.37 ± 1.32 11.70 ± 0.61*
,
**^ 9.02 ± 0.51^ 
rFWPV/H5/IL-15 10.49 ± 1.17   9.67 ± 2.51 10.79 ± 0.67^ 5.85 ± 0.87**^ 
 
Animal experiment 1 represents PBMC samples of nine chickens pooled in threes (n=3), sampled 
at Weeks 2 and 5. Animal experiment 2 represents individual PBMC samples of five chickens 
(n=5), sampled at Weeks 2 and 4. 
Each value represents the means ± SEM (error bars). Significant differences between vaccinated 
groups and control (*), or between vaccinated groups and WT FP9 (**) were determined by one-
way ANOVA (P≤0.05). Significant differences within the same group at different points, 
indicated by a caret (^), were determined by paired-samples T-test (P≤0.05) 
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Figure 4.4. CD8+ T cell immunophenotyping of lymphocytes from chickens after mock-treatment 
with PBS (Control), or vaccination with WT FP9, rFWPV/H5 or rFWPV/H5/IL-15. A) PBMC 
samples of nine chickens pooled in threes (n=3), sampled at Weeks 2 and 5. B) Individual PBMC 
samples of five chickens (n=5), sampled at Weeks 2 and 4. 
Each value represents the means ± SEM (error bars). Significant differences between vaccinated 
groups and control (*), or between vaccinated groups and WT FP9 (**) were determined by one-
way ANOVA (P≤0.05). Significant differences within the same group at different points, 
indicated by a horizontal line, were determined by paired-samples T-test (P≤0.05) 
A 
B 
  * * 
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4.2.2.3 CD4+/CD8+ T cell population ratio at different weeks 
Ratios of CD4+ to CD8+ T cells (CD4+/CD8+), obtained from the flow cytometric 
analyses described above, were calculated to determine the relative fluctuation of CD8 
cells in comparison to CD4 cells. A higher ratio indicates a smaller CD8 cell fraction 
present in circulating T lymphocytes. As presented in Table 4.5, the control group had the 
highest ratio of CD4+ to CD8+ at Week 2 of both experiments (1.83 ± 0.24 and 1.26 ± 
0.21), and Week 5 (2.02 ± 0.50) of the first animal experiments. This is to be expected as 
unvaccinated host does not trigger CD8 cells which respond to an antigen presented by 
Class I MHC molecule. Chickens vaccinated with rFWPV/H5 and rFWPV/H5/IL-15 had 
lower ratio at Week 2, 0.89 ± 0.08 and 1.37 ± 0.17, respectively, in comparison to WT 
FP9. However, the ratios augmented over time, suggesting less CD8 cell populations or 
more CD4 cell populations were present in both vaccine groups than WT FP9. 
Importantly, rFWPV/H5 carrying IL-15 had the highest ratio between vaccinated groups 
at later weeks. This suggests that IL-15 co-expression in rFWPV either suppresses CD8 
cell population or promotes CD4 cell population, in a delayed manner.  
 
Table 4.5. Ratios of CD4+ to CD8+ T lymphocyte cells, CD4/CD8, post vaccination with 
different vaccines, at different weeks in two animal experiments. 
Vaccine Animal experiment 
 1 2 
 Week 2 Week 5 Week 2 Week 4 
Control 
 
1.83 ± 0.24 
 
2.02 ± 0.50 
 
1.26 ± 0.21 
 
1.35 ± 0.24 
 
WT FP9 
 
1.48 ± 0.22 
 
1.58 ± 0.14 
 
1.19 ± 0.18 
 
0.99 ± 0.14 
 
rFWPV/H5 
 
1.45 ± 0.15 
 
1.72 ± 0.38 
 
0.89 ± 0.08 
 
1.07 ± 0.10 
 
rFWPV/H5/IL-15 
 
1.37 ± 0.17 
 
1.81 ± 0.59 
 
1.21 ± 0.12 
 
1.44 ± 0.24 
 
Pooled PBMC samples of nine chickens into three, n=3, were used in animal experiment 1, while 
individual PBMC samples of five chickens (n=5) in animal experiment 2. CD4+ and CD8+ cell 
population percentage was obtained from flow cytometry immunophenotyping analysis. Each 
value represents the ratios of the means ± SEM.  
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4.3  Discussion 
Studies have shown that the most important component host immune reponse that confers 
protection against AIV is the humoral response against the haemagglutinin (HA) protein 
(Swayne et al., 2008). To achieve this, several different types of vaccines have been 
developed with some implemented in the field. Although vaccines which are based on 
inactivated low pathogenic AIV of H5 subtypes have traditionally been used, a 
replicative virus-based vector expressing H5 offers several advantages to becoming a 
favourable vaccination strategy. The advantages include (i) the ability to differentiate 
between infected and vaccinated birds (DIVA) using a commercial assay, (ii) the lesser 
risk of accidental influenza virus release, (iii) the potency of providing bivalent 
protection against different pathogens (depending on the vector), and (iv) the avoidance 
of adjuvant, such as mineral oil, which is a component of an inactivated vaccine.   
 
In this study, a safe, laboratory-adapted fowlpox virus (FWPV)-based vector expressing 
the HA of AIV strain H5N1 was modified to co-express a chicken IL-15 cytokine gene to 
test if it would in any way enhance the host CMI response, which is likely to be critical in 
clearance of AIV during primary infection. Since we did not perform any protective or 
challenge study, the evaluation of immunogenicity elicited by the constructed vaccines 
should also consider the host response against typical FWPV infection. 
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4.3.1 Humoral immune response 
As shown in Table 4.2, inoculation of chickens with PBS or WT FP9 did not induce the 
production of antibody against the HA protein, a result which was expected and is 
comparable to results demonstrated by Taylor et al. and Webster et al. using different 
strains of FWPV (Taylor et al., 1988; Webster et al., 1991). Low but detectable levels of 
antibodies specific for H5 were observed as early as Week 2 in chickens vaccinated with 
rFWPV/H5 carrying IL-15. The vaccine also produced a higher antibody titre at Week 3, 
compared to rFWPV expressing H5 alone, which suggests that IL-15 could play a role in 
enhancing the host humoral immune response. This finding corresponds with several 
studies conducted in mice, including that by Perera et al. (2007) who observed a two-fold 
higher neutralizing antibody titre in human IL-15-integrated recombinant vaccines 
against Vaccinia virus (VV). The group also showed that recombinant VV strain Wyeth 
adjuvanted with human IL-15 and five influenza genes induced stronger neutralizing 
antibodies against AIV H5 (Poon et al., 2009). Further studies should be done before we 
can assume that chicken IL-15 induces a co-stimulatory effect similar to that of human 
(Armitage et al., 1995) or mouse (Gill et al., 2009) IL-15 on B cell proliferation and 
differentiation, as well as IgA antibody synthesis (Hiroi et al., 2000).  
 
The mean HI titres induced by vaccination with either rFWPV/H5 or rFWPV/H5/IL-15 
decreased after reaching the highest reading at Week 3, and no antibodies were detected 
from Week 5 onwards. The result might have been influenced by our use of a 
heterologous antigen (A/Duck/Malaysia/8443/2004 (H5N2)), sharing 91.1 % amino acid 
identity with the H5 in our recombinant vaccine in the HI assays. Taylor and co-workers 
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(Taylor et al., 1988) reported that mean HI titres of less than 10 were observed in 6-
week-old chickens vaccinated with rFWPV expressing the H5 from an H5N8 strain, 
when heterologous antigen (H5N2) was used in the HI test. When homologous antigen 
was used, a higher mean HI titre of 15 was observed. In another report, heterologous 
antigen with 83.5 % to 93.2 % amino acid identity to the studied HA gene, failed to 
produce consistent HI titres for 3-week-old chickens, post-vaccination with rFWPV 
expressing H5 of the H5N1 strain (Swayne et al., 2007). However, in recent report, 
Bublot et al. showed the highest HI titres induced by a rFWPV expressing H5 of the 
H5N1 strain were detected with heterologous H5 from the H5N8 strain or from an H5N1 
virus of a different clade (Bublot et al., 2010). Phylogenetic relationships of the HA 
genes of nine representative influenza A viruses isolated in Asia in 2004, including that 
of the strain (Chicken/Malaysia/5858/2004) used as a source of HA for this study and the 
H5N2 strain (A/Duck/Malaysia/8443/2004) used as a heterologous antigen for the HI 
test, are shown in Figure 4.5. 
 
Since the template HA used for the recombinant vaccines was derived from HPAI virus 
Chicken/Malaysia/5858/2004, high-level biosafety containment is needed to produce the 
antigen, which is a limitation in our study. The same is of course true of virus 
neutralisation assays used to measure antibodies capable of virus neutralization. Reverse-
genetic technology could be used to incorporate the HA gene into an apathogenic virus 
background (for instance PR8, as used in the case of the RG16 pre-pandemic vaccine 
candidate produced at NIBSC, UK) but this has not yet been done. Although the most 
suitable antigen might not have been used for HI testing, the results provide useful 
comparisons of HI antibody levels elicited by rFWPV/H5 and rFWPV/H5/IL-15.  
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Figure 4.5. Phylogenetic relationships of the haemagglutinin (HA) genes of nine representative 
influenza A viruses isolated in Asia in 2004, including that of the strain 
(Chicken/Malaysia/5858/2004) used as a source of HA for this study. The mutated HA sequence 
of the study strain is also included. The tree was generated by the neighbour-joining method in 
MEGA 4.0 (Kumar and Nei, 1994) with bootstrap of 1000 replications. Numbers on the 
branches indicate neighbour-joining bootstrap values. Analysis was based on nucleotide 
sequences of the HA genes. Viruses are isolates from poultry during the H5N1 outbreak in 2004, 
with Vietnam/1203/2004, Malaysia/5858/2004 and Malaysia/6309/2004 belonging to sublineage 
VTM (Vietnam/Thailand/Malaysia), which is closely related to the Guangdong sublineage of 
viruses isolated from domestic and migratory birds in Hong Kong in early 2002 and late 2003 
(Chen et al., 2006). The H5N2/Malaysia/8443/2004 sequence has not been published elsewhere. 
The scale bar represents 0.01 nucleotide per site. 
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Several studies have shown rFWPV expressing HA can provide complete or nearly 
complete protection against lethal challenge, even when achieving pre-challenge HI titres 
of as low as 3 log2 (Beard et al., 1991; Webster et al., 1991; Qiao et al., 2006; Bublot et 
al., 2010). Though not directly comparable, rFWPV FP9 expressing the F gene of NDV 
were able to induce 86 % protection with HI titres of less than 2 (Boursnell et al., 1990). 
These findings indicate that post-vaccination protection of chickens against AIV is not 
dependent entirely on HI antibodies but also on non-HI antibodies and possibly also on 
cellular mediated immunity. Although cellular immunity appears unable to protect 
chickens from infection with lethal virus, it may help in viral clearance before virus-
induced pathology reaches a critical stage, thus reducing the rate of morbidity and 
mortality of immunized chickens. It may also play a more critical role in eradication of 
LPAI viruses from the individual bird and from the flock. 
 
4.3.2 Cell-mediated immune response 
4.3.2.1 CD4+ T cells 
In comparison to its documented effects on CD8+ T cells (Oh et al., 2003; Mueller et al., 
2005; Tang et al., 2009), the effect of IL-15 expression on CD4+ T cells is not yet well 
established. Studies of phenotypic CD4+ T cells in mice suggest that IL-15 has little or 
no effect on naïve (Kanegane et al., 1996; Zhang et al., 1998; Marks-Konczalik et al., 
2000; Nishimura et al., 2000; Picker et al., 2006), memory (Tan et al., 2002; Mueller et 
al., 2005) and central memory (Picker et al., 2006) CD4+ T cells. However, there are 
contradictory reports that IL-15 enhances in vitro priming of naïve CD4+ T cells 
(Niedbala et al., 2002).  
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The flow cytometry results for Experiment 1 (Table 4.3, Figure 4.3(A)) demonstrated that 
rFWPV/H5/IL-15 did not increase CD4+ T cell population but results for Experiment 2 
(Table 4.3, Figure 4.3(B)) showed a slight increase of the CD4+ T cell population at 
Week 2 (n=5) upon rFWPV/H5/IL-15 vaccination, although not statistically significant. 
These findings are consistent with previous reports that IL-15 only has profound effects 
on the proliferation and survival of memory CD8+ T cells, not on CD4+ T cells (Zhang et 
al., 1998; Marks-Konczalik et al., 2000; Nishimura et al., 2000). It is not known whether 
antigenic or immunomodulatory proteins from FP9 can influence the IL-15 cytokine 
milieu in vaccinated chickens. Several reports showed that IL-15 can only activate CD4+ 
T cell proliferation when at high concentration (Kanegane et al., 1996; Seder, 1996). 
Niedbala et al. (2002) showed that 2 to 4 fold higher concentrations of IL-15 are required 
to achieve optimal CD4+ T cell proliferation, compared to the concentrations required to 
promote CD8+ T cell response. However, overexpression of IL-15 has also been 
observed to lower the number of Herpes Simplex Virus-2 specific CD4+ T cells (Gill and 
Ashkar, 2009).  
 
We observed no increase in CD4+ T cells in individual chickens vaccinated with WT 
FP9, a result similar to those described in other reports using chickens (Chen et al., 
2010a) and mice (Jin et al., 2004). More importantly, although pooled blood samples 
from chickens vaccinated with rFWPV/H5 in Experiment 1 showed a significant increase 
of CD4+ T cell compared to the control, CD4+ T cells from individual samples showed 
no augmentation. This contradicts the basis of vaccination, where CD4+ T cells 
population should increase in response to foreign antigens, in this case haemagglutinin 
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H5 gene of the vaccine, since they are the basis of Th cells. Furthermore, CD4+ T cells of 
mice have been shown to be induced following influenza virus infection (Swain et al., 
2006), although they are not essential to "help" cytotoxic T lymphocyte activation (Ridge 
et al., 1998). We speculate that individual chickens elicit different level of 
lymphoproliferative response towards rFWPV/H5. It should be noted that despite the 
extensive study on immune response against influenza in mammals, understanding of 
chicken T cell responses against influenza virus is very limited (Haghighi et al., 2009).  
 
4.3.2.2 CD8+ T cells 
The co-stimulatory effects of IL-15 on CD8 cells have been studied widely, especially 
with regard to proliferation and survival of memory CD8+ T cells.  IL-15 has been found 
to directly stimulate purified CD8+ memory cells in vitro (Zhang et al., 1998; Ku et al., 
2000; Becker et al., 2002; Oh et al., 2004). Transgenic mice which constitutively 
expressed a significant level of IL-15 in the serum had higher numbers of memory CD8+ 
T cells (Nishimura et al., 2000; Marks-Konczalik et al., 2000), while a correspondingly 
inverse effect was observed in IL-15-deficient mice (Kennedy et al., 2000). As presented 
in Table 4.4 and Figure 4.4, pooled and individual samples from chickens vaccinated 
with rFWPV/H5 co-expressing IL-15 showed an increase, although not significant, in 
CD8+ cell population in comparison to unvaccinated chickens. This result suggests 
chicken and mouse IL-15 share a similar capability of enhancing CD8+ T cells. The 
higher, significant increase of CD8+ T cells in rFWPV/H5 compared to rFWPV/H5/IL-
15 raises two possible explanations:  
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(i) Over-expression of IL-15 in rFWPV/H5/IL-15 decreases the population percentage of 
CD8+ T cells specific for H5 antigen expressed by the recombinant vaccine. This 
possibility is compatible with the results of Yin et al., who showed that low doses of 
plasmid encoding macaque IL-15, co-inoculated with an influenza DNA-based vaccine, 
enhanced CD4+ and CD8+ T cell population, but that high doses lead to a decrease in the 
production of both classes of T cells (Yin et al., 2009). Unfortunately, in this study, we 
did not measure the levels of IL-15, secreted by cells infected with an initial dose of 10
5
 
PFU rFWPV/H5/IL-15, in peripheral blood prior to flow analysis. Since a strong 
synthetic/hybrid promoter was used for IL-15 co-expression, over-expression is possible, 
with consequential influence on the level of immune responses generated (Boyle and 
Heine, 1993). 
(ii) FWPV infection, possibly by expression of as yet undefined immunomodulatory 
proteins encoded by this avipoxvirus, might down-regulate expression of chicken IL-15. 
Therefore, the heterologous co-expression of chicken IL-15 in cells infected with 
rFWPV/H5/IL-15 might tend to compensate for the down-regulation of levels of IL-15 
seen after vaccination with rFWPV/H5, achieving a more optimal CD4+/CD8+ ratio. 
Although human IL-15 has been shown to stimulate CD8+ T cells population and 
promote the maintenance of CD8+CD44hi memory T cells, the responsiveness of CD8+ 
T cells to IL-15 might depends on the cytokine background (Niedbala et al., 2002; Oh et 
al., 2003).  
 
A pattern of decreasing CD4+ and CD8+ T cell populations over time suggests that 
incorporation of the IL-15 gene in the rFWPV does not induce a sustained T cell response 
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in chickens. This is in agreement with an in vivo study examining T cell populations in 
the peripheral blood of rhesus macaques treated with rhesus IL-15, where the level of 
CD4+ and CD8+ memory, but not naïve, T cells peaked at Week 1 to 2 and returned to 
baseline by Weeks 3 to 4. In addition, extended treatment with IL-15 after day 10 often 
failed to maintain the peak lymphoproliferative response (Picker et al., 2006). 
  
4.3.2.3 CD4+/CD8+ T cell population ratio 
In healthy humans, the ratio of CD4+ to CD8 + cells is between 0.9 and 1.9, which is 
equivalent to 1 to 2 CD4 cells for every CD8 cell. In HIV-infected individuals, the 
CD4+/CD8+ ratio is used as an indication of immune suppression, where a lower ratio 
represents higher immune suppression. In the context of very limited knowledge on 
chicken CD4+/CD8+ ratios upon FWPV infection, Chen et al. (2010) demonstrated an 
elevated CD4+/CD8+ ratio at Weeks 2 and 5 in chickens vaccinated with a parental 
Chinese FWPV (strain S-FPV-017), a recombinant S-FPV-017 expressing the S1 gene of 
IBDV, and recombinant S-FV-017/S1 carrying recombinant chicken IL-18, compared to 
an unvaccinated group, with fluctuations at Weeks 3 and 4. We also noted that the 
CD4+/CD8+ ratios of PBS-treated, White Leghorn SPF chickens from Experiment 2 
were 1.26 ± 0.21 at Week 2 and 1.35 ± 0.24 at Week 5, which is consistent with 
observation by Chen et al. (1.26 ± 0.05 at Week 2; 1.33 ± 0.09 at Week 4) (Chen et al., 
2010a). Thus, we considered the results of Experiment 2 to be more reliable for data 
interpretation. 
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From our study (Table 4.5), we observed a lower CD4+/CD8+ ratio in birds vaccinated 
with FWPV carrying recombinant IL-15, compared to mock-vaccinated control. 
However, the ratio for both rFWPV/H5 and rFWPV/H5/IL-15 groups increases over 
time. Bridle et al. reported that commercially raised chickens with genetic selection, 
intense immunization and other environmental factors involved in commercial poultry 
operations have significantly altered T lymphocyte subpopulations, manifest as lower 
CD4+/CD8+ ratios, compared to unimmunized, laboratory-raised, outbred chickens 
(Bridle et al., 2006).  
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CHAPTER 5 
Co-immunostimulatory effect of IL-12 co-expressed in N1-recombinant fowlpox 
viruses on host immune responses 
 
5.1 Introduction 
Neuraminidase (NA) is enzymatically active to cleave α-2,3 or α-2,6-linked sialic acid 
residues from carbohydrate moieties on the surfaces of infected cells, promoting the 
release of budded virus particles from the cell membrane. In comparison to the extensive 
characterization of haemagglutinin (HA) antibodies to protect against influenza virus 
infection, the role of NA-specific antibodies as protective agents is less well understood. 
Several factors might influence the bias between the study of HA and NA as protective 
agents. Firstly, the levels of HA glycoprotein on the surface of infectious influenza 
virions are four (Webster and Pereira, 1968), six or even seven (Harris et al., 2006) times 
higher than those of NA, with a consequently skewed humoral response towards HA after 
influenza virus infection. The higher level response against HA has been demonstrated in 
mice by Johansson and colleagues (1987), who showed that responses to HA and NA are 
competitive towards each other, with that against HA dominating in the priming of B and 
T cells (Johansson et al., 1987a). Although the effect is less clear in birds and other 
mammals, susceptible species tend to respond with higher levels of serum antibodies 
against HA than NA. Secondly, the quantity of NA in licensed vaccines is not 
standardized (Gerentes et al., 1999). This might be due to the lability of NA during 
storage, and exposure to various chemical treatments during its production, or the 
difficulty in measuring the level of NA in each vaccine (Tanimoto et al., 2005). 
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Consequently, the response against HA has been viewed as a more important subject for 
study than that against NA, and has therefore been the subject of more intense scrutiny. 
However, it has been shown that humans exposed to H7N2 virus produced higher levels 
of antibodies against N2 than did those exposed to H3N2. This suggests that host immune 
responses against the NA protein of a vaccine can be influenced by existing humoral 
immunity against HA subtypes (Johansson et al., 1987b). 
 
Despite the overall paucity of studies on NA, vaccination with purified recombinant NA 
protein (Deroo et al., 1996; Martinet et al., 1997) or NA-encoding DNA (Chen et al., 
2000) has been demonstrated to protect mice against homologous, but not heterologous, 
lethal influenza virus challenge. Similar results were obtained using NA-expressing 
recombinant virus vaccines, including VV (Webster et al., 1988), adenovirus (Guo et al., 
2006) and alphavirus replicon-based virus-like particles (Sylte et al., 2007). A rFWPV 
co-expressing HA and NA of AIV has been shown to offer complete protection upon 
lethal homologous challenge in poultry (Qiao et al., 2003). No NA-only rFWPV was 
included in the study, making it difficult to evaluate the specific role of NA-specific 
antibodies. However, it has been shown that induced antibodies against HA and NA 
confer different functions in defending against influenza. Unlike HA antibodies, which 
neutralize and block the interaction between viral HA and host receptors directly, NA 
antibodies still permit infection but limit viral replication and prevent the release of 
progeny virus from infected cells, thus reducing viral spread within the host and viral 
shedding into the environment (Kilbourne et al., 1968; Deroo et al., 1996).  
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The main aim of this chapter was to characterize the immunogenicity of two recombinant 
vaccines, rFWPV/N1 and rFWPV/N1/IL-12, which were constructed at Imperial College 
London, as described in Chapter 3. The in vivo studies were conducted at the 
Experimental House, Faculty of Veterinary Medicine, UPM, Malaysia, with parental, 
‘wild type’ (WT) FWPV strain FP9 and PBS-mock inocula implemented as controls. 
 
IL-12 was chosen as a co-stimulatory molecule due to its significant role in promoting 
cellular mediated immunity (CMI) responses. In humans and mice, IL-12 induces 
tyrosine phosphorylation of Janus kinase 2 and STAT4 selectively in Th1, but not Th2 
cells (Szabo et al., 1995; Rogge et al., 1999). This is probably due to the inability of Th2 
cells to express the β-subunit of the high-affinity IL-12 receptor, IL-12R, which is 
important for IL-12 signaling to activate STAT4 and induce the expression of IFN-γ in T 
lymphocytes or NK cells (Rogge et al., 1999; Smits et al., 2001). However, in a few 
contradictory reports, IL-12 was shown to bind directly to B cells and induce the 
expression of transcripts for β1 and β2-chains of the IL-12 receptor (Vogel et al., 1996; 
Airoldi et al., 2000) and induce production of Th2 IL-4 cytokine (Skok et al., 1999). 
These stimulatory effects of IL-12 suggest its potential for use as an immunomodulator in 
vaccine development. 
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5.2 Results 
5.2.1 Humoral immune responses following rFWPV/N1 or rFWPV/N1/IL-12 
vaccination 
A commercial competitive enzyme-linked immunosorbent assay (c-ELISA) kit, ID 
Screen Influenza N1 Antibody Competition, obtained from ID.Vet (France), was used to 
detect NA-specific antibodies in the sera of vaccinated chickens. Negative and positive 
controls were provided in the kit to validate the test. 
To determine the competition percentage, the OD (optical density) value of each sample, 
which was read using a spectrophotometer at 450 nm, was used in the equation below: 
                OD of sample              X 100 
       OD of negative control    
 
 
N1 antibodies were considered to be present in the sample if the competition percentage 
of the sample was less than 60 %, and absent if the percentage was equal to or more than 
60 %. 
 
As expected, all sera from chickens inoculated with PBS (control) or WT FP9 had 
competitive percentages of more than 60 % for five weeks post-vaccination, which 
indicated the absence of N1-specific antibodies (Table 5.1). Chickens vaccinated with 
rFWPV/N1 and rFWPV/N1/IL-12 developed N1 antibodies after 28 days post 
vaccination, with competition percentages of 53.9 ± 1.9 % and 51.9 ± 1.2 %, 
respectively. The antibodies persisted until the following week, 54.3 ± 1.6 % for 
rFWPV/N1 and 55.6 ± 1.6 % for rFWPV/N1/IL-12. 
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Table 5.1. Mean competitive ELISA percentage, %, for N1 antibodies detected from chicken sera 
at interval weeks, post vaccination with different treatments. 
 
Vaccine 
 
Days, post inoculation 
 
7 14 21 28 35 
Control 63.4 ± 1.0 71.6 ± 1.8 70.5 ± 1.3 73.4 ± 2.5 74.6 ± 1.8 
WT FP9 68.2 ± 2.2 74.1 ± 1.8 72.2 ± 1.2 94.4 ± 17.9 84.8 ± 4.1 
rFWPV/N1 62.8 ± 1.1 70.2 ± 1.4 70.4 ± 2.1 53.9 ± 1.9 54.3 ± 1.6 
rFWPV/N1/IL-12 64.4 ± 1.8 66.3 ± 1.1 77.2 ± 13.3 51.9 ± 1.2 55.6 ± 1.6 
Each value represents the means ± SEM. Competitive percentages were calculated by dividing 
the sample OD with the negative control OD, and multiply by 100, where each OD value was 
read at 450 nm. N1 antibodies are considered present in the sera if the percentage is ≤60%, while 
absent if >60%. 
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5.2.2 Cell-mediated immune responses following rFWPV/N1 or rFWPV/N1/IL-12 
vaccination 
In order to understand the immunomodulatory effect of chicken IL-12 on T cell 
populations, T cell immunophenotyping was carried out and the results are presented in 
Figure 5.1. Circulating CD4+ and CD8+ T lymphocyte cells in rFPWPV/N1 and 
rFWPV/N1/IL-12-vaccinated chickens were enumerated using a triple-staining, flow 
cytometric counting analysis. To represent changes of the T cell populations, a fraction of 
100 (percentage) was calculated using the equation below: 
   Final population percentage – initial population percentage         X 100 
                             Initial population percentage  
 
In the equation, ‘initial population percentage’ refers to flow cytometry values of a 
particular T cell population at two weeks post-vaccination, while ‘final population 
percentage’ refers to values at Weeks 5 or 4, post-vaccination, for Experiments 1 or 2, 
respectively.    
 
However, to represent differences of population percentage between similar T cell subset 
of a particular vaccine groups, at a particular week, ‘initial population percentage’ was 
referred to values from the control or WT FP9, while ‘final population percentage’ was 
referred to a particular vaccine group. 
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5.2.2.1 PBMC CD4+ T cell population 
In the first animal experiment, pooled peripheral blood of chickens vaccinated with 
rFWPV/N1 or rFWPV/N1/IL-12, in which n=3, showed no significant increase in the 
level of CD4+ compared to the control group (Table 5.2, Figure 5.1 (A)). However, WT 
FP9 demonstrated a significant increase at Week 2 and 5 (described in Section 4.2.2.1). 
In term of changes in population level over time, CD4+ T cells of rFWPV/N1/IL-12 
decreased from 16.36 ± 1.97 % to 12.41 ± 1.29 % (24.14 % or 3.95 % points), but this 
was not statistically significant. The CD4+ T cell population in the control (15.64 ± 1.75 
% and 16.54 ± 3.33 %) and rFWPV/N1 (14.92 ± 1.06 % and 14.09 ± 0.82 %) groups was 
consistent at Week 2 and 5, with differences of only 5.75 % (0.9 % points) and 5.56 % 
(0.83 % points), respectively. 
 
At Week 2, individual peripheral blood samples obtained from the second experiment, in 
which n=5, rFWPV/N1 and rFWPV/N1/IL-12 groups showed an increase of 20.4 % and 
7.82 % in CD4+ T cell population, respectively, compared to the control. The levels of 
CD4+ T cells in rFWPV/N1 and rFWPV/N1/IL-12 groups showed a drastic decrease 
from 12.64 ± 0.55 % to 7.79 ± 1.19 % (38.37 % or 4.85 % points) and from 11.31 ± 0.90 
% to 6.94 ± 2.57 % (38.64% or 4.37 % points) over time, respectively. However, the WT 
FP9 group showed a 9.96 % of increase, from 9.94 ± 1.17 % to 10.93 ± 0.89 % (Table 
5.2, Figure 5.1 (B)).  
 
Overall, co-expression of IL-12 in rFWPV/N1 does not influence persistence of total 
CD4+ T cells in PBMC. Increase of CD4+ T cell populations was observed in 
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rFWPV/N1 and rFWPV/N1/IL-12, although not at a significant level. The patterns of 
results for pooled and individual samples were divergent. However, the second 
experiment in which the WT FP9-vaccinated chickens showed levels of CD4+ T cells 
relatively comparable to the control, as previously reported by others (Jin et al., 2004; 
Chen et al., 2010a), may be more reliable.  
 
 
Table 5.2. CD4+ T cell immunophenotyping of lymphocytes from chickens after mock-
treatment with PBS (Control), or vaccination with WT FP9, rFWPV/N1 or rFWPV/N1/IL-12. 
 Animal experiment 
Vaccine 1 (n=3) 2 (n=5) 
 Week 2 Week 5 Week 2 Week 4 
Control 15.64 ± 1.75   16.54 ± 3.33 10.49 ± 1.29   7.37 ± 0.91 
Wild Type FP9 18.75 ± 2.53    20.81 ± 0.84   9.94 ± 1.17 10.93 ± 0.89 
rFWPV/N1 14.92 ± 1.06 14.09 ± 0.82** 12.64 ± 0.55^   7.79 ± 1.19^ 
rFWPV/N1/IL-12 16.36 ± 1.97 12.41 ± 1.29** 11.31 ± 0.90   6.94 ± 2.57 
Animal experiment 1 represents PBMC samples of nine chickens pooled in threes (n=3), sampled 
at Weeks 2 and 5. Animal experiment 2 represents individual PBMC samples of five chickens 
(n=5), sampled at Weeks 2 and 4. 
Each value represents the means ± SEM (error bars). Significant differences between vaccinated 
and WT FP9 groups, indicated by double asterisks (**), were determined by one-way ANOVA 
(P≤0.05). Significant differences within the same group at different points, indicated by a caret 
(^), were determined by paired-samples T-test (P≤0.05). No statistically significant differences 
observed between vaccinated and control groups. 
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Figure 5.1. CD4+ T cell immunophenotyping of lymphocytes from chickens after mock-treatment 
with PBS (Control), or vaccination with WT FP9, rFWPV/N1 or rFWPV/N1/IL-12. A) PBMC 
samples of nine chickens pooled in threes (n=3), sampled at Weeks 2 and 5. B) Individual PBMC 
samples of five chickens (n=5), sampled at Weeks 2 and 4.  
Each value represents the means ± SEM (error bars). Significant differences between vaccinated 
and WT FP9 groups, indicated by double asterisks (**), were determined by one-way ANOVA 
(P≤0.05). Significant differences within the same group at different points, indicated by a 
horizontal line, were determined by paired-samples T-test (P≤0.05). 
A 
B 
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5.2.2.2 PBMC CD8+ T cell population 
In the first animal experiment, in which n=3, the CD8+ T cell population increased only 
in the WT FP9-vaccinated group (as described in Section 4.2.2.2). These levels were 
higher than those of the control (8.54 ± 0.55 % and 8.17 ± 1.15 %), rFWPV/N1 (9.49 ± 
1.93 % and 8.56 ± 1.43 %) and rFWPV/N1/IL-12 (9.91 ± 1.89 % and 8.73 ± 0.71 %) 
groups. No statistically significant increase was observed for rFWPV/N1 and 
rFWPV/N1/IL-12 groups relative to the control at either sampling point (Table 5.3, 
Figure 5.2 (A)). 
 
A different pattern was observed for T-cell populations in individual samples (in which 
n=5) from animal experiment 2 (Table 5.3, Figure 5.2 (B)). At Week 2, the level of CD8+ 
T cells in the control (8.35 ± 0.99 %) and WT FP9 (8.36 ± 0.73 %)-vaccinated chickens 
was similar, making the results of this experiment more consistent than the first 
experiment with the results of others (Jin et al., 2004; Chen et al., 2010a). At the same 
time point, rFWPV/N1 and rFWPV/N1/IL-12 showed an increase of 37.96 % (or 3.17 % 
points) and 50.18 % (or 4.19 % points), respectively, compared to the control. However, 
those CD8+ T cell levels decreased by 41.84 % or 4.82 % points for rFWPV/N1 (from 
11.52 ± 1.37 % to 6.7 ± 1.33 %), and by 38.76 % or 4.86 % points for rFWPV/N1/IL-12 
(from 12.54 ± 1.79 to 7.68 ± 2.36 %), at the following sampling point. No significant 
difference in the CD8+ T cell population was observed between groups vaccinated with 
rFWPV/N1 or rFWPV/N1/IL-12 (Table 5.3, Figure 5.2 (B)). 
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In conclusion, population percentage of CD8+ T cells was increased in response to 
rFWPV/N1 and rFWPV/N1/IL-12. However, the raised levels did not persist until Week 
4. Co-expression of IL-12 did induce a higher level of CD8+ T cells, but not statistically 
significant compared to rFWPV expressing N1 antigen alone, and only in experiment 2. 
  
 
Table 5.3. CD8+ T cell immunophenotyping of lymphocytes from chickens after mock-
treatment with PBS (Control), or vaccination with WT FP9, rFWPV/N1 or rFWPV/N1/IL-12. 
 Animal experiment 
Vaccine 1 (n=3) 2 (n=5) 
 Week 2 Week 5 Week 2 Week 4 
Control     8.54 ± 0.55   8.17 ± 1.15   8.35 ± 0.99   5.46 ± 0.69 
Wild Type FP9   12.71 ± 0.82*    13.28 ± 1.06*   8.36 ± 0.73 11.01 ± 1.21* 
rFWPV/N1 1.49 ± 1.93   8.56 ± 1.43 11.52 ± 1.37^   6.70 ± 1.33^ 
rFWPV/N1/IL-12 9.91 ± 1.89 8.73 ± 0.71** 12.54 ± 1.79   7.68 ± 2.36 
Animal experiment 1 represents PBMC samples of nine chickens pooled in threes (n=3), sampled 
at Weeks 2 and 5. Animal experiment 2 represents individual PBMC samples of five chickens 
(n=5), sampled at Weeks 2 and 4. 
Each value represents the means ± SEM (error bars). Significant differences between vaccinated 
and control groups, indicated by asterisks (*), or between vaccinated and WT FP9 groups, 
indicated by double asterisks (**), were determined by one-way ANOVA (P≤0.05). Significant 
differences within the same group at different points, indicated by a caret (^), were determined by 
paired-samples T-test (P≤0.05).  
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Figure 5.2. CD8+ T cell immunophenotyping of lymphocytes from chickens after mock-treatment 
with PBS (Control), or vaccination with WT FP9, rFWPV/N1 or rFWPV/N1/IL-12. A) PBMC 
samples of nine chickens pooled in threes (n=3), sampled at Weeks 2 and 5. B) Individual PBMC 
samples of five chickens (n=5), sampled at Weeks 2 and 4.  
Each value represents the means ± SEM (error bars). Significant differences between vaccinated 
and control groups, indicated by asterisks (*), or between vaccinated and WT FP9 groups, 
indicated by double asterisks (**), were determined by one-way ANOVA (P≤0.05). Significant 
differences within the same group at different points, indicated by a horizontal line, were 
determined by paired-samples T-test (P≤0.05). 
A 
B 
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5.2.2.3 CD4+/CD8+ T cell population ratios 
To study the relative flux of CD4+ and CD8+ T cell in a sample, ratios of CD4+ to CD8+ 
T cell percentages (CD4+/CD8+) were calculated (Table 5.4). A higher ratio represents a 
decrease in CD8+ or an increase in CD4+ T lymphocyte cells in peripheral blood 
samples.  
 
According to the results obtained, the control group had the highest ratio of CD4+ to 
CD8+ in both experiments at all sampling points; Week 2 (1.83 ± 0.24 and 1.26 ± 0.21), 
Week 4 (1.35 ± 0.24) and Week 5 (2.02 ± 0.50). In the first experiment, in which n=3, the 
CD4+/CD8+ ratio increased in the WT FP9 (from 1.48 ± 0.22 at Week 2 to 1.58 ± 0.14 at 
Week 5) and rFWPV/N1 (from 1.57 ± 0.34 to 1.71 ± 0.29) groups, while that in the 
rFWPV/N1/IL-12 group decreased from 1.65 ± 0.37 to 1.42 ± 0.19. However, in the 
second experiment (in which n=5), both groups showed a decrease; from 1.19 ± 0.18 to  
0.99 ± 0.14 for WT FP9, and from 1.20 ± 0.14 to 1.16 ± 0.29 for rFWPV/N1. The 
CD4+/CD8+ ratio of the rFWV/N1/IL-12 group showed a constant CD4+/CD8+ ratio in 
the following experiment (0.9 ± 0.15 and 0.9 ± 0.43, respectively). 
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Table 5.4. Ratios of CD4+ to CD8+ T lymphocyte cells, CD4/CD8, post vaccination with 
different vaccines, at different sample points in two animal experiments. 
Vaccine Animal experiment 
 1 (n=3) 2 (n=5) 
 Week 2 Week 5 Week 2 Week 4 
Control 
 
1.83 ± 0.24 
 
2.02 ± 0.50 
 
1.26 ± 0.21 
 
1.35 ± 0.24 
 
WT FP9 
 
1.48 ± 0.22 
 
1.58 ± 0.14 
 
1.19 ± 0.18 
 
0.99 ± 0.14 
 
rFWPV/N1 
 
1.57 ± 0.34 
 
1.71 ± 0.29 
 
1.20 ± 0.14 
 
1.16 ± 0.29 
 
rFWPV/N1/IL-12 
 
1.65 ± 0.37 
 
1.42 ± 0.19 
 
0.90 ± 0.15 
 
0.90 ± 0.43 
 
PBMC samples from nine chickens, pooled in threes (giving n=3), were used in animal 
experiment 1, while individual PBMC samples from five chickens (n=5) were used in animal 
experiment 2. CD4+ and CD8+ cell population percentages were obtained by flow cytometry 
immunophenotyping analysis. Each value represents the ratio of the means ± SEM.  
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5.3  Discussion 
NA inhibitors have been developed as antiviral drugs and have been used widely in 
humans, to combat circulating influenza virus. They are not used in poultry because of 
their cost, the speed with which resistant viruses would then develop and because 
antibiotic residues in meat and eggs are undesirable.  
 
In poultry, NA normally performs as an additional component alongside HA in whole, 
killed or inactivated AIV vaccines, since HA-mediated immunity is more effective than 
NA-mediated immunity for AIV protection. Consequently, potential infection-permissive 
immunity (i.e. NA antibodies permit infection of influenza viruses, but block the release 
of infectious virions from the apical surface of the infected cells) upon administration of 
NA as a primary component is less exploited. In this study, the immunogenicity of 
rFWPV co-expressing NA N1 and chicken IL-12 vaccines was evaluated by assessing the 
antibody and cellular response of the host. Since no protective or challenge study has yet 
been performed, it was only possible to evaluate host humoral and cellular responses after 
FWPV inoculation.   
 
5.3.1 The humoral immune response  
As expected, control or WT FP9-vaccinated chickens did not induce antibodies to NA 
antigen throughout the experiment (Table 5.1). Chickens inoculated with rFWPV/N1 or 
rFWPV/N1/IL-12 developed N1 antibodies 4 weeks post-vaccination. This response is 
somewhat late for a typical host antibody response induced by rFWPV against a foreign 
antigen. As a comparison, HA antibodies can be detected as early as one week, after 
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vaccination with rFWPV co-expressing H5 and N1 genes (Qiao et al., 2003). There are 
several possible explanations for this result. Firstly, the rFWPV might not have expressed 
N1 at levels sufficient to stimulate antibody response in the first few weeks post 
inoculation. Secondly, circulating antibodies against N1 during the initial weeks might 
have been present, but below detection limits for the c-ELISA. Liu et al. has 
demonstrated that Neuraminidase Inhibition (NI) is a more sensitive assay for NA 
detection, probably due to the different substrate systems (Liu et al., 2010). However, 
unlike c-ELISA, which is rapid and effective for high numbers of serum samples, the NI 
assay is laborious and requires propagation and handling of infectious virus, with 
consequential biosafety implications. Thirdly, the result might be specific to NA, as a 
unique feature of this particular antigen, though possibly in combination with the 
particular (FWPV) expression system. It may be that there are unusual aspects to the 
presentation of NA by APC to induce MHC Class II restricted CD4+ T cells that account 
for this observation, particularly in the context of the largely uncharacterised 
immunomodulation that is undoubtedly induced by the FWPV vector. 
 
The same expression vector (pEFL29) and promoter (VV 7.5 early/late) combination has 
been used successfully for a range of diverse proteins, including the H5 protein 
considered in the previous chapter. In this study, the scale and kinetics of N1 expression 
in vaccinated birds was not addressed but it has been shown that in skin sections from the 
inoculation site of birds vaccinated with rFWPV FP9 expressing an IBDV VP2/lacZ 
fusion protein, B cells started to aggregate in germinal centre (GC)-like structures at 8 
days post vaccination onwards (Eldaghayes, 2005). GC are sites for the growth and 
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differentiation of B cells into immunoglobulin-producing plasma cells, and are thus 
important for the humoral immune response. That particular system was also poor at 
inducing VP2-specific antibodies compared to antibodies against parental FP9, with none 
detectable even 31 days post vaccination (Shaw and Davison, 2000) but this is viewed as 
a consequence of the artificial nature of the expression of the capsid protein of this 
icosahedral virus as a fusion with the large β-galactosidase protein (M. A. Skinner, 
personal communication). Other expression systems, particularly those expressing VP2 in 
the context of virus-like particles, have successfully induced high levels of VP2-specific 
antibodies (Fernandez-Arias, 1998). 
 
It is possible that the host B cell receptors were biased against N1 towards 
immunodominant FWPV antigens (such as fpv140, fpv168 and fpv191; Boulanger et al., 
1998) in the first few weeks post-vaccination. As such effects have not been observed 
with other antigens, it is possible that it is a unique feature of the expression of NA in 
rFWPV that led to the observed delay in host seroconversion. The same observation or 
other NA expression has not been reported elsewhere. Although anti-β-galactosidase 
responses could have been evaluated, clear demonstration of this effect would ideally 
have required the inclusion of another, similar antigen in the rFWPV, to serve as a 
control for the timing of seroconversion.  
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5.3.2    Cellular immune response  
IL-12 has been demonstrated to induce priming for high production of IFN-γ in both 
CD4+ and CD8+ T cell clones (Manetti et al., 1995; Paganin et al., 1995). However, the 
cytokine has a short life-span (5 to 6 hours) in blood circulation, thus leading to a 
dramatic decrease of IFN-γ levels after peak release (Lui et al., 2002). However, it was 
conceivable that co-expression of chicken IL-12 from rFWPV/N1 might initiate and 
maintain circulating IFN-γ concentration for a longer duration. This was assessed by 
measuring the preponderance of predominantly IFN-γ producers, namely CD4+ and 
CD8+ T cells. 
 
5.3.2.1 CD4+ T cells 
For Experiment 1, flow cytometry results showed that neither rFWPV/N1 nor 
rFWPV/N1/IL-12 increased CD4+ T cell population percentage (Table 5.2, Figure 5.1A). 
For Experiment 2, a slight, although not statistically significant, increase in the CD4+ T 
cell population was observed at Week 2 (n=5) upon rFWPV/N1 or rFWPV/N1/IL-12 
vaccination (Figure 5.1B). This result suggests that the presence of NA antigen alone 
might be able to increase CD4+ T cell population. In fact, de novo synthesis of NA is not 
required to enhance T cell proliferation (Oh and Eichelberger, 1999). Several studies 
have demonstrated that sialic acid cleavage by NA contributes to distortion of charge at 
dendritic, T lymphocyte or B cell surface, thus enhance the avidity of APC for T cells, T 
cell responses and proliferation (Oh and Eichelberger, 1999). It was later demonstrated 
that sialidase from Clostrodium perfringens (Garcia et al., 2005) and Salmonella 
typhimurium (Berger et al., 2006) improves CD4+ T cell function in both young and old 
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mice by cleaving α2,3- and/or α2,6-linked terminal sialic acid residues of specific 
proteins that regulate interaction between T cell receptor and APC. However, the effect 
of the cleavage on CD4+ T cell proliferation was not addressed in either report. Their 
findings suggested that desialylation might be a useful strategy to enhance 
immunogenicity of a vaccine. 
 
We observed similar levels of percentage of CD4+ T cells in rFWPV/N1 and 
rFWPV/N1/IL-12, indicating that IL-12 co-expression did not influence CD4+ T cell 
populations significantly, at least not in PBMC samples at 2 or 4 weeks post-vaccination. 
A pattern of decreasing CD4+ T cell populations over time suggests that incorporation of 
the IL-12 gene in rFWPV does not lead to sustained T cell response in chickens. This is 
consistent with recent in vivo findings, where IFN-γ appears rapidly in circulation on day 
3 post-vaccination with rFWPV expressing IBDV VP2 plus rFWPV expressing 
recombinant chicken IL-12, but decreased to the basal level 14 and 28 days later (Su et 
al., 2011). Upon lethal IBDV challenge at day 28 post-vaccination, 83 to 100 % 
protection was observed in these dually-vaccinated chickens, in comparison to 17 % and 
50 % protection in chickens vaccinated only with rFWPV expressing VP2 (Su et al., 
2011). Their finding suggests that the level of protection is increased upon IL-12 
administration, even though only a low IFN-γ level was detected prior to challenge.  
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5.3.2.2 CD8+ T cells 
Although no significant, augmentation of CD8+ T cell level was observed for rFWPV/N1 
in Experiment 1, the vaccine led to an increase, although not statistically significant, in 
the CD8+ T cell population in Experiment 2. NA-specific CD8+ T cell-mediated 
responses upon influenza virus infection have been described (Oh et al., 2001) but that is 
in a very different context. The proliferations of the self-regulating CD8+ T cells, which 
are not dependent on CD4+ T cell activation, indicate that influenza virus alters the 
capacity of antigen-presenting cells (APC) to stimulate T cell proliferation (Oh and 
Eichelberger, 1999) though it is not clear how large a specific role NA might play in this 
mechanism.  
 
Increasing proliferation levels or nonspecific expansion of CD8+ T cells after IL-12 
treatment have been reported extensively, including in in vitro studies using Myeloid-
derived suppressor cells (Steding et al., 2011) and Lewis lung carcinoma cells (Yin et al., 
2011) from mice, describing the pivotal role of IL-12 in CMI responses. In vivo studies 
using recombinant VV expressing IL-12-infected mice showed that reduction of VV 
titres correlate with the increased number of specific CD8+ T cells seen after expression 
of high levels of IL-12 (Gherardi et al., 1999; Gherardi et al., 2003). Our flow cytometry 
results for Experiment 1 (Figure 5.2A) demonstrated that rFWPV/N1/IL-12 did not 
increase CD8+ T cell percentage but results for Experiment 2 (Figure 5.2B) showed a 
significant increase of the CD8+ T cell population at Week 2 (n=5) after rFWPV/N1/IL-
12 vaccination. The significant differences in population levels between rFWPV/N1/IL-
12 and control or WT FP9 indicates that co-expression of chicken IL-12 induced high 
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levels of circulating CD8+ T cells present even at 2 weeks post vaccination. Two weeks 
later, we observed that the level had dropped to levels comparable to the control. It is 
possible that this was due to over-expression of IL-12 from the strong synthetic/hybrid 
promoter. High levels of recombinant chicken IL-12 have been shown to elicit lower 
levels of IBDV-specific IFN-γ production (Su et al., 2011). 
 
A slight increase over time in the CD8+ T cell population percentage in birds vaccinated 
with WT FP9 was noted, contradicting the observations with rFWPV/N1 and 
rFWPV/N1/IL-12. There are two possible explanations for this apparent discrepancy: 
(i) WT FP9 encodes undefined immunomodulatory proteins, which can induce persistent 
CD8+ T cell proliferation, although not markedly high. This is not surprising since 
FWPV strain FP9 has been shown to be more immunogenic in eliciting CD8+ T cell 
responses in mice against the circumsporozoite protein of a liver-stage, Plasmodium 
berghei malaria, than the commercially available Webster's FWPV vaccine strain 
(Anderson et al., 2004; Cottingham et al., 2006). 
(ii) Expression of NA N1 from rFWPV triggers, by an unknown mechanism, interaction 
between immune cells, leading to the reduction of the CD8+ T cell population to the 
basal state. It has been reported that pre-existing CD8+ T cell responses against viral 
epitopes in a boosting agent can inhibit the boosting of the CD8+ T cell response against 
the recombinant antigen (Anderson et al., 2004). It is not known whether the immediate 
CD8+ T cell responses against N1 after vaccination suppress further increase of of CD8+ 
T cells. 
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5.3.2.3 CD4+/CD8+ T cell population ratio  
As reported in the previous chapter, the ratio of CD4+ to CD8+ cells was shown to 
provide a general comparison on immune fluctuation after vaccination (Table 5.3).  Since 
there is no standard range of CD4+/CD8+ ratio for SPF White Leghorn chickens in any 
literature, ratios of control group served as benchmarks. We considered the results of 
Experiment 2 to be more reliable for data interpretation (Section 4.3.2.3). In comparison 
to the control, we observed a lower level of CD4+/CD8+ ratio in WT FP9, rFWPV/N1 
and rFWPV/N1/IL-12-vaccinated birds at both sampling points. Interestingly, the 
CD4+/CD8+ ratio of rFWPV/N1/IL-12-vaccinated birds was indistinguishable at Week 2 
and Week 4 of the second animal experiment, indicating that IL-12 might be a potent 
CMI-regulator for the flux of both CD4+ and CD8+ T cells in circulating blood.  
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CHAPTER 6 
Effect on host body weight of chicken IL-15 or IL-12 coexpressed from recombinant 
fowlpox viruses 
 
6.1 Introduction 
In the intensive and massive global poultry industry, vaccination is the most commonly 
applied strategy to control infectious diseases. Recombinant fowlpox virus (rFWPV) has 
been identified as a safe, important vaccine vector for numerous infectious pathogens of 
poultry, including avian influenza virus (e.g. Bublot et al., 2006), Newcastle disease 
virus, NDV (e.g. Sun et al., 2006), Marek's disease virus (e.g. Lee et al., 2003), 
Infectious bursal disease virus, IBDV (e.g. Su et al., 2011) and Infectious bronchitis virus 
(Chen et al., 2010a). Despite the efficacy, vaccination with rFWPV in ovo or in young 
chickens can slow the rate of growth and induce weight loss (Springer and Truman, 1981; 
Karaca et al., 1998; Mingxiao et al., 2006). This condition might not give a significant 
impact on small flocks. However, in the intensive commercial industry, a minor weight 
loss or retarded growth of large numbers of broiler chickens can influence the meat 
production greatly.  
 
Co-expression of chicken Type I IFN (Karaca et al., 1998), IFN-γ (Wang et al., 2009) or 
IL-18 (Mingxiao et al., 2006; Chen et al., 2010b) from rFWPV expressing various 
antigens has been shown to normalize the negative effect of FWPV vaccination on body 
weight. In our study, an animal experiment was carried out, described in Chapter 2.4.2.1, 
to demonstrate the effect of IL-15 or IL-12 co-expression from rFWPV vaccines, on 
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chicken body weight. Briefly, fifty-four 1-day-old chicks were randomly assigned into 
six groups. Each group of nine chicks was inoculated with rFWPV constructed 
previously, namely; rFWPV/H5, rFWPV/H5/IL-15, rFWPV/N1 or rFWPV/N1/IL-12. 
Another two groups were inoculated with WT FP9 or PBS, as controls. Weights of the 
chickens were measured in one-week intervals, for four weeks.  
 
In order to represent the differences in body weight, the percentage change was 
calculated using the equation below: 
   Weight of a particular vaccine group – Weight of PBS-treated control      X 100 
                             Weight of PBS-treated control 
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6.2 Results 
To measure body weights, all chickens were weighed at Week 1 until Week 4, post-
vaccination. The chickens were left until Week 7 to distinguish their sexes (Table 6.1). 
As shown in Figure 6.2, body weights of chickens in WT FP9 (93.9 ± 9.9 g), rFWPV/H5 
(98.9 ± 12.7 g), rFWPV/H5/IL-15 (101.1 ± 3.5 g) and rFWPV/N1 (102.2 ± 10.9 g) 
decreased 10.6 %, 5.8 %, 3.7 % and 2.7 %, respectively, compared to control chickens 
(105.0 ± 10.0 g), with rFWPV/N1/IL-12 having the highest weight loss of 25.9 % or 27.2 
g (77.8 ± 11.5 g), after one week post-vaccination. At Week 2, the relative weight 
reduction was irreversible for WT FP9 (164.2 ± 18.4 g), rFWPV/H5 (162.2 ± 41.6 g), 
rFWPV/N1 (165.1 ± 19.0 g) and rFWPV/N1/IL-12 (146.3 ± 19.0 g). However, 
rFWPV/H5/IL-15 (189.7 ± 9.5 g) showed a weight similar to the control (190.9 ± 16.9 g), 
with difference of only 0.6 % or 1.2 g. This weight pattern was consistent for all groups 
until Week 4, with WT FP9, rFWPV/H5, rFWPV/N1, rFWPV/N1/IL-12 having a 
statistically significant weight loss compared to the control (P≤0.05). The body weight of 
chickens vaccinated with rFWPV/H5/IL-15 was higher compared to other vaccine 
groups, indicating a potential effect of IL-15 in reversing the rFWPV side effect of 
weight loss. The weight gain was gender independent, as the control group had two more 
male chickens than the rFWPV/H5/IL-15 group. 
 
 
Table 6.1. Sex of nine experimental chickens, determined at Week 7 post immunization. 
Vaccine Males Females Total 
Mock-treated (Control) 6 3 9 
WT FP9 5 4 9 
rFWPV/H5 5 4 9 
rFWPV/H5/IL-15 4 5 9 
rFWPV/N1 5 4 9 
rFWPV/N1/IL-12 3 6 9 
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Vaccine 
Mean body weight in grams at different weeks,  
post-vaccination 
 Week 1 Week 2 Week 3 Week 4 
Control 105.0 ± 10.0 190.9 ±   16.9 285.0 ±   21.9 392.1 ±   25.0 
WT FP9 93.9 ± 9.9* 164.2 ± 18.4* 256.8 ±   35.3 350.0 ± 44.5* 
rFWPV/H5 98.9 ± 12.7 162.2 ± 41.6* 251.1 ± 56.3* 350.1 ± 70.2* 
rFWPV/H5/IL-15 101.1 ±   3.5 189.7 ±     9.5      272.1 ±   30.0 378.6 ±   32.7 
rFWPV/N1 102.2 ± 10.9 165.1 ± 19.0* 249.6 ± 28.4* 345.3 ± 35.0* 
rFWPV/N1/IL-12 77.8 ± 11.5* 146.3 ± 19.1* 228.7 ± 24.0* 280.4 ± 30.3* 
 
Figure 6.1. Effect of WT FP9 or rFWPV inoculation of 1-day-old chicks on mean body weight 
(grams) at Weeks 1, 2, 3 and 4. Data were presented in a bar graph (A) or table (B). Each value 
represents the means ± SD (error bars) of nine samples (n=9). Significant differences between 
control and vaccinated groups were determined by one-way ANOVA (P≤0.05) and indicated by 
an asterisk (*). 
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6.3 Discussion 
6.3.1 Effect of IL-15 co-expression from rFWPV on body weight of chickens 
IL-15 is among the most abundant cytokines in skeletal muscle. In humans and other 
mammals, IL-15 has been shown to regulate the fat-to-lean pathway by several means, 
including; (i) stimulating protein synthesis and inhibiting proteolysis of skeletal muscle 
(Quinn et al., 2002; Busquets et al., 2005), (ii) increasing glucose uptake
 
into skeletal 
muscle (Busquets
 
et al., 2006), (iii) stimulating lipid oxidation of skeletal muscle 
(Almendro
 
et al., 2006) and (iv) reducing fat composition in adipocytes (Alvarez et al., 
2002). In one study, lean human subjects showed higher levels of muscle IL-15 mRNA 
expression and circulating/plasma IL-15, compared to obese subjects. However, muscle 
IL-15 protein level of obese subjects was increased, suggesting that the role of IL-15 in 
regulating obesity involves processes downstream of transcription (Nielsen et al., 2008). 
The involvement of avian IL-15 in fat decomposition and muscle anabolism has not been 
described.  
 
From our experiment, the growth of chickens immunized with rFWPV/H5/IL-15 was 
similar to that of the control group, indirectly suggesting IL-15 can ameliorate the weight 
loss effect of rFWPV vaccines. Similar observations were reported after in ovo (Ding et 
al., 2004; Lillehoj et al., 2005) and intramuscular leg injection (Ma et al., 2011) of DNA 
vaccines coexpressing chicken IL-15 with the 3-1E gene of Eimeria acervulina, a 
parasite which can also cause weight loss. It is clear that the host responses to rFWPV 
expressing AIV H5 and to the DNA vaccine expressing the parasite E. acervulina 3-1E 
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gene are likely to be very different. However, both experiments indicate that IL-15 can 
reverse the weight-suppressive effect of pathogens of chickens.   
 
Similar results have also been shown in mice. Despite the effect of recombinant IL-15 
protein treatment in significantly reducing the body weight of IL-15-deficient mice 
(Barra et al., 2010), the same treatment reversed the suppressive effect of Coxsackievirus 
B3 on body weight (Bigalke et al., 2009). However, in macaques infected with Simian 
Immunodeficiency Virus, which does not induce weight loss, no weight gain was 
observed upon treatment of IL-15 protein, despite an increase in effector memory CD8+ 
T cells and NK cells (Mueller et al., 2005). 
 
It is interesting to note that co-administration of chicken IL-18 (expressed from a 
different plasmid DNA vector) with a DNA vaccine expressing the 3-1E gene of E. 
acervulina introduces weight loss upon E. acervulina infection, relative to PBS-
vaccinated group (Lillehoj et al., 2005), though this contradicts its observed effect of 
inducing weight gain in chickens vaccinated with rFWPV expressing AIV H5 (Ding et 
al., 2004). It appears that, compared to IL-18, IL-15 plays a more consistent role in 
sparing disease-related weight loss in chickens. It is of course possible that IL-15 reduced 
weight loss by inhibiting FWPV replication. The replication of FWPV, which would have 
required sampling at the site of inoculation as FP9 does not spread, was not monitored 
but the induction of HI titres observed by rFWPV/H5/IL-15 (Section 4.2.1) argues 
against this explanation. 
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6.3.2 Effect of IL-12 co-expression from rFWPV on body weight of chickens 
It has been reported that IL-12-deficient mice have normal size and weight, despite 
having defective IFN-γ production and type 1 cytokine responses (Magram et al., 1996). 
However, weight loss of more than 10 % in uninfected, with more than 20 % in 
lymphocytic choriomeningitis virus-infected, IL-12-deficient mice, was observed upon 
high-dose administration of recombinant IL-12, following 6 days of daily treatment 
(Orange et al., 1995). This finding suggests that high concentrations of IL-12 might 
increase host stress, and severity of disease, as indicated by weight loss. 
 
In this study, exacerbated weight loss was observed as early as one week post-inoculation 
with rFWPV/N1/IL-12. The weight loss was not accompanied by loss of appetite, 
suggesting the suppressive effect of IL-12 co-expression from rFWPV/N1/IL-12 on body 
weight of chickens did not involve restricted food consumption. In vivo studies in mice 
have suggested that administration of high dose IL-12 can increase the level of TNF-α 
(Orange et al., 1994; Orange et al., 1995; Ciftci et al., 2010), a cytokine that can regulate 
physiological and pathological changes, and can promote weight loss or anorexia 
(Langhans and Hrupka, 1999). Unfortunately, the levels of TNF-α were not not measured 
during the course of the experiment, so it is not possible to conclude whether or not the 
weight loss was TNF-α-dependent. There is also a possibility that the effect of IL-12 in 
our study involved either FWPV or AIV antigen-specific interaction. In the latter case, 
we did not managed to construct rFWPV co-expressing H5 gene of AIV and IL-12, 
which can serve as a comparison to rFWPV/N1/IL-12. Hence, more studies involving 
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measurement of viral load, viral antigens, host antibodies and specific cytokine 
productions are needed to support such theory. 
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CHAPTER 7 
General Discussion and Conclusions 
 
7.1 Poultry vaccination against avian influenza virus  
The poultry sector has been a steady-growing industry in most parts of the world 
developed and developing, due to an increasing global population and purchasing power. 
In addition, poultry products are highly demanded due to their relatively low pricing 
compared to other meat, absence of religious barriers and nutritional (protein) qualities 
(Magdelaine et al., 2008). Moreover poultry production is viewed as more 
environmentally sustainable than alternative sources of animal protein. The trend is 
reciprocal to a constant production of healthy chickens, thus indicating the need to 
control the occurrence and circulation of infectious diseases of poultry. Although several 
disease pathogens only cause mild distress, and consequent reduction in production 
levels, several other important pathogens including avian influenza virus (AIV), 
Newcastle disease virus (NDV) and infectious bursal disease virus (IBDV), can lead to 
severe illness with high mortality rate. In commercial production of poultry, the risk of 
rapid spread of infectious diseases is increased due to: (i) the centralisation of chick 
production, (ii) the close-rearing environment of large numbers of the birds and (iii) the 
frequent requirement for migratory labour to handle large numbers of poultry. The most 
common preventive tool in controlling the occurence of infectious disease, especially 
viral, is vaccination, normally implemented in the first few weeks of the animal's life to 
provide lifelong protection (though for the modern broiler this need only be as little as 6 
to 7 weeks). However, depending on the nature of the particular vaccine, they can possess 
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several disadvantages, such as: slow stimulation of host immunity, weak cross protection 
against diverse field viruses or subtypes, difficulty in large scale production in a short 
period of time, variable antigen quantity, requirement for adjuvant, and difficult to 
differentiate between infected or vaccinated birds in routine serological tests. New 
vaccination strategies, including recombinant viral vectors, are designed to minimise 
these weaknesses thus improving overall vaccine efficacy. 
 
In this study, we constructed recombinant fowlpox virus (rFWPV) vaccines co-
expressing the H5 or N1 antigens of AIV with chicken cytokines, IL-15 or IL-12. AIV is 
an important pathogen for poultry and still enzootic in certain parts of the world, 
particularly in Asia. Of the greatest concern is the highly pathogenic avian influenza A 
(H5N1), which is species-adapted and may be evolving inconspicuously to start a new 
panzootic. The vaccines were constructed to allow laboratory-based studies to provide 
more knowledge on chicken immune responses upon infection of recombinant vaccines 
against AIV. The cytokines were chosen due to their profound effect on Th1 responses, 
which are critical for host cellular-mediated immune (CMI) response for viral clearance 
and defence against intracellular pathogens (AIV). Expression of AIV antigens proteins, 
HA or NA, in the recombinant vaccines normally triggers host Th2 responses. Hence, we 
hypothesized that our recombinant vaccines might also be able to induce strong cellular 
responses for efficient virus clearance associated with reduced virus shedding in 
vaccinated, challenged chickens. 
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7.2 Restrictions of chicken experiment 
In comparison to mammals, less is known about modulation of the avian immune system 
in response to physiological processes or infections. In this study, we tried to provide 
more perspectives on chicken immune system upon recombinant viral infection. Despite 
some advantages, notably the direct relevance of the avian pathogen antigens, conducting 
animal experiments in chickens rather than mammals actually poses several major 
challenges. Firstly, more effort is needed to rear chickens compared to smaller 
mammalians, such as mice or ferrets. Mammalian model studies are performed in a 
smaller environment, allowing are easier care and management. Unlike chickens, those 
small animals require less effort for sanitizing, feeding and blood sampling purposes. 
Secondly, the availability of avian research reagents, including antibodies to avian cell 
surface markers and cytokine proteins, is limited. Despite an increasing number of 
reagents and a growing profile of avian cytokines, the accessibility still lags far behind.  
 
To negate some of these issues and to study whether the rFWPV vaccines could elicit 
good immune responses at an early stage of life, comparable to the gold standard rFWPV 
vaccines developed by Merial (Bublot et al., 2007), the vaccines were inoculated into 
one-day-old chicks. This practice allowed the study of larger numbers of birds, while 
limiting the total volume of whole blood and sera that could be sampled from them.  
 
To determine the blood volume to be sampled from each chicken, we considered the 
chicken body weight, frequency (once a week) and period (seven weeks) over which the 
blood will be collected. In this study, we sampled 0.2 mL blood at Week 1 and 2, 0.3 mL 
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at Week 3 and 4, 0.5 mL at Week 5 and 1 mL at Week 6 and 7. Extra blood volume was 
sampled for flow cytometry analysis (0.2 mL at Week 2 and Week 5 for Experiment 1; 
0.5 mL at Week 2 and 4 for Experiment 2). This etiquette was advised by veterinarians 
and approved by the local IACUC. The general guide allows a maximum of 10 % of the 
total blood volume for weekly-repeat bleeds, in which ten percent of chicken body weight 
(g) is estimated to represent the total blood volume (mL) of an individual chicken (Dr 
Mustapha Abu Bakar and Dr Kartini Ahmad, personal communication). Frequent 
samplings of a large volume of blood may allow a short-term hypovolaemic shock or in a 
longer term, anaemia (British Veterinary Association (BVA), 1993). 
 
7.2.1 Limitations and suggestions for improved evaluation of cellular mediated 
immune responses   
For the assessment of CMI responses, T lymphocyte cell subsets were measured in 
peripheral blood mononuclear cells (PBMC). Other than lymphocytes (T cells, B cells 
and NK cells), PBMC of whole blood extracted using ficoll contains monocytes. 
Therefore, in our flow cytometry results, we do not know the absolute number of PBMC 
per volume of blood, and thus it is impossible to deduce accurate estimates of cell 
proliferation in response to vaccination For example, variation in the number of 
monocytes would change the apparent % of T cells, even if the absolute number of T 
cells had not changed. To improve the assay, cell counting should be done in addition to 
antibody staining, either by using an automated analyzer or manually. To increase the 
assay specificity, antigen-specific responses could be measured by staining for 
intracellular cytokine such as IFN-γ after in vitro stimulation of PBMC with appropriate 
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antigen. However, availability of commercialised anti-chicken cytokine markers is the 
major limitation compared to those of mammals.  
 
An alternative approach of not using PBMC would have been to measure the magnitude 
of T lymphocyte cell populations from organs such as the spleen, the largest secondary 
lymphoid organ. However, this approach would have restricted the experiment to single 
time-point data, requiring higher numbers of birds.  
 
7.3 Experimental design 
In this study, four recombinant vaccines, rFWPV/H5, rFWPV/H5/IL-15, rFWPV/N1 and 
rFWPV/N1/IL-12 were characterized. It had originally been the intention to isolate more 
recombinants for comparative study, namely rFWPV/H5/IL-12, rFWPV/N1/IL-15, 
rFWPV/NP/IL-15 and rFWPV/NP/IL-12 but it proved impossible to isolate resolved and 
stable recombinant clones within the limited time available for rFWPV construction in 
the UK (Chapter 3). It had also been the intention to challenge chickens vaccinated with 
homologous HPAIV. Unfortunately delays to the construction and licensure of 
appropriate facilities in Malaysia, together with the scarcity of and high demand upon 
such facilities elsewhere, means that this objective has had to be deferred.  Therefore, the 
study did not evaluate the protective efficacy of the vaccines against lethal viral 
challenge, but only their immunogenicity and general effects upon vaccinated hosts. 
Those vaccines which induced stronger humoral and cellular-mediated responses will be 
subjected to protection/challenge studies when the facilities eventually become available. 
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7.4 Characterization of rFWPV/H5 and rFWPV/H5/IL-15 
The results showed that inoculation of rFWPV/H5/IL-15 did not induce any adverse 
effect in the host. In fact, co-expression of IL-15 induced gain in body weight relative to 
birds vaccinated with rFWPV not expressing IL-15, indicating its ameliorating effect on 
the suppressive effect of rFWPV on body weight. rFWPV/H5/IL-15 showed a stronger 
humoral response, compared to rFWPV/H5, indicated by a higher HI titre at peak week 
(Week 3).  The vaccine induced higher, although not statistically significant, CD4+ T 
cells and similar CD8+ T cells level compared to rFWPV/H5. This suggests that the level 
of IL-15 co-expressed from rFWPV/H5/IL-15 was sufficient to enhance CD4+ T cell 
population (Kanegane et al., 1996; Seder, 1996; Niedbala et al., 2002). CD4+ T cell 
proliferation is a multifaceted process, which relies on activation of recognition and 
verification signals. These signals are critical in recognizing extracellular, soluble 
materials that are released from infected cells and ensuring that a T cell is responding to 
that foreign antigen. Once the signals are activated, proliferation of CD4+ T cells is 
allowed through a further complex process involving IL-2 (also called T cell growth 
factor) and expression of IL-2 receptor. Since Lillehoj et al. showed that chicken IL-15 
and chicken IL-2 share similar functional characteristic in increasing the level of T cells 
(Lillehoj et al., 2001), we showed indirectly that the chicken IL-15 co-expressed from 
rFWPV/H5/IL-15 was biologically active, indicated by its preferential increase of CD4+ 
T cells compared to rFWPV/H5. Interestingly, no significant difference in the level of 
CD8+ T cells of rFWPV/H5 and rFWPV/H5/IL-15 was observed. It is possible that the 
host cytotoxic response is H5 antigen-dependent and IL-15-independent. Alternatively 
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over-expression of IL-15 might have been at such levels that CD8+ responses were not 
stimulated (Niedbala et al., 2002; Oh et al., 2003).  
 
Collectively, rFWPV/H5/IL-15 showed enhanced immunogenicity and might prove to be 
a valuable adjunct to recombinant vaccines against AIV. However, further study should 
be done to evaluate its effect on the protective efficacy of the vaccines against lethal 
challenge infection.  
 
7.5 Characterization of rFWPV/N1 and rFWPV/N1/IL-12 
Neuraminidase (NA) is less-well recognized as a potentially protective antigen in AIV 
vaccine candidates. Considering the ability of NA antibodies to limit viral replication and 
reduce the release of progeny virus from infected cells, we constructed rFWPV/N1 and 
rFWPV/N1/IL-12 and evaluated their levels of immunogenicity. Humoral responses 
induced by each vaccine appeared four weeks after vaccination, suggesting a late 
induction of immunity, which is a disadvantage in vaccine development. It is likely that 
the delayed induction of immunity was attributable to the expression of the 
neuraminidase itself. CD4+ T cell population percentage in rFWPV/N1 and 
rFWPV/N1/IL-12-vaccinated groups was indistinguishable, whereas the CD8+ T cell 
population was higher in the rFWPV/N1/IL-12 group, suggesting a predominant effect of 
IL-12 in modulating cytotoxic T cell activity against foreign antigens. 
 
Despite the enhanced CD8+ T cell response, rFWPV/N1/IL-12 would not be desirable as 
a vaccine candidate due to the unforeseen, suppressive effect on chicken body weight. 
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Until further tests are done on the levels of TNF-α, thymic athrophy or corticosterone 
(Orange et al., 1995; Matsushita et al., 1999) concurrently with weighing, the loss of 
weight and possible toxicities, which could be triggered by IL-12, could not be explained 
mechanistically. In conclusion, the study showed that IL-12 co-expression from a 
recombinant poultry vaccine would require careful consideration due to the detrimental 
effect on body weight, despite possible enhancements of host CMI responses. 
 
7.6 Future experiments 
The animal experiments conducted have allowed evaluation of immunogenicity of the 
vaccines pre-challenge. Further assays would be necessary to provide a broader 
perspective, particularly to the cellular responses in chickens post-vaccination. Harvested 
organs from the 7-week-old experimental chickens have been reserved for real-time 
quantitative reverse transcription-PCR assay. The assay will allow quantification of 
cytokine targets, including IFN-α, IFN-γ, IL-1β, IL-2, IL-10, IL-12, IL-15, IL-18 (Th1 or 
Th1-related cytokines) and TGF-β4, IL-4 (Th2 cytokines) (Hong et al., 2006; Park et al., 
2008). A transcription factor, named lipopolysaccharide-induced TNF-α factor (LITAF) 
can be used for a direct indication of TNF-α levels in the host (Hong et al., 2006), which 
may be related to body weight (Orange et al., 1995; Tanaka et al., 2001). An alternative 
experimental design for this assay would be to quantitate the mRNA levels in specific 
organs every week, post vaccination, although it will not reflect responses of the same, 
individual chicken. 
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Due to constraints of time and containment facilities, it was not possible to conduct a 
protective/challenge study using live, homologous H5N1 virus strain 
A/Chicken/Malaysia/5858/2004. This final stage will allow measurements of viral 
replication, viral shedding and mortality/survival rate, thus indicating whether the 
enhanced humoral and CMI responses, which were elicited by the vaccines, can confer 
protection against lethal infection. 
 
7.7 Concluding remarks 
In summary, this study showed diverse immunogenicity of H5N1-rFWPV co-expressing 
IL-12 or IL-15, with rFWPV/H5/IL-15 being a better vaccine candidate compared to 
rFWPV/N1/IL-12. It also demonstrates a weight sparing effect of co-expressing IL-15 in 
rFWPV vaccines. The results provide the basis for future homologous challenge studies, 
using live H5N1 virus to evaluate the protective efficacy of the rFWPV vaccines.  
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Appendix 1 
Primers used in this study. Restriction enzyme sites are shown in bold. 
 
Primer Description Sequence (5 ’- 3’) 
H5-F +EcoRV site ATCGGATATCATGGAGAAAATAGTGC 
H5-R +EcoRV site GACTGATATCTTAAATGCAAATTCTGC 
N1-F +Ssp site ACCGAATATTATGAATCCAAATAAGAAG 
N1-R +Ssp site AGGCAATATTCTACTTGTCAATGGTG 
NP-F +EcoRV site ACTGATATCATGGCGTCTCAAGG 
NP-R +EcoRV site ACGTGATATCTCAATTGTCATATTCCTC 
S(2-F) Mutagenic 
primer 
CAAAGAGAGACAAGAGGATTATTTGGAGCTATAG 
S(1-R) Mutagenic 
primer 
CAAATAATCCTCTTGTCTCTCTTTGAGGGCTATTTC 
H5-F1 For screening ATGGAGAAAATAGTGCTTCTTTTTG 
H5-R1 For screening TTAAATGCAAATTCTGCATTGTAACG 
N1-F1 For screening ATGAATCCAAATAAGAAGATAATAACCATCG 
N1-R1 For screening CTACTTGTCAATGGTGAATGGCAACT 
NP-F1 For screening ATGGCGTCTCAAGGCACCA 
NP-R1 For screening TCAATTGTCATATTCCTCTGCATTG 
pEFL29-F For screening CGGAGACCATATCCATACGC 
pEFL29-R For screening CGTAAAAGTAGAAAATATATTC 
pEFGPT12S-F For screening AGTAAGAGAACCGGGAGCG 
pEFGPT12S-R For screening ACCCACATGATAAGAGATTGTATC 
pPC1.X-F For screening ATGAAAAATAGTACCACTATGG 
pPC1.X-R For screening ATCCGATACTAGTATTAGGTTAGC 
IL15-F For screening ATGCTGGGGATGGCACAGCC 
IL15-R For screening ACAGAGTTTTGTAAAGGTTATACAGAGG     
IL12-F For screening ATGTCTCACCTGCTATTTGCC    
IL12-R For screening ACCACCCTTGGCTCCTTCCAGG 
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Appendix 2 
Media Constituents 
 
Media I – 2 % Newborn bovine serum (NBBS) in DMEM 
Component Volume 
1 bottle DMEM (Sigma) 500 mL 
Newborn bovine serum (NBBS) (Autogen Bioclear) 10 mL 
Nystatin (Sigma) 5 mL 
Pen-Strep 500 uL 
Tryptose Phosphate Broth (TPB) 5 mL 
 
Media II – 10 % Newborn bovine serum (NBBS) in DMEM 
Component Volume 
1 bottle DMEM (Sigma) 500 mL 
Newborn bovine serum (NBBS) (Autogen Bioclear) 10 mL 
Nystatin (Sigma) 5 mL 
Pen-Strep 500 uL 
Tryptose Phosphate Broth (TPB) 5 mL 
 
Media III – For agarose overlay 
2 % Newborn bovine serum (NBBS) in 2X MEM 
Component Volume 
1 bottle 2X MEM (Sigma) 250 mL 
Newborn bovine serum (NBBS) (Autogen Bioclear) 10 mL 
Nystatin (Sigma) 5 mL 
Pen-Strep 500 uL 
 
Media III was mixed with 2 % Low Gelling Agarose, LGA (diluted in distilled water), to 
make the agarose medium. 
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Appendix III 
Data of CD4+ and CD8+ T cell population (n=3 for Experiment 1, n=5 for Experiment 2) 
 
Experiment 1 
Vaccine 
Number 
of 
Chickens 
CD4+ T cell population, 
% 
Week 2 Week 5 
Control 
  
  
1 12.26 10.14 
2 16.51 21.36 
3 18.14 18.11 
Wild Type FP9 
  
  
1 22.80 19.17 
2 14.10 21.31 
3 19.35 21.96 
rFWPV/H5 
  
  
1 21.74 17.80 
2 25.60 10.77 
3 23.66 19.71 
rFWPV/H5/IL-15 
  
  
1 15.74 24.14 
2 13.97 12.33 
3 13.43 16.16 
 
 
Experiment 1 
Vaccine 
Number 
of 
Chickens 
CD8+ T cell population, 
% 
Week 2 Week 5 
Control 
  
  
1 7.56 5.93 
2 9.47 9.75 
3 8.58 8.84 
Wild Type FP9 
  
  
1 14.12 13.74 
2 11.29 14.84 
3 12.71 11.27 
rFWPV/H5 
  
  
1 14.12 11.21 
2 19.35 6.82 
3 15.38 10.08 
rFWPV/H5/IL-15 
  
  
1 12.53 13.08 
2 8.46 11.16 
3 10.47 4.77 
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Experiment 1 
Vaccine 
Number 
of 
Chickens 
CD4+ T cell population, % 
Week 2 Week 5 
Control 
  
  
1 12.26 10.14 
2 16.51 21.36 
3 18.14 18.11 
Wild Type FP9 
  
  
1 22.80 19.17 
2 14.10 21.31 
3 19.35 21.96 
rFWPV/N1 
  
  
1 16.50 15.64 
2 15.37 12.86 
3 12.90 13.76 
rFWPV/N1/IL-12 
  
  
1 12.57 13.58 
2 19.20 9.84 
3 17.30 13.82 
 
 
Experiment 1 
Vaccine 
Number 
of 
Chickens 
CD8+ T cell population, % 
Week 2 Week 5 
Control 
  
  
1 7.56 5.93 
2 9.47 9.75 
3 8.58 8.84 
Wild Type FP9 
  
  
1 14.12 13.74 
2 11.29 14.84 
3 12.71 11.27 
rFWPV/N1 
  
  
1 13.16 11.19 
2 8.66 8.23 
3 6.64 6.26 
rFWPV/N1/IL-12 
  
  
1 8.52 8.63 
2 7.56 7.54 
3 13.64 10.01 
 
 
 
 
 
 
 
 
 
 206 
Experiment 2 
Vaccine 
Number 
of 
Chickens 
CD4+ T cell population, 
% 
Week 2 Week 4 
Control 
  
  
  
  
1 13.73 5.54 
2 7.96 10.16 
3 7.03 8.57 
4 11.33 5.43 
5 12.40 7.15 
Wild Type FP9 
  
  
  
  
1 7.90 11.34 
2 8.06 7.71 
3 14.25 12.73 
4 8.98 12.29 
5 10.49 10.58 
rFWPV/H5 
  
  
  
  
1 13.65 9.49 
2 9.83 10.90 
3 9.38 10.12 
4 9.50 10.75 
5 9.48 6.99 
rFWPV/H5/IL-15 
  
  
  
  
1 13.33 7.42 
2 11.78 7.51 
3 15.57 8.74 
4 14.80 7.80 
5 9.77 10.73 
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Experiment 2 
Vaccine 
Number 
of 
Chickens 
CD8+ T cell population, 
% 
Week 2 Week 4 
Control 
  
  
  
  
1 10.40 4.43 
2 6.30 5.20 
3 11.05 4.60 
4 6.78 5.23 
5 7.20 7.83 
Wild Type FP9 
  
  
  
  
1 7.10 14.62 
2 7.14 9.46 
3 9.05 10.51 
4 10.94 7.75 
5 7.59 12.72 
rFWPV/H5 
  
  
  
  
1 11.81 9.87 
2 13.84 9.08 
3 11.88 7.17 
4 10.45 10.02 
5 10.54 8.96 
rFWPV/H5/IL-15 
  
  
  
  
1 11.47 4.59 
2 10.88 8.88 
3 12.84 4.75 
4 9.01 4.30 
5 9.75 6.74 
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Experiment 2 
Vaccine 
Number 
of 
Chickens 
CD4+ T cell population, % 
Week 2 Week 4 
Control 
  
  
  
  
1 13.73 5.54 
2 7.96 10.16 
3 7.03 8.57 
4 11.33 5.43 
5 12.40 7.15 
Wild Type FP9 
  
  
  
  
1 7.90 11.34 
2 8.06 7.71 
3 14.25 12.73 
4 8.98 12.29 
5 10.49 10.58 
rFWPV/N1 
  
  
  
  
1 12.40 12.45 
2 14.20 6.81 
3 11.06 6.68 
4 12.09 5.79 
5 13.46 7.23 
rFWPV/N1/IL-12 
  
  
  
  
1 13.79 6.39 
2 12.81 3.72 
3 11.22 3.65 
4 9.18 3.92 
5 9.55 17.01 
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Experiment 2 
Vaccine 
Number 
of 
Chickens 
CD8+ T cell population, % 
Week 2 Week 4 
Control 
  
  
  
  
1 10.40 4.43 
2 6.30 5.20 
3 11.05 4.60 
4 6.78 5.23 
5 7.20 7.83 
Wild Type FP9 
  
  
  
  
1 7.10 14.62 
2 7.14 9.46 
3 9.05 10.51 
4 10.94 7.75 
5 7.59 12.72 
rFWPV/N1 
  
  
  
  
1 14.08 11.46 
2 10.13 7.76 
3 9.92 5.08 
4 15.36 4.66 
5 8.12 4.55 
rFWPV/N1/IL-12 
  
  
  
  
1 12.08 3.82 
2 15.87 3.23 
3 17.37 4.49 
4 8.46 13.90 
5 8.92 12.98 
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